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There is a general consensus in the scientific community that psychosis is a complex disorder and 
that its causes cannot be discovered by focusing only on one aspect. Several genes of small effect 
together with environmental exposure such as drug abuse are known to be important risk factors. 
Cannabis is the most popular recreational drug in the world and it is estimated that 40% of young 
people have tried cannabis sativa at least once in their life.  
This study examines the role of common variations within the cannabinoid receptor 1 (CNR1) gene 
and the catechol-o-methyl transferase COMT gene and their interaction with cannabis use in the 
aetiology of psychosis.  
Specifically, it analyses the main effect of 15 SNPs, namely rs10485171, rs806365, rs806366, 
rs12189668, rs1049353, rs806369, rs806371, rs806374, rs12195101, rs806375, rs806377, 
rs806378, rs2023239, rs1535355, rs6454672 and the AATn microsatellite within the CNR1 gene 
on psychosis and their relationship and interaction with cannabis use.  
Furthermore, this study analysed the main effect of 7 SNPs, namely rs737865, rs6269, rs4633, 
rs4818, rs165599, rs4680 and rs2075507 within the COMT gene (4 of which form the LPS 
haplotype) and the LPS haplotype on psychosis and the relationship of rs4680 and the LPS 
haplotype with cannabis use, frequency of use and self reported experiences upon use. 
Samples under investigation are part of two large studies of first episode of psychosis: the Psychosis 
Incident Cohort Outcome Study (PICOS) and the Genetics and Psychosis study (GAP). The GAP 
Study sample consisted of 2 populations, Caucasian European and Black African/Black Caribbean 
populations, analysed separately. The GAP Caucasian sample included 174 psychotic patients and 
45 healthy subjects; the GAP Black group included 113 psychotic patients and 93 healthy 
individuals. The PICOS Study is based in Verona, Italy and consisted of 347 first episode psychosis 
patients and 307 healthy volunteers.  
Results showed that rs1049353 and rs806378 within the CNR1 gene were associated with psychosis 
in the GAP Caucasian sample (adjusted p-value=0.03) and (adjusted p-value=0.05).  
Subjects with 2 copies of the LPS haplotype experienced more perception abnormalities. This 
however did not retain significance after Bonferroni correction for multiple testing (adjusted p-
value=0.08 and p-value= 0.16 respectively). 
Subjects using cannabis more than 3 times per week were more likely to respond with anxiety and 
or paranoia to the drug (adjusted p-value=0.004). 
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Subjects using cannabis more than 3 times per week were also more likely to have a pleasurable 
experience upon cannabis consumption. This did not however retain significance after multiple 
testing correction (adjusted p-value=0.2). 
Associations observed were not disease group or ethnicity dependent. 
No other association was found to be significant before or after Bonferroni correction for multiple 
testing. 
Because of the few samples available, this study is underpowered and in light of many other 
limitations it is unable to detect any true association. Results though should be interpreted as 






















PSYCHOSIS: CLINICAL PRESENTATION  
 
1.1 Psychosis 
Psychosis is a term derived from the Greek ψυχή – psyche – meaning ‘soul’ and the suffix ωσις – 
osis – meaning ‘abnormal condition’. The American Diagnostic and Statistical Manual of Mental 
Disorder (DSM-IV) (American Psychiatric Association, 1994) includes in the psychosis spectrum, 
nine formal psychotic disorders: schizophrenia, schizoaffective disorder, schizophreniform 
disorder, brief psychotic disorder, delusional disorder, shared psychotic disorder, psychosis not 
otherwise specified (psychosis NOS) and psychosis caused by medical condition (organic 
psychosis). Psychotic symptoms may be also present in major depressive disorder and bipolar 
disorder. They are grouped together to facilitate the differential diagnosis of disorders that include 
psychotic symptoms with their presentation, like for example, Alzheimer’s dementia or substance 
induced delirium. 
At present, psychosis is used as an ‘umbrella’ term used to identify a group of heterogeneous 
disorders. They are all characterised by behavioural and perceptual disturbances, severe impairment 
in function at social and personal level preventing the affected individual from performing everyday 
tasks.  
The disorder we now call Schizophrenia was first described in 1896 by Emil Kraepelin, a German 
professor of psychiatry. It was characterised by an early an age of onset, deteriorating clinical course 
and poor outcome, symptoms of hallucinations and delusions were also present. Kraepelin named 
the disorder ‘Dementia praecox’ which was different from manic-depressive insanity in familiarity, 
temperament and onset. Kraepelin particularly stressed the importance of family history, cognitive 
impairment and thought it was of organic origin (Lehmann 1980; Hoenig 1983). He described a 
mixture of symptoms of motor deficits, delusions, hallucinations, avolition and social isolation. 
This was therefore the first description of a psychotic disorder with a genetic basis. 
The term schizophrenia was then introduced in 1908 by Eugen Bleuler, a psychiatrist from 
Switzerland. The term comes from the Greek ‘schizo’ – split – and ‘phrene’ – mind- to emphasise 
the fragmented thinking characteristic of affected individuals. Bleuler described schizophrenia with 
the ‘four A’s’: loosening of Association, Autism, Ambivalence and blunted Affect; ‘thought 
disorder’ was therefore the main symptom at the centre of his classification. 
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According to the DSM-IV (American Psychiatric Association, 1994), schizophrenia presents with 
a mixture of positive and negative symptoms that have to be present for a consistent proportion of 
time during 1 month period with some signs persisting for at least 6 months time. 
Both the DSM-IV and the International Classification of Diseases 10th edition (ICD-10) take the 
first three sub-types from the original Kraepelian classification. 
According to the DSM-IV there are six criteria to diagnose schizophrenia: 
Criterion A – Characteristic symptoms (delusions, hallucinations, disorganized speech, grossly 
disorganized or catatonic behaviour): two symptoms have to be present for at least the duration of 
1 month. However, only 1 characteristic has to be present if delusions are bizarre, or hallucinations 
consist of one or more voices conversing together, or if a voice runs a commentary about the 
behaviour of the person. 
Criterion B –Social/occupational dysfunction: one or more areas of self care, work or interpersonal 
relationships are below the level it was prior the onset of the disturbance. 
Criterion C –Duration: signs must persist for at least six months with 1 month of symptoms from 
criterion A. 
Criterion D –Schizoaffective and Mood disorder exclusions: schizoaffective disorder and mood 
disorder with psychotic features must be ruled out. 
Criterion E –Substance/general medical condition exclusion 
Criterion F –Relationship to a pervasive developmental disorder (PDD): the diagnosis of 
schizophrenia can be made in the presence of PDD only if delusions and hallucinations are 
predominant for at least the duration of 1 month. 
The DSM-IV TR in the section of Schizophrenia and other psychotic Disorders also includes: 
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief 
Psychotic Disorder, Shared Psychotic Disorder, Psychotic Disorder Due to a General Medical 
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Schizoaffective Disorder 
Schizoaffective disorder is characterised by mood symptoms as well as psychotic symptoms. To 
meet the criteria for diagnosis, together with the symptoms that meet criterion A for schizophrenia, 
there have to be present a major depressive episode, a manic episode or a mixed episode or 
psychotic symptoms for at least two weeks in absence of mood symptoms. 
 
Brief psychotic episode 
The diagnosis of brief psychotic disorder is made when psychotic symptoms like delusions, 
hallucinations, disorganised speech and grossly or catatonic behaviour are present for at least a day 
but less than a month. 
 
Delusional disorder 
Delusional disorder is mainly characterised by the presence of delusions for at least 1 month 
duration. Tactile or olfactory hallucinations can also be present if part of the delusion. Functioning 
is maintained apart from the impact of the delusion itself and mood episodes, if present are usually 
brief. The disorder is not due to the effect of abuse of drugs. 
 
Schizophreniform Disorder 
Schizophreniform disorder can be characterised by confusion or perplexity at the height of the 
psychotic episode but the subject can function properly socially and occupationally during the 
premorbid phase. Blunted or flat affect are absent. For the diagnosis of schizophreniform disorder, 
criteria A, D and E for schizophrenia are met. The episode should last at least 1 month but less than 
6 months. 
 
Shared psychotic disorder 
Shared psychotic disorder is characterised by the development of psychosis by an individual in a 
close relationship with another with established delusions. It has also been called ‘Folie a deux’ and 
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1.2 Psychotic symptoms 
Psychotic symptoms are divided into positive and negative symptoms, where positive indicates an 
excess or distortion of normal functioning and negative indicates a reduction or total loss of normal 
function. According to the DSM-IV TR (American Psychiatric Association, 1994) positive 
symptoms include: hallucinations, delusions, disorganised speech, grossly disorganised or catatonic 
behaviour whereas negative symptoms include: alogia, affective flattening and avolition. 
Positive symptoms 
Hallucinations 
The term hallucination comes from the Latin word ‘alucinari’ meaning ‘to wonder in mind’ and 
was introduced in 1837 by Esquirol. 
Hallucinations can be defined as perceptions in conscious state in absence of the stimuli which have 
qualities of real perception. Hallucinations are usually vivid and located in external object space 
and can occur in many modalities: visual, auditory, olfactory and gustatory. The most common type 
by far is auditory hallucinations which are perceived as familiar or unfamiliar voices clearly distinct 
from a person own thoughts. Voices are usually nasty and can be threatening for the individual; 
they can be in the form of derogatory comments or commands. Very characteristic of schizophrenia 
are hallucinations consisting of two or more voices running a commentary on the person’s 
behaviour, if this is present, it is enough to meet the criteria for the diagnosis of schizophrenia. 
Visual hallucinations:  phenomena of seeing things that are not present and do not reflect reality.  
Olfactory hallucinations:  phenomena of smelling odours that are not derived from any physical 
stimuli. Odours are often unpleasant.  
Tactile hallucinations: phenomena of a sensation of tactile stimuli with the absence of concrete 
stimuli. Tactile hallucinations are much less frequent than auditory hallucinations. 
Gustatory hallucinations: involve the sense of taste. The individual may report simple tastes like 
sweet or salty and the phenomena are usually associated with olfactory hallucinations.  
Delusions 
Delusion can be defined as false beliefs. They are usually not consistent with the individual’s 
religious or cultural background. Delusions are very challenging because they are very difficult to 
eradicate. They are usually not open for discussion and can also be much elaborated. Types of 
delusions can be divided into: delusions of control, delusions of jealousy, nihilistic delusions, 
delusions of reference, delusions of grandiosity, persecutory delusions, somatic delusions, 
erotomanic delusions and mixed type delusions. 
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Delusions of control: false belief where the individual is certain somebody else, some external force 
or a group of people, is controlling their actions or thoughts.  
Delusions of jealousy: false belief of the individual’s partner being unfaithful. The individual may 
gather evidence and confront the partner about non-existent facts.  
Nihilistic delusions: false beliefs that focuses on the non existence of self or part of self.  
Delusions of reference: false beliefs that insignificant remarks or insignificant words have a 
personal significance to the affected individual. The individual may take as personal and very 
meaningful newspapers heading or words overheard from people passing by.  
Delusions of grandiosity: the delusion is often well articulated, the individual is strongly convinced 
to have an occupation or a role of prestige and does not show any sign of insight. 
Persecutory delusions: belief of an individual that he or she is being persecuted. The subject often 
reports the feeling of being spied on or followed and as a result can be dangerous.  
Somatic delusions: false belief concerning body part or loss of body functions.  
Erotomanic delusions: false belief of an affected individual that another person, often a stranger, is 
in love with him/her.  
Mixed type delusion: all kind of delusions that do not specifically fall into any of the above 
categories.  
Disorganised speech 
Disorganised speech is diagnosed when speech and behaviour are considerably disorganised or 
jumbled. The individual may continue to ask the same question or jump from a subject to another 
without giving proper notice. When this occurs, there can be the impression of an overflow of 
thoughts going on in the individual’s mind. The subject may also attempt to express feelings or to 
tell a story without managing to keep the point, the conversation is therefore perceived by others as 
incoherent or illogical. 
Negative symptoms 
Alogia 
The term alogia comes from the Greek words ‘α’ meaning without and ‘λόγος’ meaning speech. 
Alogia is used to indicate lack of speech or poverty of speech, or more often, a lack of unprompted 
speech seen in normal situations. 
Affective flattening 
Affective flattening can be observed in individuals presenting with psychotic symptoms and 
consists of a blunt response to emotions. The individual may present with total absence of emotional 
response or with a restricted response.  
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Avolition 
Symptoms of avolition are characterised by lack of drive, desire and goal directed behaviour. It can 
sometimes be mistaken for disinterest but it differs in severity. The individual may become 
disinterested in going out with friends or carrying out everyday activities; the result can be a total 
absence of any social interaction or activity. Usually, negative symptoms tend to cluster and present 


































GENETICS AND PSYCHOSIS 
 
2.1 Early genetic findings 
 
Psychosis, as mentioned earlier, is an ‘umbrella’ term used to indicate several disorders with similar 
features. The incidence of schizophrenia is thought to be between 0.5 and 1% of the general 
population (Jablesky A. et al., 1992).  
 
Since Emil Kraepelin coined the term ’Dementia Precox’ referring to today’s diagnosis of 
schizophrenia, there has been significant amount of research done aiming to understand the 
aetiology of psychosis. The very first evidences of a possible genetic basis for psychosis date back 
to 1916. Ernst Rudin performed the first family study on what was then called ‘Dementia precox’ 
and found that the rate of the disease was significantly higher among siblings of probands.  More 
recently, family studies as well as molecular studies highlight the likely presence of shared genetic 
risk factors between schizophrenia and bipolar disorders. Familiarity of schizophrenia has been 
shown to be between 41% and 87% (Cardno et al, 1999; Kendler et al, 1983) familiarity of bipolar 
disorder to be between 73% and 87% (Cardno et al, 1999; Kendler et al, 1995, McGuffin et al, 
2003). Moreover, the risk of developing bipolar disorder is also increased by having a relative with 
schizophrenia (Kendler et al, 1993a,b,c; Maier et al., 1993, 2002). These findings have been 
supported by a recent study in 2009 by Lichtenstein et al, where the authors linked multi-generation 
register and hospital discharge register identifying more than 2 million nuclear families between 
1973 and 2004. The results indicate an overall increase in relative risk for both schizophrenia and 
bipolar disorder. These findings are consistent with several genetic and neurobiological findings 
further discussed in this thesis. 
2.1.1 Twin and Family Studies 
Family studies have shown familiarity of the disorder giving us insight into possible genetic cause 
of psychiatric disorders. However, one cannot be sure whether such findings are due to genetic 
sharing or to environment sharing. Twin studies are very valuable in the search for genetic basis of 
psychosis since identical twins are thought to share 100% of their DNA. The first twin study was 
carried in Munich by Luxenberger in 1928. Subsequently Kendler in 1983 carried out a systematic 
review of all twin studies to date and concluded that indeed there were higher concordance rates 
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between MZ twins (concordance rate between 41% and 87%) highlighting the genetic influence in 
psychotic disorders.  
In order to explore the role of environmental sharing, adoption studies are design to allow us to 
control for post-natal family environment. Adoption studies can follow three different designs:  
1. Adoptees studies where adopted away offspring of affected parents are compared with adopted 
away offspring of non affected parents;  
2. Adoptees family study where the adoptees biological parents are compared to adoptees adoptive 
parents for risk of disease and;  
3. Cross-fostering studies where offspring of affected individuals are reared by healthy adoptive 
parents are compared with children born from non affected individuals and reared in a family where 
a parent develops the disease.  
First studies using adoptees study design were performed by Heston in 1966 and Rosenthal et al. in 
1971. They both concluded that there was significant higher risk of schizophrenia in adoptees born 
from an affected parent. Lately a Finnish study results showed an increase morbid risk (8.1%) in 
adopted away children of affected mothers compared with children of non affected mother where 
the morbid risk was 2.3%. (Tienari et al., 2000). 
All these studies suggest that schizophrenia and in fact psychotic disorders cluster in families and 
that genetic liability plays an important role. However, as suggested by Tienari et al in 2004, high 
risk adopted away children do experience more adverse life events than children reared with healthy 
parents, putting forward the argument for gene and environment interaction. 
2.1.2 Linkage Studies 
One of the main classical methods of detecting chromosomal regions associated with schizophrenia 
has been linkage analysis. The principle of genetic linkage is that given one or more alleles on 
different loci which are closely localised on the same chromosome, tend to be co-transmitted as 
there is a low probability of recombination between them.  
The Schizophrenia Research Forum quotes that to date 32 major linkage studies have been 
performed in schizophrenia spectrum disorders and also four meta- linkage analyses. Results from 
a meta-analysis performed by Badner and Gershon in 2002 identified three main regions: 
chromosome 8p, 13p and 22q.  
One of the most interesting results of the linkage studies is the discovery of region 22q. A deletion 
on 22q11 causes a disorder called Velo-Cardio-Facial syndrome. Affected individuals are at higher 
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risk of developing schizophrenia compared to the general population. In a study by Murphy et al., 
in 1999, rates of schizophrenia among 50 adult males with Velo-Cardio-Facial syndrome were 
estimated to be 24%, therefore, putting this population at very high risk. Although this deletion does 
not account for the majority of cases of schizophrenia, certainly gives some insight to a genetic loci 
implicated in the disease. Interestingly, among many the genes lying on the 22q area of the 
chromosome, the COMT gene analysed in this study is one of them. The COMT gene is particularly 
interesting as it plays a key role in the catabolism of dopamine, and of course dopamine is 
implicated in the pathogenesis of schizophrenia (Howes and Kapur, 2010). Linkage studies 
nowadays can be carried out in much larger scale with genome wide linkage studies. Suarez et al., 
(2006) conducted a study in 409 European and American ancestry families and found areas in 
chromosome 8p23.3-p21.2 in schizophrenia and areas in 11p13.1-q14.1 in both schizophrenia and 
bipolar disorder.  
Even more recently, the work of Byerley et al., (2011) implicated chromosome 16p in bipolar 
disorder. Vassos et al., (2012) suggested strong association at the 3p21.1 locus for bipolar disorder.  
However, linkage studies have not been successful in consistently identifying loci in schizophrenia. 
Some of the reasons of this lack of consistency might be related to the facts that Schizophrenia is 
now considered a complex disorder consequent upon many small genes of small effect rather than 
few genes of major effect. In addition, it may also be due to the heterogeneity of the sample studied 
given the fact that schizophrenia can be considered a spectrum rather than a single disorder.  
2.3 Association Studies 
Association studies examine whether genetic variants are associated with a disease trait. Alleles or 
genotypes frequencies are analysed in both diseased and control populations. Although study 
designs may vary, there are three main ones:  
1. Cohort study design using a sample to be followed up (prospective study);  
2. Family based design using families with one or multiple affected individual or trios, usually 
proband and both parents;  
3. case-control design using the same number of case and matched controls (some studies may 
require larger number of controls in order to reach enough statistical power).  
Genetic markers can be of different types with the most commonly analysed being Single 
Nucleotide Polymorphisms (SNPs). SNPs are point mutations occurring on a single nucleotide and 
are frequent within the general population with allele frequency of >1%. Association studies 
explore the difference in allele frequency between cases and controls with the hypothesis of:  if the 
studied allele is involved in the pathophysiology of the disorder, it should be over expressed in the 
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cases population. Other types of markers analysed in association studies can be rarer point 
mutations (freq. <1% in general population) or Copy Number Variations. Association studies in 
psychosis as in other complex disorders have been proven to be difficult because of multi-factorial 
or multiple genes involved and also their interaction with environmental factors.  
From association studies it is possible to detect both directly and indirectly associated variants, 
where the first is directly interacting with the trait and the second in Linkage Disequilibrium with 
an untyped causative variant. Linkage Disequilibrium refers to the non random association of alleles 
at two or more loci. In a recent review it was shown that there are over 1400 association studies 
have been carried out in schizophrenia covering around 6550 polymorphisms within 761 genes 
(Hon-Cheong et al., 2009). Molecular genetics techniques have evolved exponentially in the past 
few years allowing the analysis of many variants at the same time in much larger samples. This has 
led to the increase in positive as well as negative associations. During the years, the research for 
genetic markers has focused on candidate genes, mainly important genes in the regulation of 
implicated neurotransmitters or genes located on or in the proximity of an area that returned 
significant results after linkage analysis (The Schizophrenia Research Forum) 
With the candidate gene approach, genes within the dopaminergic system have widely been 
investigated with the dopaminergic receptor genes DRD2 and DRD3 being among the favoured 
candidates (Ariami et al., 1994) (Kaneshima et al., 1997) (Dubertret et al. 2001) (Crocq et al., 1992) 
(William et al., 1998). However, many associations failed to be replicated (Harano et al, 1997) 
(Nanko et al., 1994) (Sanders et al., 1993) and other findings seem not to agree with previous studies 
(Elvidge et al., 2001). 
The DAO and DAOA genes situated on chromosome 13q have been also extensively studied in 
schizophrenia. Both showed association with schizophrenia (Sullivan et al., 2000) (Detera-
Wadleigh et al., 2006) with DAOA also implicated in Bipolar Disorder (Prichard et al., 1992) 
(Williams et al., 2006). 
In addition, another widely investigated dopaminergic gene has been COMT gene. As mentioned 
before, COMT is situated on the long arm of chromosome 22 at 22q11 position. The same region 
returned positive results in several linkage analysis and meta-analysis (Pulver et al., 1994) (Badner 
and Gershon, 2002). A functional polymorphism (Val158Met) situated in the COMT gene has been 
extensively studied and a haplotype within the COMT gene has been found significant both in 
schizophrenia (Shifman et al., 2002) and bipolar disorder (Shifman et al., 2004). Further details on 
the COMT gene and its implications in schizophrenia are given in chapter 3 of this thesis. 
Another gene that has gained attention as a candidate gene in schizophrenia is RGS4. It is situated 
on the long arm of chromosome 1 and has been found to be expressed less in brains of patients with 
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schizophrenia (Mirnics et al., 2001). In addition, RGS4 has been associated with schizophrenia by 
several studies, with stronger evidences coming from a haplotype at the 5’ end of the gene 
(Chowdari et al., 2002). 
Association studies are based on the association of a specific phenotype or marker for the disease 
with the candidate gene with a putative role in that disease trait. These studies should be more 
powerful than linkage studies as it directly tests the disease marker. However, although many of 
the described association studies have shown positive results, they are not consistently replicated. 
It has been argued to be related to small sample size to detect a genetic effect and therefore, GWAS 
approach has reached more popularity in genetic research. 
2.4 Genome Wide Association Studies 
The aim of GWAS is to genotype very large numbers of SNPs genome wide in a case-control design 
analysis. GWAS represent the newest method that offers a hypothesis-free analysis as it analyses 
the whole genome and have been crucial to the identification of genetic variations associated with 
many diseases including for example Type II Diabetes, Crohn’s Disease and breast cancer. GWAs 
commonly used panels include up to 1 million SNPs plus markers in linkage disequilibrium (non-
random associations of SNPs). In a GWAS, all subjects included in the group of cases should meet 
lifetime criteria for the disease and controls should be drawn from the same population and should 
never have met the criteria for the disease (Corvin et al., 2010). GWAS are used to test individuals 
for point mutation within the DNA, but they are also an important tool to detect Copy Number 
Variations (CNVs), DNA duplications and deletions (Hosak et al., 2012).  
In association studies such as GWAS, the strength or effect size is usually measured with Odds 
Ratio (OR) as proportion of variance explained for “quantitative trait” such as brain volume or for 
“discrete trait” such as diagnosis. In this way, the SNPs identified are believed to mark a region of 
the human genome that increases the risk for the illness (Pearson and Manolio, 2008). The 
advantages of the GWAS over candidate gene association studies lies in the possibility of looking 
at the whole genome at once rather one or few genetic regions. Moreover, the quality control that 
these studies undergo is much more restrictive than candidate gene approach. For example 
population stratification can be adjusted using information from the genetic markers that enable the 
fine estimation of ethnic stratification. In this way, ancestral genetic heterogeneity can be better 
controlled for. Despite these advantages, GWAS studies also carry some disadvantages, for 
instance, in order to reach Genome Wide significant, a multiple correction is needed, that is to 
correct for the number of SNPs analysed. Significant p-values in GWAS are therefore smaller than 
ordinary association studies and less than 10-8. Association can be replicated in an independent and 
larger sample which is usually more difficult to attain (Pearson and Manolio, 2008) or explored 
further with meta-analysis. 
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The first GWAS was published in 2005 by Klein et al. for macular degeneration disease, and to 
date there have been several systematic Genome Wide Studies (GWAS) in schizophrenia. In the 
last years there has been an increase in findings of susceptibility loci in schizophrenia thanks to the 
newest techniques and collaborations like the Schizophrenia Consortium. More than 70 
independently associated alleles were found with GWAS studies, all of which of a small effect size 
which together they may explain less than 5% of the genetic variance in schizophrenia (Corvin A., 
2013).  
GWAS performed in schizophrenia supports the idea of a polygenic disorder with a complex 
biological aetiology; therefore, several genes of very small effect may each contribute to the 
heterogeneous phenotype observed clinically. By increasing the sample size, several genes 
implicated in neurodevelopment, immunology, neuroplasticity and neuroendocrinology are 
emerging, following the trend previously observed in other diseases like Type 2 diabetes and Crohn 
disease (Corvin A., 2013). However, as noted by Corvin, some variants will have such a small 
effect, that could go undetected. One of the genes emerging from the GWAS studies is the 
ZNF804A (O’Donovan et al., 2008) (Shi et al., 2009) which has also been associated with neural 
activation during memory tasks in healthy volunteers by Hashimoto et al. in 2010. Hashimoto et al. 
(2010) also demonstrated poorer performance on verbal and visual memory and delayed recall in 
patients with schizophrenia (p<0.001). Other genes found significant in GWAS, like CACNA1C, 
TCF4 and NRGN (Stefannson et al., 2009) (Bergen at al., 2012) (ISGC&WT, 2012) (Arberg et al., 
2013) (Smoller et al., 2013) are genes involved in ion channel and synaptic function and target of 
specific miRNA (O’Donovan et al., 2012). 
Neurodevelopmental genes have also been implicated in other disorders such Intellectual Disability 
and Autism with the latest findings coming from the GWAS performed by Smoller et al., in 2013. 
Several overlapping genes have been found, thus suggesting the possible implication of factors 
important for neuroplasticity and neurodevelopment, like synapse maturation and receptor 
abnormalities (Hosak et al., 2012). Furthermore, the PRODH gene, also reported significantly 
associated by GWAS (Alkelai et al., 2011) in pre-frontal cortex and striatum connectivity and 
function in a family based study of schizophrenia. Moreover, it has also been described in the 
pathophysiology of schizophrenia with a risk haplotype associated with decreased striatal volume 
(Li et al., 2008). It was also found that the striatal frontal functional connectivity was increased (Li 
et al., 2008).  
In addition, genes like the HLA gene, significant in GWAS (Stefannson et al., 2009) (Shi et al., 
2009) (Purcell et al., 2009) (Bergen et al., 2012) (ISGC&WT, 2012) has given rise to an 
immunological hypothesis of schizophrenia.  
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It is important to note that findings of GWAS, although highlighting the tip of the iceberg, give us 
important clues on the biology underlying the disorder. It is quite striking the fact that previously 
associated loci by association studies in candidate genes are not being seen significant in GWAS. 
This could be due to the fact that previous effect sizes might have been over estimated in these 
studies. With the current hypothesis of schizophrenia, like other complex disorders, being a 
polygenic syndromic disorder, we know of the presence of many variants of very small effect each. 
As mentioned earlier, some variant may have such a small effect that would be undetected by 
statistical analysis; we therefore understand the importance of a very large sample size, which is 
achieved mainly through collaboration in GWAS. This is one of the strength points of this type of 
association studies. It is perhaps only now, despite of many years in search for pathogenic variants, 
that the genetic structure of schizophrenia is being unrevealed; one of the next steps will surely be 
sequencing of the whole exome in a large sample size. This will not only underpin common variants 
of small effect, but also larger rarer variants of a much bigger effect, thus helping resolving a step 
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Table 2.1 Latest findings from GWAS performed in Schizophrenia 
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Purcell et al., 
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Bergen et al., 
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2.5 Copy Number Variation Studies 
Copy Number Variations (CNVs) are polymorphic structural variations of a segment of DNA of at 
least 1kb in size. Variation of less than 500K in human DNA in copy numbers, are far more common 
than initially thought, as demonstrated by Sebat et al. and Lafrate et al., in 2004. Although estimated 
to be of approximately more than 1000 in the genome, and therefore far less in number compared 
to SNPs, their estimated contribution to the total variation in the human genome is thought to be 
very similar, due to their size (Malhotra and Sebat., 2012). This is to say that although CNVs 
occurrence is lower and their rate of structural mutation is also low, they can span tens of thousands 
of kilobases per site and therefore have a larger functional impact (Melhotra and Sebat., 2012). 
CNVs have revolutionised the way we understand the genetic architecture of complex disorders 
like Autism Spectrum Disorders, Intellectual Disabilities, Bipolar Disorder and Schizophrenia. 
Sebat et al., in 2009 demonstrated a significant role of rare (<1%) and large (>100kb) in 
schizophrenia and several studies observed a 1 to 3 folds enrichment in cases versus controls (Walsh 
et al., 2008) (ISC, 2008) (Kirov et al., 2009) and in “sporadic” cases versus “familial” cases (Xu et 
al., 2008). These findings were however not replicated by subsequent studies, although a higher 
rate (5%) of de novo CNVs was observed in patients versus controls. (Kirov et al., 2012) (Malhotra 
et al., 2011).  
Several regions of the genome have been implicated in schizophrenia, with the most common being 
in genes related to neurodevelopment (Walsh et al., 2008), in support of the neurodevelopmental 
hypothesis of Schizophrenia. Kirov et al., in 2012 demonstrated in a recent experiment that 
components of postsynaptic density like the neuronal activity-regulated cytoskeleton-associated 
protein postsynaptic signalling complex and the NMDAR receptor were significantly more present 
in de novo CNVs (Kirov et al., 2012). 
The two models that are coming out in view of the recent findings are the Common Variants 
Common Disease model, where multiple variants at multiple loci play small and different role in 
the pathophysiology of the disorder (causative, modulator, protector, and mediator) and; the Rare 
Variant Common Disease model, where larger rarer structural variants confer a higher risk for the 
disease. However, these two models are not mutually exclusive as it is plausible that both models 
could act together within the same disorder.  Schizophrenia is a syndromic disorder characterised 
by three main clusters of symptoms, such as positive, negative and cognitive symptoms, as 
discussed in Van Os and Kapur, 2009. Therefore, it is thought that different structural variations or 
common polymorphisms might produce different symptomatology on a continuous scale giving 
rise to the development of a particular symptom, the variety in intensity of symptoms or the duration 
particular symptoms in psychotic illnesses. Furthermore, the same structural variation may be found 
at a lower rate in the control population, as noted by Malhotra and Sebat in 2012 highlighting the 
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issue of possible modulators like epigenetic factors or the role of the environment for the 
development of the disorder.   
2.6 Gene x Environment Interaction Studies  
In order to understand complex disorders such as schizophrenia, genetic information should be 
analyzed together with the putative influential environmental factors. This thought has led to a 
prolific area of research in schizophrenia with several interesting findings on the role of the 
environment in the development of the illness. 
Studies looking at the role of environmental factors have described that early environmental insults 
such as winter birth can influence the development of schizophrenia. In addition, obstetric 
complications have been widely studied and it is now accepted that they confer an increase risk of 
schizophrenic disease. Cannon, Jones and Murray in 2002 conducted a systematic meta-analysis of 
all paper published on the subject and found that obstetrical complications could be grouped in 
three separate groups: 1. Complications during pregnancy; 2. abnormal foetal growth and 3. 
complications during delivery. All categories conferred higher risk of the disease with effect sizes 
of less than two (Cannon, Jones and Murray, 2002). Nutritional deficiency during pregnancy has 
been associated with risk of schizophrenia and in patients with schizophrenia has been shown to be 
associated with decreased intracranial volume and other brain abnormalities (Hullshoff et al., 2000).  
Another well reported environmental factor to influence the development of psychosis is “stressful 
life events” which started to gain recognition as a risk factor for psychosis after the study by Brown 
and Birley in 1968. Since then, an increase in stressful life events in the months prior to the onset 
of a psychotic episode have been reported (Bebbington et al., 1993). Interestingly, stress has also 
been associated with relapses in psychosis (Ventura et al., 1989). Despite these promising results 
where there seems to be a correlation between stressful life events and the risk of developing 
psychosis, it is very important to further explore whether stress has a causal relationship with 
psychosis or if it is a consequence of the disorder.  
Another field of investigation into environmental predisposing factors is investigating in traumatic 
experiences that happen early in childhood, in particular childhood physical and sexual abuse or 
loss of a parent. Many studies have shown an association with exposure to trauma early in life and 
predisposition to psychiatric disorders (Nemeroff, 2004, Stein et al., 1996). For instance, early 
childhood traumatic experiences have been reported to occur in excess in psychosis and also in 
anxiety disorders (Stein et al., 1996).  
Another environmental factor is urbanicity which has also long been considered a risk factor for 
psychosis. The first studies linking urban cities to increased risk of psychosis date back to 1956 by 
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Hare. In a meta-analysis McGrath et al., in 2004 showed that the risk of Schizophrenia is higher in 
cities rather than in mixed or rural areas. The incidence of psychotic disorders in the UK can be 
considerate higher in certain areas like the South-East London (Kirkbride et al., 2006). In a meta-
analysis, Jim Van Os and colleagues analysed findings from 10 separate studies. They found that 
the rate of schizophrenia in urban cities can be considered doubled compared to rural areas; the 
statistical analysis was corrected for several confounders like gender, age, education and drug abuse 
(Van Os et al., 2005). These finding seem to be robust across Countries and Cultures. 
Finally, substance misuse is another environmental factor that has captured a lot of attention for the 
schizophrenia research in particular gene environment interaction. It is estimated that the 
schizophrenia population has one of the highest rates of nicotine dependence. Cannabis is also 
among the most used recreational drugs by both the psychiatric and general population.  Moreover, 
cannabis use in the psychiatric population has been shown to be double than in the general 
population (Bernett et al., 2007). Very often, people in general report the use of cannabis to 
overcome negative feeling or to “feel happier” supporting the “self medication” hypothesis of 
schizophrenia (Howes et al., 2004). In his paper, the authors formulate several hypotheses to explain 
these findings: 1. Psychotic patients are more likely to consume cannabis for the self medication 
hypothesis; 2. Cannabis could cause psychosis; 3. Cannabis could contribute to the risk of psychosis 
by precipitating a chain of events; 4. Cannabis could prolong psychotic illness in people already 
affected.  
 
In order to further explore the role of environmental factors in the development of psychosis I aim 
to investigate the presence of an interaction between cannabis sativa and several markers within the 
Cannabinoid 1 receptor gene and the COMT gene in the aetiology of schizophrenia. The role of 
cannabis is also investigated to check for a main effect on this illness in a case-control analysis and 
for a mediation role. Literature on cannabis consumption and psychosis is reviewed in light of the 
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3.1 Cannabis Sativa and its origins 
Cannabis is the world’s most popular recreational drug. In Europe, use increased significantly 
across the continent in the last three decades of the 20th century, and it is now estimated that 40% 
of young Europeans have tried cannabis at least once in their life (United Nations Office on Drugs 
and Crime, 2006). Cannabis was first grown in Central Asia and then spread to the rest of the world. 
Nowadays, numerous names are given to cannabis, depending on the cultivation method, 
consumption method, plant strain and parts of the plant but traditionally, there were three main 
varieties: cannabis sativa (found in warmer climates like Thailand, Mexico and South Africa); 
cannabis indica (found mainly in Northern India) and cannabis ruderalis (less common and grown 
wild in Central Asia). In recent years, a fourth variety of cannabis has become popular; “sinsemilla” 
which refers to plants cultivated with a method which uses the non-fertilized female plant. In this 
way, the female plant grows to maturity without any contact with the male plant, producing flowers 
without seed; hence its name from the Spanish language “sinsemilla” “without seeds”.  
The various types of cannabis differ in their concentration of Δ9Tetrahydrocannabinol (THC), the 
main psychoactive component, and the other major ingredient, cannabidiol (CBD); the latter does 
not impair cognition and may have anti-psychotic effects. During recent decades, certain types of 
cannabis have been re-engineered in order to maximize the level of THC, minimize the size of the 
plants and increase their strength for better survival. It is estimated that since the 1960s, the potency 
of street cannabis has almost doubled, partly due to plant crossing (United Nations Office on Drugs 
and Crime 2006). However, levels of THC may also vary depending on type of production and 
preservation techniques.  
The CNR1 and the COMT genes in First Episode of Psychosis Page 41 
 
3.2 Cannabis and Psychosis 
It is well known that in those with established psychosis, continued use of cannabis is associated 
with poor outcome and with more frequent and earlier relapses (Grech et al., 2005). More 
worryingly, a number of studies have indicated that exposure to cannabis is associated with 
cognitive impairment and increased risk of developing psychosis (Ashton, 2002; Arseneault et al., 
2004; Moore et al, 2007). As far back as 1987, Andreasson described an association between 
cannabis use and onset of schizophrenia (Andreasson et al., 1987). This landmark cohort-study of 
more than 45,000  Swedish male conscripts (representing 97 percent of men age 18-20 in the 
population) and a 15-year follow up, found that heavy use of marijuana at age 18 increased the risk 
of schizophrenia later in life by six times. There was a dose-response relationship between cannabis 
use at age eighteen and the diagnosis of schizophrenia 15 years later. However only 3% of heavy 
cannabis users went on to develop schizophrenia, suggesting that cannabis might exert its causal 
role only in already vulnerable individuals. Since then a number of studies have investigated the 
association between cannabis and psychosis. These were summarised in a meta-analysis by Henquet 
et al. 2005a, which concluded that overall cannabis consumption was associated with a doubling of 
the risk of schizophrenia. More recently, Kuepper et al., conducted a 10 years follow up study, 
demonstrating that continued cannabis use, increased the risk of incident and persistent psychotic 
symptoms (Kuepper et al., 2011). 
Verdoux et al. studied the interaction of cannabis use and psychosis in a non clinical population. 
The authors concluded that subject’s level of vulnerability can modify the effect of cannabis such 
as subjects with high vulnerability are more likely to report adverse or unusual experiences during 
cannabis consumption (Verdoux et al., 2003). However, there was no evidence that cannabis use 
was increased following onset of psychotic symptoms (Verdoux et al., 2003).  
Henquet et al., 2005b showed that baseline psychosis liability (attenuated psychotic symptoms 
and/or positive family history of psychosis) did not predict later cannabis use. Similarly, the 
longitudinal cohort study from Christchurch, New Zealand, which used statistical modelling in an 
attempt to distinguish between the causal and self-medication hypotheses, reported that the data 
were more compatible with a causal rather than a self-medication explanation. Thus, cannabis use 
increased risk of later psychosis, but the development of psychotic symptoms tended to decrease 
the subsequent consumption of cannabis (Fergusson et al, 2003). 
Lately, Griffith-Lendering et al., proposed a model of bidirectional causal association between 
cannabis and psychosis. It was found that psychosis vulnerability at age 13, predicted cannabis use 
at 16 and 19 years of age (Griffith-Lendering et al., 2012). Furthermore, it was also found that 
cannabis use at 16 years of age, predicted psychosis vulnerability at 19 years of age (Griffith-
Lendering et al., 2012). Most recently, Freeman et al., analysed 1714 individuals from the general 
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population, with the assumption that psychotic experience can occur as a quantitative trait in the 
general population (Freeman et al., 2013). Results showed a significantly higher level of 
persecutory ideation within the group of people using cannabis; furthermore, these subjects were 
twice as likely to report any paranoid ideation within the last month (Freeman et al., 2013). 
3.3 Are some individuals at greater risk? 
The above evidence suggests that cannabis consumption may have long term effects on mental 
health.  Recent research has found that the risk is greater in those subjects who initially show some 
psychosis predisposition such as attenuated psychotic symptoms and/or positive family history for 
psychosis (Henquet al al., 2005b). Moreover, it appears that the timing of use may be important; 
use in adolescence seems to be more hazardous (Arsenault et al, 2002). These finding have also 
been confirmed by Estrada et al., who reported that subjects that were exposed to cannabis earlier, 
had an earlier onset of psychiatric disorders (Estrada et al., 2011). Dragt et al., also demonstrated 
that the younger the age of consumption, the earlier the onset of psychotic symptoms (Dragt et al., 
2010). Genetic vulnerability is supported by evidence of a gene by environment (G x E) interaction 
between a functional polymorphism in the Catechol-O-Methyltransferase gene (COMT) and 
exposure to cannabis; the enzyme produced by the COMT gene has an important role in the 
breakdown of dopamine in the prefrontal cortex. COMT appears to moderate the influence of 
adolescent cannabis use on the development of adult psychosis, with a five-fold increased risk of 
developing schizophreniform disorder in cannabis users with the high activity Val allele (COMT) 
(Caspi et al., 2005).  
Furthermore, Henquet et al. in a double blind, placebo controlled cross over study with psychotic 
patients, relatives and healthy controls showed that carriers of the Val allele were more sensitive to 
psychotic experience induced by the compound and to worst results in memory and attention tasks; 
the same subjects showed prior psychometric psychosis liability (Henquet et al., 2006). Lately, 
Estrada et al., in the previous mentioned study, also reported that the Val allele carrier, showed an 
earlier onset of psychiatric disorders compared to Met carriers, therefore suggesting that the COMT 
rs4680 polymorphism modulates the interaction between cannabis and psychiatric disorders 
(Estrada et al., 2011). Such findings are supported by O’Tualthaigh et al., who conducted an animal 
study on COMT KO versus WT mice and found a gene X environment interaction (COMT X 
cannabis) on schizophrenia endophenotypes (O’Tualthaigh et al. 2012). The authors reported that 
COMT KO mice showed more vulnerability to the effects of cannabis on prepulse inhibition (PPI). 
Furthermore, cannabis adolescent exposure also had differential effects on anxiety and social 
behaviour in COMT KO mice versus WT mice (O’Tualthaigh et al. 2012). Acute inhibition of 
COMT also modified cannabis effects on startle and PPI reactivity (O’Tualthaigh et al., 2012).  
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Many studies, however, also failed to demonstrate the existence of an interaction between the 
COMT gene and schizophrenia. Munafo et al., found no association of rs4680 within the COMT 
gene and schizophrenia in a meta-analysis of case control studies (Munafo et al., 2005); furthermore 
Costas et al, also found no evidence of interaction between COMT haplotypes and cannabis in a 
case control study of schizophrenia (Costas et al., 2011). Zammit et al, in a well presented 
longitudinal study of 2630 individuals, on the interaction of COMT and cannabis in schizophrenia, 
found that cannabis was associated with self-reported psychotic experiences, but polymorphisms 
within the COMT gene, did not show any significant statistical interaction (Zammit et al., 2011). 
The COMT Val/Met allele also failed to be associated with Cognitive Remediation Therapy (CRT) 
in schizophrenia, thus not acting as a useful biomarker for cognitive improvement (Greenwood et 
al., 2011). 
3.4 Experimental studies of the effects of cannabis on psychopathology 
Acute cannabis intoxication can elicit transient psychotic symptoms. This has been documented in 
both clinical and experimental settings (D’Souza et al, 2004). Makela et al conducted a double 
blind, placebo controlled, and within-subject study in 19 healthy subjects. 5mg of sublingual Δ9-
THC and placebo were administered and all subjects tested for spatial working memory using tasks 
known to be depended upon frontotemporal neural circuits (Makela et al., 2006).  Results showed 
a significant increase in intrusion errors during spatial working memory tasks performance in males, 
however, in females, Δ9-THC seemed to enhance performance (Makela et al., 2006).  
Leweke et al., studied the effect of nabilone, a psychoactive synthetic 9-trans-ketocannabinoid and 
cannabidiol in a group of healthy volunteers on binocular depth inversion and behavioural state 
(Leweke et al., 1999). It was found that an impairment of binocular depth inversion after nabilone 
administration was attenuated by subsequent administration of cannabidiol (Leweke et al., 1999).  
Henquet et al., conducted a double blind, placebo controlled cross over study with psychotic 
patients, relatives and healthy controls. All subjects were exposed to 300μg/Kg of Δ9-THC in 
tobacco cigarettes or placebo and assessed with cognitive tests done by computer (Henquet et al., 
2006). Tests were used to assess verbal and visual memory and attention and were analysed together 
with COMT genotyping data (Henquet et al., 2006). Results showed that Δ9-THC generally 
worsened performances on cognitive tests and that, carriers of the Val COMT allele were more 
sensitive to psychotic experience induced by the compound and to worst results in memory and 
attention tasks if they showed prior psychometric psychosis liability (Henquet et al., 2006). Data 
thus suggest that the COMT gene and particularly the rs4680 SNP may moderate the effect of Δ9-
THC, where pre-existing psychometric psychosis liability exists (Henquet et al., 2006).  
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Pisano et al., in 2006 demonstrated that in hippocampus and prefrontal cortex an increase in 
dopaminergic activity following administration of THC is observed (Pisanu et al., 2006).  
Morrison et al., completed a randomized double blind study of the effects of intravenous THC 
(2.5mg) in 22 psychiatrically well male subjects (Morrison et al., 2009). Similar to the findings of 
D’Souza and colleagues, THC elicited a transient increase in positive psychotic symptoms as 
measured by the PANSS (Morrison et al., 2009). Participants also rated themselves on the CAPE 
scale (Community Assessment of Psychic Experiences; Stefanis et al 2002) and a reasonable 
correlation in psychosis scores between both scales (Spearman’s rho, r= 0.63, p<0.001) was 
observed (Morrison et al., 2009). The same author also found that THC elicited schizophrenia-like 
negative symptoms in a study of 22 psychiatric well male subjects, after intravenous administration 
of THC (2.5mg) (Morrison and Stone, 2011). Plasma levels of THC could be compared to the ones 
observed in recreational use (Morrison and Stone, 2011). Englund et al., in a between-subjects 
design study, found that in subjects who were administered CBD before THC, psychotic symptoms 
were less likely to occur compared to those who had a placebo before the THC; post-THC paranoia 
was also less present in the CBD group (Englund et al., 2013). Furthermore, the same group of 
subjects experienced less memory impairment (Englund et al., 2013). CBD appears therefore to 
moderate the effect of THC-elicited paranoid symptoms and memory impairment.  
3.5 Endocannabinoid Mechanisms 
The psychotogenic properties of cannabis are, almost certainly, attributable to Δ-9-
tetrahydrocannibinol (THC) via stimulation of the CB1 receptors in the brain.   
The CB1 receptor is the most common G-protein coupled CNS receptor. Levels are high in the 
frontal cortex, the basal ganglia, the hippocampus and the cerebellum. (Perhaps not coincidentally, 
each of the aforementioned regions has been proposed as a locus for the pathophysiology of 
schizophrenia, at one time or another).  
Studies of the hippocampus and cerebellum have been invaluable in establishing general features 
of the endogenous cannabinoid (endocannabinoid, eCB) system (Kawamura et al., 2006; Matyas et 
al., 2006; Uchigashima et al. 2007; Eggan et al. 2000). Briefly, principal output neurons (Purkinje 
cells, pyramidal neurones) synthesize and release endocannabinoids (eCBs) from their dendritic 
spines. Released eCBs stimulate CB1 receptors on neighbouring pre-synaptic terminals, which 
couple to Gi/o proteins and inhibit neurotransmitter (NT) release. Whilst short-term inhibition of NT 
release appears to be mediated by a direct effect of βγ subunits on Ca2+ and K+ currents, sustained 
inhibition requires effects on pre-synaptic intracellular signalling pathways (cAMP, MAPK). 
Across all the major brain structures where eCB signalling has been explored, both glutamatergic 
(excitatory) and GABA-ergic (inhibitory) terminals are direct targets for endocannabinoids. There 
is considerable current interest in exploring how eCBs are synthesized under physiological 
conditions and how different patterns of synthesis evoke short or long-term pre-synaptic inhibition.  
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Endocannabinoid dependent long-term depression (LTD) of synapses has been demonstrated in the 
hippocampus, the amygdala, the cerebellum and the ventral and dorsal striatum. At the behavioural 
level, it has been demonstrated that eCB signalling is necessary for new learning in the cerebellum 
and amygdala. In sensory cortices, eCBs are essential mediators of spike-timing dependent LTD 
(Bailey et al., 2000; Freund et al., 2003).  
Recently it has become apparent that the endocannabinoids function as crucial molecular cues in 
the development of the foetal nervous system (Harkany et al. 2007; Harkany et al. 2008). 
Endocannabinoids stimulate the proliferation of neural progenitors, provide instructions for glial 
cell fate, direct the migration of immature neurones and regulate axonal growth, pathfinding and 
target selection (Aguado et al. 2006; Berghuis et al. 2005; Berghuis et al. 2007; Mulder et al. 2008). 
In immature networks, where GABA is excitatory, eCBs function as key inhibitory transmitters 
(Bernard et al. 2005). Animal work has shown that perturbation of the endocannabinoid system 
during early development, either pharmacologically with agonists or antagonists or genetically, can 
lead to marked alterations at the cellular and circuit levels, (Bernard et al. 2005; Harkany et al. 
2007), and in-uterine exposure to CB1 receptor agonists can elicit long-term changes which impact 
on learning and memory performance in later life (Antonelli et al. 2005; Mereu et al. 2003). Given 
that the eCBs are involved in fundamental neurodevelopmental processes, it seems intuitive that 
human brains exposed to cannabis in-utero might show catastrophic, long-lasting 
psychopathological impairments. The available evidence does not support this; instead the long-
term effects of prenatal cannabis appear to be subtle, suggesting that compensatory molecular 
pathways may have developed (Fried and Smith 2001; Huizink and Mulder 2006). Several animal 
studies have investigated the effects of prenatal cannabis exposure (Antonelli et al., 2005) (Castelli 
et al., 2007) (Ferrari et al., 2009), thus reaching the conclusion that systematic cannabis exposure 
during the prenatal period, indeed leads to changes observed in behaviour and brain of the offspring.  
Two major studies, the Ottawa Prenatal Prospective Study (OPPS) and The Maternal Health 
Practices and Child Development Study (MHPCD) have followed up cohorts of children born to 
mothers who smoked cannabis (heavily) during pregnancy. Findings from the OPPS showed that 
in-uterine exposure to cannabis had no effect on the full-scale IQ as measured by the WISC-III 
(Fried 2002).  However children exposed to cannabis prenatally had an excess of impulsive, 
hyperactive and delinquent behaviours (Fried et al. 1992; Goldschmidt et al. 2000; Leech et al. 
1999), displayed poorer performance in tasks of verbal memory and executive functioning (Fried 
2002; Huizink and Mulder 2006) and showed poorer attainment of reading skills (Goldschmidt et 
al. 2004).  The effects of prenatal exposure to cannabis may operate by impacting on prefrontal 
performance in later life (Fried 2002).  
More recently, DiNieri et al., examined striatal dopamine and opioid genes in human fetal subjects 
exposed to cannabis (DiNieri et al., 2011). The author showed that D2 (DRD2) receptor mRNA 
expression was decreased in human ventral striatum (DiNieri et al., 2011). These findings were 
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taken further by modelling a study with mice. Pregnant rats were exposed to THC and the offspring 
examined. Results showed decreased DRD2 expression and reduced D2R binding sites in offsprings 
(DiNieri et al., 2011).  
There has been less work on whether prenatal cannabis exposure predisposes to later psychiatric 
morbidity. Findings from the MHPCD show that in-utero cannabis exposure predicts depressive 
symptomatology at 10 years of age (Gray et al. 2005) and pre-natal cannabis exposure may 
predispose to subsequent illicit drug misuse (Day et al. 2006; Spano et al. 2007). El Marroun et al., 
studied the relationship between prenatal cannabis exposure and aggressive and attention behaviour 
in offspring. (El Marroun et al., 2011). Results showed that there was indeed a relationship between 
prenatal cannabis exposure and behavioural problems in children, however only in girls in the 
aggressive behaviour and attention problems areas (El Marroun et al., 2011). Psychiatric morbidity 
could also be entirely related to home environment and would need further research. As yet, no 
studies have examined whether there is an association between prenatal cannabis exposure and the 
subsequent emergence of psychotic disorders. This is clearly an important question for further 
study. Furthermore, alternative genetic mechanisms may contribute, including maternal genetic 
effects or environmental factors that interact with genetics to cause schizophrenia. Maternal genetic 
risk factors could also mediate cannabis exposure, which in turn could influence in utero 




Figure 3.1 shows the retrograde transmission. Endocannabinoids are synthesized and released post-synaptically 
inhibiting neurotransmitter release from pre-synaptic terminals (Morrison and Murray, 2007) 
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3.6 Endocannabinoids and Psychosis 
The above evidence points towards the endocannabinoid system being impaired and playing a role 
in schizophrenia. It has been suggested that eCB impairment may be a proximal pathology in some 
forms of schizophrenia. As yet, post-mortem and PET studies of altered CB1 receptor availability 
in schizophrenia have been equivocal. Studies of the genetic variation in components of the ECS 
have begun to address this speculation, however, the CB1 receptor remains the most extensively 
examined. An AAT-repeat microsatellite in the 3’ flanking region of the CNR1 gene has been 
reported to be associated with the hebephrenic sub type of schizophrenia in a Japanese population 
(Ujike et al., 2002), a finding partially replicated in a recent study (Chavarría-Siles et al, 2008).  
However, another study failed to find an association between schizophrenia and this microsatellite 
or with other polymorphisms within the gene (Seifert et al., 2007).   This study (Seifert et al., 2007) 
also failed to identify any non synonymous polymorphisms after sequencing the coding regions of 
the CNR1 gene of 50 schizophrenic patients.  Negative results also came from the study of Zammit 
et al., where no evidence of genotype effect was found in CNR1 or COMT in a case-control study 
of schizophrenia (Zammit et al., 2007). There are, however, evidences of an interaction between 
polymorphisms within the CNR1 gene and cannabis use, as shown by Ho et al., in a study of 235 
schizophrenia patients (Ho et al., 2011). The authors investigated changes in white matter and 
cognitive deficits in schizophrenic patients exposed to cannabis. Results were suggestive of an 
interaction between a SNP within the CNR1 and cannabis use, in that, patients with the risk allele 
and positive cannabis use, showed smaller fronto-temporal WM volumes and worse performances 
in neurocognitive tasks (Ho et al., 2011). In the same cohort, there was also found a significant 
main effect of MAPK14 CNR1 diplotype and a G x E interaction with cannabis on WM brain 
volumes in patients exposed to cannabis. This effect seemed to be additive (Onwuameze et al., 
2013). As suggested by the authors, MAPK phosphorylation increase precedes CNR1 induced 
apoptosis, there could therefore be, a genexgene interaction as the basis of the structural 
abnormalities in white matter observed in this group of patients exposed to cannabis (Onwuameze 
et al., 2013). The CNR1 gene has also been associated with weight gain in schizophrenia by several 
studies throughout the years. Recently Yu et al., showed an association of several polymorphisms 
within the CNR1 gene and metabolic syndrome in schizophrenia (Yu et al., 2013).  Tiwari et al., 
also showed association between a SNP on the CNR1 gene and weight gain in patients treated with 
clozapine and olanzapine (Tiwari et al., 2010). The latest GWAS however, found no association 
between schizophrenia and the endocannabinoid system. This is suggestive of the presence of 
possible false positive in the above mentioned studies. On the other hand, other measures of the 
ECS, such as endogenous ligands have shown promising results, giving rise to the biological 
plausible endocannabinoid hypothesis. 
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Altered levels of anandamide, the endogenous compound of the ECS, have also been linked to 
schizophrenia. In a study of first-episode antipsychotic-naïve schizophrenic patients, Giuffrida et 
al (2004) found that CSF levels of anandamide exceeded by 8 times those of healthy controls. More 
recently, Leweke et al (2007) showed that CSF anandamide levels were altered in patients with low 
frequency and high frequency cannabis use. This was not observed in the control group, suggesting 
that use of cannabis and indeed frequency of exposure could contribute to the alteration of 
anandamide signaling in susceptible individuals (Leweke et al., 2007). An important key point in 
the mechanism of interaction between cannabis consumption and psychotic symptoms could 
therefore be subsequent changes in levels of AEA. Parolaro et al., suggested a possible explanation 
in the down-regulation of AEA caused by excessive consumption of cannabis (Parolaro et al., 
2010). Endocannabinoid levels disregulation have also been reported in mice models (Vigano et 
al., 2009) (Seillier et al., 2009). 
 
While the main component of cannabis, Δ9Tetrahydrocannabinol (THC), is believed to be 
responsible for the psychotic like effects that follows acute cannabis intoxication, cannabidiol 
(CBD) is thought to exert antipsychotic effects. In preclinical studies, CBD showed similar 
antipsychotic activity to haloperidol but with a lack of toxicity (Zuardi et al., 1991). Partial 
improvement of symptomathology of schizophrenic patients has also been observed in small 
clinical trials (Zuardi et al., 1995) (Zuardi et al., 2006). Moreover, when co-administered, CBD can 
reverse the psychotropic effect of THC (Zuardi et al., 1982). More recently, as mentioned earlier, 
Englund et al., showed that Cannabidiol (CBD) can inhibit THC-elicited paranoid symptoms and 
memory impairment (Englund et al., 2013). To date, the neurobiology of this mechanism remains 
still unclear, but CBD is being studied as a possible and less toxic alternative to antipsychotics. To 
date there have been many studies on animal models of CBD on mice and rats (Long et al., 2010) 
(Moreira and Guimaraes, 2005) (Malone et al., 2009) to cite a few. The present view, as expoused 
by Zuardi et al., is that CBD behaves as an atypical antipsychotic in preclinical studies, improving 
symptoms but not impairing motor functions of subjects (Zuardi et al., 2012). Its action could 
depend on the facilitation of glutamate activity in the prefrontal cortex, via increase in anandamide-
mediated CNR1 activation, thus causing glutamate activity to decrease (Zuardi et al., 2012). 
 
3.7 Interaction between Endocannabinoids and Dopamine  
 
The dopamine hypothesis of schizophrenia, dating back to the 60s, suggests that up-regulation of 
dopamine transmission in the brain is the underlying cause of the disorder. In 1996, Laurelle et al., 
showed that psychotic patients released excessive striatal dopamine after an amphetamine 
challenge; this positively correlated with the severity of symptoms (Laurelle et al., 1996). In 2005, 
Kapur et al. proposed the ‘motivational salience theory’ which postulates that striatal dopamine 
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release directs the process by which stimuli are given significance. Abnormal dopamine release 
leads to excessive significance being attributed to stimuli, hence the formation of delusions to 
explain such seemingly important yet confusing experiences (Kapur et al., 2005). Mice models have 
also been used to try to establish the effect of various known risk factors for psychosis on dopamine 
function. Seeman et al. (2005) showed that high affinity to the D2 receptors could be explained by 
a range of different factors ranging from Gene knock-outs, to obstetric events and to drug use. Up-
regulation of dopamine seems more likely to be the final ‘common pathway’ rather than the 
underlying cause of schizophrenia. 
Interactions between the DA and eCB systems are extensive (and complex) but several key (and 
unusual) findings are outlined here which at least illustrate the close relationship between DA and 
eCB signalling.  
It is well established that DA acting at D2 receptors in the striatum is necessary for eCB-dependent 
LTD of corticostriatal fibres, although at present the functional significance of corticostriatal LTD 
remains theoretical. At the behavioural level, repeat administration of THC evokes cross-
sensitisation to the effects of amphetamines. Furthermore, recent work indicates that CB1Rs have 
a role in the development of amphetamine sensitisation, (although diametrically opposed findings 
with receptor knockout compared to pharmacological blockade, hinders any explanation at this 
stage). Utilising in-vivo voltammetry, Cheer and colleagues (2004) have shown that the CB1 
inverse agonist SR141716A, (rimonabant) inhibited cocaine evoked DA release in the striatum. 
It appears that the two neurochemical systems interact most intimately at the level of D2-CB1 
dimerisation: Mackie and colleagues (1995) have shown that concurrent stimulation of both 
receptors leads to formation of a D2-CB1 protein complex. Remarkably, (and in stark contrast to 
the ‘traditional’ intracellular effects of D2 and CB1) the hetero-dimer preferentially coupled to Gs, 
and increased cAMP levels. Although the implications of this finding have yet to be appreciated, 
one possibility is that, in the presence of THC, striatal D2 receptors behave (in biochemical terms 
at least) like D1 receptors.   
 
Thus, it seems that endocannabinoids modulate (excitatory and inhibitory) inputs to dopaminergic 
neurones. This is of great interest since the epidemiological evidence suggesting an interaction 
between cannabis and COMT genotype in conferring risk for schizophrenia, implies that dopamine 
is involved (at some level) in the psychotogenic effects of THC. In an elegant experimental study, 
Henquet and colleagues (2006) showed that COMT genotype determined (in-part) whether healthy 
volunteers experienced an acute psychotic reaction following a standardised cannabis ‘joint’. 
Psychotic outcomes were associated with the Val allele providing experimental support for the 
epidemiological findings of Caspi et al (2005).  
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It has become clear that in animal studies CB1 agonists elicit burst-firing of midbrain DA neurones 
and increase striatal dopamine levels. The COMT Val allele appears to be associated with increased 
DA synthesis in VTA neurones. One suggestion is that individuals possessing the Val/Val genotype 
are more likely to experience THC-psychosis, because their DA systems are already ‘primed’. 
However, further work is needed to confirm both the epidemiological and experimental studies 
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CHAPTER 4 
MATERIALS AND METHODS 
 
This chapter contains a description of the main hypothesis of this work and illustrates the 
recruitment strategy for cases and controls as well as study sample characteristics... Hypotheses are 
explained in more detail in each experimental chapter (Chapters 5-8).  This chapter also contains 
detailed methodology on DNA handling and general methodology on laboratory techniques used 
to analyse samples. Details on laboratory procedure for each technique are given in chapter 6 
(TaqMan Genotyping Assay) and 8 (Microsatellite Analysis). 
Statistical methodology is reported in detail in each of the experimental chapters. This includes a 
summary of analytic approaches used, statistical software used, command lines used and 
description of output files. 
 
4.1 Main Hypothesis 
This is a case-control study in a cohort of hospital based psychotic patients and healthy matched 
controls. 
The goal of this study is to investigate the role of the CNR1 and the COMT gene in psychosis. In 
light of the published literature and knowledge of the biology of the Endocannabinoid and 
Dopaminergic Systems (outlined in the introductory chapters), I hypothesize that common 
variations within the CNR1 and the COMT gene play a role on the pathophysiology of psychosis 
and may also give an increase risk for the disorder by interacting with cannabis use.  
 
The two main areas of investigation of this work are: 
The involvement of common variants within the CNR1 and the COMT gene in the aetiology of 
psychosis 
The interplay of the CNR1 and the COMT gene with the environment - cannabis use- to give an 
increase of risk for psychosis. 
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4.2 Samples under investigation 
The samples under investigation are part of two large studies on first episode of psychosis: the 
Psychosis Incident Cohort Outcome Study (PICOS) and the Genetics and Psychosis study (GAP). 
The GAP Study is based in London at the Institute of Psychiatry, department of Psychosis Studies. 
The PICOS Study is based in Verona, Italy at the department of Psychiatry at Verona University. 
Both study samples consists of first episode psychosis subjects and non-psychotic volunteers. The 
recruitment strategy for both studies is a hospital-based incident case study for first episode patients. 
In the next sections there are details on cases and controls recruitment. 
4.2.1 The Genetics and Psychosis Study (GAP) 
4.2.1.1 Patients Recruitment 
Subjects were recruited from five hospital/health centres: Maudsley Hospital (Eileen Skellern 1, 
Eileen Skellern 2, Jim Birley Unit, Douglas Bennett 2 and Douglas Bennett 3); Guy’s hospital 
(Ruskin ward, John Dixon ward); Bethlem Royal Hospital (Alexandra ground floor ward, Gresham 
Psychiatric Intensive care unit, Gresham 1 & 2 wards); Lambeth Hospital (Lambeth Early Onset 
inpatient unit); and Croydon (COAST – Early Intervention Psychosis Service). The strategy for 
recruitment consists of regular contact of inpatients services by researchers of the GAP group. 
When a case of first episode of psychosis is identified, the subject is approached on site and 
carefully explained about study aims and assessment involved. The subject is then included in the 
study if all inclusion criteria are fulfilled and he or she agrees. Inclusion criteria are: 1. English 
fluency; 2. South East London residency; 3. Age between 18 and 65 years; 4. Being at the first 
episode of psychosis; 5.Subjects are within three months of the first contact with the psychiatric 
services. The exclusion criteria are: 1. Poor English fluency; 2. Psychosis due to acute intoxication; 
3. Suspected organic psychosis; 4. Presence of any disability that could impair judgment on giving 
consent for the study; 5. Age below 18 years. Subjects needed to consent to be sampled for DNA 
(through phlebotomy or collection of buccal cells) as this is the minimum requirement for 
participation in the study. Assessments were conducted at the various hospitals or at the IoP 
throughout several sessions. All subjects were reimbursed for their time according to ethical 
permission n. 0546734 and had the right to end their collaboration with the study at any time. 
Diagnosis was confirmed by the clinical research team through consensus meeting carried out by 
groups of four psychiatrists. Schedules for Clinical Assessment in Neuropsychiatry (SCAN) (World 
Health Organization Assessment, Classification and Epidemiology, Geneva 1999), Positive and 
Negative Syndrome Scale (PANSS) (Kay et al., 1987) and notes obtained from the electronic 
Patient Journey System are taken into consideration in order to reach a consensus diagnosis. SCANs 
and PANSS assessments are carried out by trained researchers of the GAP group. 
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4.2.1.2 Controls Recruitment 
Healthy volunteers were recruited in the south east London area (i.e. the same area as the patients). 
The study was advertised in local newspapers, job centres and two volunteer databases: Mindsearch 
(www.mindsearch.com) and Biotrax (www.biotrax.com). Prior to inclusion in the study, all 
volunteers were screened for psychosis by researchers of the GAP group by using the Psychosis 
Screening Questionnaire (PSQ) (Bebbington et al., 1995). Subjects were excluded if they scored 
positively for psychosis or for history of mental disorders or if sustained head injury or if 
undergoing hormonal treatment. 
If the Psychosis Screening Questionnaire did not outline any reason for exclusion from the study, 
subjects were asked contact details and joined a queue. Researchers would then call back and 
arrange a suitable time for meeting. All healthy individuals needed to also consent to be sampled 
for DNA (through phlebotomy of collection of buccal cells) as this was the minimum requirement 
for participation in the study. Assessments were carried out by researchers of the GAP group at the 
IoP in several sessions and subjects had the right to withdraw consent at any time. 
All subject recruited were carefully matched with the disease population for ethnicity, socio 
economical status, gender and age. 
4.2.1.3 Socio-demographic questionnaire 
The socio demographic questionnaire used in the present study is a modified version of the MRC 
Sociodemographic Schedule (Mallett et al., 2003). The SDS questionnaire was used for both cases 
and controls in order to collect data regarding age, gender, self rated ethnicity, level of education 
achieved and employment status. It comprises 19 items with multiple choice answers rated by the 
researchers. The Family Interview for Genetics Study (FIGS; Maxwell, 1992) questionnaire was 
also used. The FIGS allows collecting specific data regarding the family pedigree of probands and 
controls by asking the birth place of parents and grandparents. It also helps tracking migration 
status. 
In this study, all Caucasian subjects were grouped together including those reported to be British or 
white other by the questionnaire and all Black African, black Caribbean and mixed ethnicity with 
either black African, black Caribbean or black British were also grouped together. Subjects were 
therefore divided in two main groups: Caucasian and Black/mixed ethnicity when the study sample 
was ethnically stratified. When data analysis was carried out in the whole GAP study sample, all 
other ethnicities were included (Further details are given in the “Sample characteristics” section). 
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4.2.1.4 The Cannabis Experience Questionnaire (CEQ) 
Cannabis data were obtained by a screening questionnaire used for both cases and controls. The 
questionnaire is the revised version of the Cannabis Experience Questionnaire (Barkus et al., 2006) 
and it includes date of first use, preferred mode of use, frequency as well as data on self reported 
feelings before and after consumption.  The Cannabis experience questionnaire contains 19 items 
with multiple choice answers as well as an open answer. From item 14 onwards it collects perceived 
experiences while smoking and after. It also establishes type of cannabis used and quantity smoked 
during adolescence and adulthood. The questionnaire also collects information on other drugs used 
in combination or during the same period of time as cannabis consumption, this helps to correct 
data for possible confounders. The GAP Cannabis Experience Questionnaire is further explained in 
chapter 7 with reference to literature available and hypothesis under investigation. 
4.2.1.5 Sample characteristics 
The Genetics and Psychosis Study sample consisted of 516 participants: 169 non psychotic controls 
and 347 first episode patients. Cannabis data (cannabis ever used yes/no) were available for 459 
individuals: 312 cases and 147 controls. 
In this work and for all statistical analyses the GAP sample has been divided into two groups: 
Caucasian group 
Black group 
The two groups have always been analysed separately unless otherwise stated. 
The Caucasian group consisted of 219 individuals and the Black group (black Caribbean, black 
African and mixed ethnicity with either black Caribbean or black African) consisted of 208 
individuals. All individuals (89) with any other self reported ethnicity were excluded from any 
analysis. A summary of the GAP Study samples characteristics is shown in table 4.1. 
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4.2.2 The Psychosis Incident Cohort Outcome Study (PICOS) 
4.2.2.1 Patients Recruitment 
First Episode Psychotic patients were recruited by researchers of the PICOS study in Veneto 
Region, in North-East Italy. A representative cohort of subjects presenting at services with 
psychotic symptoms were included in the study from January 2005 to December 2008. Follow up 
was also carried out at 1 year, 2 years and 5 years. Inclusion criteria were: 1. Age between 15 and 
54 years old; 2. Being resident in the Veneto Region Community Mental Health Services catchment 
area; 3. presence of (a) at least 1 of the following: hallucinations, delusions, qualitative speech 
disorder, qualitative psychomotor disorder, bizarre or grossly inappropriate behaviour, or (b) at 
least 2 of the following: loss of interest, initiative and drive, social withdrawal, episodic severe 
excitement, purposeless destructiveness, overwhelming fear, marked self-neglect; 4. Being at the 
first contact with psychiatric services and not having received treatment for psychosis for more than 
3 months. Patients were excluded from the study if they met the criteria for organic brain disease.  
Patients were assessed with a set of standardised measures as follow: 
Schedule for Clinical Assessment in Neuropsychiatry (SCAN; WHO, 1992) 
Psychosocial and Environmental Stressors (APA, 1994), the Axis IV of DSM-IV, 
Scale for the Assessment of  Positive and Negative Symptoms (PANSS, Andreasen, 1984) 




  total number male % female % Cannabis users % 
Caucasian cases 174 65.7 34.3 39.1 
Caucasian controls 45 55.8 44.2 44.4 
Black cases 113 69.9 30.1 34.5 
Black controls 95 68.8 31.2 30.5 
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4.2.2.2 Controls Recruitment 
Non psychotic controls were recruited via the Blood Transfusion Service from the same catchment 
area of Verona, Italy. Subjects were excluded if personal or family history of psychotic disorders 
was positive, they were assessed with the SCID-NP (Spitzer et al, 1992) and the Family Interview 
for Genetics Study (FIGS; Maxwell, 1992). Data on self reported ethnicity was also collected to 
match cases and controls. Controls were recruited from the same area as cases; they were not 
matched for socio economic status. 
4.2.2.3 Sample characteristics 
The PICOS Study samples consisted of 654 participants (347 cases and 307 controls) of Italian 
Caucasian origins (99%). Cannabis data (Lifetime cannabis use yes/no) were only available for 
psychotic patients as non psychotic controls were recruited via the Blood Transfusion Centre (BDC) 
in Verona (Italy) and always tested negative for cannabis use during routine tests run by the BDC. 
No cannabis data were therefore used in any of the statistical analyses. No gender information was 
available. Details about numbers of subjects available for each statistical test are reported in each 
of the experimental chapters. 
4.3 DNA handling 
4.3.1 DNA extraction from blood 
Blood samples were collected using 1x 6ml EDTA tubes. DNA was extracted using the standard 
phenol chloroform extraction protocol. During the first day the EDTA tubes containing blood were 
placed in the cold room and subsequently the blood poured into a 50ml Falcon tube and made up 
to 45ml by adding red cell lysis buffer (RCLB). They were then mixed vigorously and placed on a 
shaker for 20mins. Falcon tubes were centrifuged at 1600rpm 25mins 18oC and carefully decanted 
to discard the supernatant.  Tubes were then left upside down on tissue to get rid of the last of the 
red cell debris. The pellet was resuspended in 1ml lysis buffer Slagboom and 2X (2ml per 100ml) 
and transferred to 15ml Falcon tube. They were placed on a rotator overnight (180rpm). 
The second day the Falcon tubes were incubated in a water bath at 65oC for 2.5 hours. The contents 
were poured into a single15ml tube and 0.25ml Majik Mix were added then all tubes were caped 
and again shaken vigorously. Tubes were subsequently centrifuged at 13000rpm for 20mins at 
18oC. 
The supernatant was decanted into fresh 15ml tubes and pellet discarded. 800uL of 100% 
isopropanol were then added; tubes inverted for 30 minutes and then again centrifuged at 13000rpm 
for a total time of 20mins at 18oC of temperature. On rack they were tipped upside down and 
supernatant discarded. Tissue paper was used to pat the top of the tubes before leaving them upside 
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down for a couple of minutes, then 1ml 70% ethanol was added. Tubes were then centrifuged again 
at 13000rpm for 20mins at 18oC and the supernatant discarded. Tubes were then left to dry on tissue 
paper for approximately 1.5 hours. Finally 980μL of TE were added and tubes placed in incubator 
oven overnight. 
 
Red Cell Lysis Buffer: 




100ml NaCl  1M 
10ml Tris HCl 1M pH 8 
20ml EDTA  0.5M pH 8  (EDTA will not dissolve until pH 8) 
50ml SDS  10% 
820ml dH2O 
Add 2% Proteinase K just before use. 
 
4.3.2 DNA extraction from cheek swabs 
Cheek swabs kits are created as follow: 2.5ml of Lysis buffer with Proteinase K was inserted in a 
15ml Falcon tube. Ten cheek swab buds are then placed in each tube. The dose for 100 kits is 250ml 
lysis buffer and 2.5ml Proteinase K. 
Proteinase K is consists of 1g Proteinase K (from Sigma)  50ml dH2O which is then aliquoted 
into 1ml and frozen. 
4.3.3 DNA volume measurement and quantification 
DNA volume for all extracted samples was calculated by weighing each sample on a digital scale 
in the laboratory. Firstly the tare was calculated by measuring the weight of an empty tube of the 
same kind, then one by one, all samples were weighed. Assuming that the 1ml of DNA at 4 oC 
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weighs 1gram, values expressed in grams on the scale were then simply changed to ml and then 
multiplied by 1000 in order to obtain values in μl. 
All data were entered in an excel file and subsequently in SADMAN, a smart database system 
created by Bernard Freeman (unpublished in literature and only used at the SGDP facility, Institute 
of Psychiatry, KCL) that allows fast tracking of individual samples as well as entire plates. 
SADMAN also stores information regarding date of extraction, date of quantification, methodology 
used and up to date volume and concentration of each sample. Quality control was performed in 
three plates and no discrepancies were found. 
DNA concentration was measured using the UV- Vis Spectophotometer NanoDrop machine from 
Thermo Scientific. The retention system used by the NanoDrop 2000 (UV-Vis Spectophotometer, 
Thermo Scientific) analysed very small quantities of DNA, the range can vary between 0.5μl to 
2.0μl. In this study it was decided to use 1.5μl because there is a consistent less possibility that air 
bubbles get inserted in the machine causing errors and therefore waste of DNA due to forced 
repetition of the measurement. All samples were decapped and prepared for the reading. The arm 
of the machine was cleaned with ddH2O and then vigorously wiped with laboratory paper wipes. 
Subsequently, 1.5μl of ddH2O was inserted in the arm in order to initiate the process and 1,5μl of 
ddH2O for a second time in order for the software to establish the blank measure. 1.5μl was then 
taken from each sample and pipetted onto the arm; the pedestal was then moved down to adjust for 
path length (0.05mm – 1mm) and then the arm was wiped clean. In order to obtain minimise errors; 
each sample is entered on the computer before measuring. This procedure was repeated for each 
sample. Quality control was carried out for 40 samples and discrepancies were not significant. Data 
are stored in the software of the NanoDrop and acquired in Tab format simply by using a USB 
memory and then converted into excel format in order to be analyzed. Data of all samples have 
been entered in SADMAN and are now available together with all information for each sample. 
All samples were diluted in ddH2O by using the Tecan Freedom Evo 200 Maschine (Tecan 
Integration Group) at the SGDP laboratory facility. 
Work plates were created using matrix storage plates of 96 wells and samples were diluted to 
10ηg/μl. Firstly a FX file was created in order to exactly calculate volumes and concentrations of 
each sample. To do this, information for SADMAN were used and then the file runs in the Tecan 
maschines computer. Few samples (around 10) were less concentrated due to problems during DNA 
extraction; they were kept at their original concentration and did not cause problems during 
genotyping for the majority of cases. Plates were stored at -20oC or at 4 oC during the day when 
experiments were being carried out. 
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4.3.4 DNA storage  
All samples are bar-coded, entered in SADMAN database system and stored at -80oC in freezer at 
the SGDP centre. Barcodes are created in sequence by the manager of the SGDP laboratory at the 
IoP after request is made by the GAP group. Barcodes are made of letters and numbers and are 
matched to progressive numbers on original folders stored at the main building of the IoP in order 
to facilitate tracking. Patients and controls are randomly assigned barcodes so that laboratory work 
can be blind and not be subject to bias. Clinical assessments of patients and controls can only be 
matched by following identification numbers present on paper folders. DNA is stored in storage 
matrix 96 wells plates and each tube is individually barcoded as well as the plate with its own 
identification name. All barcodes are then scanned into SADMAN and subsequentely all plates 
were stored at -80oC in freezers at the SGDP laboratory centre. 
4.4 SNPs selection 
4.4.1 SNPS within the CNR1 gene 
Markers of the CNR 1 gene have been selected using the international HapMap data and haploview 
program for tagging SNPs (Barrett et al., 2005).  
The HapMap is a catalog of common genetic variants that occur in humans.  
The construction of the HapMap occurs in three steps 
(1) Single nucleotide polymorphisms (SNPs) are recognized in DNA samples from various 
individuals. 
(2) Adjoining SNPs that are inherited together are compiled into "haplotypes" 
(3) "Tag" SNPs inside haplotypes are recognized that exclusively identify those haplotypes. By 
genotyping the three tag SNPs; researchers can recognize which of the four haplotypes are present 
in each individual. 
 
HapMap data have been generated thanks to the Human Genome Project and is now a public 
database of common variation in the human genome, accounting for more the a million Single 
Nucleotide Polymorphisms. Data on SNPs have been obtained by genotyping 269 DNA samples of 
four populations: CEU (collected from the CEPH for Utah residents with European ancestry), JPT 
(Japanese population from Tokyo), CHB (Chinese population from Beijing) and the YRI (Yoruba 
from Nigeria). Data generated by the HapMap document the generality of recombination hotspots, 
the structure of linkage disequilibrium and low haplotype diversity (The International HapMap 
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Consortium, 2005). The advantage of using the HapMap data is that SNPs are presented graphically 
in a linkage disequilibrium plot, so that only a subset of them needs to be genotyped. 
 
In Phase II of the HapMap consortium released in 2007, 2.1 million SNPs were added to the original 
map, in the same individuals. This certainly improves choice on tag SNPs giving also a better 
understanding of genetic variation (The HapMap Consortium www.Hapmap.org). 
In the latest phase, the HapMap consortium also added seven more populations to the four already 
genotyped: Maasai in Kinyawa, Kenya; Luhya in Webuye, Kenya; Chinese in metropolitan Denver, 
CO, USA; Gujarati Indians in Houston, TX, USA; Toscani in Italia (Tuscans in Italy); African 
ancestry in the Southwest USA; and Mexican ancestry in Los Angeles, CA, USA. These 
populations were both genotyped for 1.6 million SNPs and sequenced in 2Mb of the ENCODE II 
regions (The HapMap Consortium www.Hapmap.org). 
After choosing the gene and the reference population, the HapMap web page produces a diagram 
of the gene with all SNPs present in the exact area under investigation. 
Finally, Tag SNPs have been selected using the Haploview software. Haploview is a bioinformatic 
software that allows the analysis of patterns of linkage disequilibrium (LD) in a given set of genetic 
data (Barrett et al., 2005). Details on setting used in this thesis are in chapter 5. Linkage 
Disequilibrium between SNPs within the CNR1 gene and the COMT gene was computed using 
Haploview version 3.32 (Barrett et al., 2005). Haploview only computes pairwise LD statistics for 
markers within a certain distance of each other, the accepted default value is set to 500K (Barrett et 
al., 2005). Haploview excludes individuals with less than 50% complete genotypes and generates 
LD blocks only if 95% of informative comparisons are "strong LD". Markers with MAF < 0.05 are 
therefore ignored by default (Barrett et al., 2005). 
The AATn microsatellite has been chosen because of its previous association with schizophrenia 
described in the literature publicly available. Details are given in chapter 8. 
4.4.2 SNPs within the COMT gene 
Markers within the COMT gene were chosen because they were considered logical candidates. 
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4.5 Laboratory techniques 
4.5.1 TaqMan Genotyping: 
TaqMan® SNP Genotyping Assays from Applied Biosystems is based on 5’ chemistry and 
amplifies specific SNPs in genomic DNA samples. Most of the assays were pre-designed and 
validated by Applied Biosystems apart for one SNP further discussed in chapter four. As shown in 
Figure 7, the TaqMan probe contains two types of dye: a reporter dye located at the 5’ end and a 
quencher dye, located at the 3’ end. The reporter dye is separated from the quencher dye during the 
reaction. The fluorescence increase can be detected only if the target sequence is present and has 





Figure 4.1  (TaqMan Gene Expression assay Protocol) shows the nuclease activity of the 
Polymerase system 
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From working dilution plates, 2 ųl of DNA was taken from each sample and then transferred into 
optically clear 384 well plates ordered from Thermo-fast diamond, ABgene. Plates were wrapped 
in foil paper and left over night on the laboratory bench in order for the samples to dry. The 
following day a PCR reaction was prepared following standard Applied Biosystems dry DNA 
protocol. 
Plates were sealed with an optically clear “absolute QPCR” adhesive cover ordered from ABGENE 
and the PCR reaction was carried out in the Applied Biosystems 7900HT Fast Real-Time PCR 
System machine.  
Plates were then subjected to reading using the Applied Biosystems 7900HT Fast Real-Time PCR 
System. Genotyping calls are made using a clustering algorithm with quality value of 95%. 
Presence of each allele is marked by colour and position on a generated plot due to level of 
fluorescence present in each allele. Homozygotes are displayed on extremities of the Y and the X 
axes whereas heterozygotes are displayed in the middle. Allele discrimination can be visualized in 
a plot showing the two alleles and the distribution of the three genotypes, the two homozygous and 
the heterozygous one (Figure 4.2). 
 
 




Figure 4.2 shows the allelic discrimination plot resulting from the TaqMan gene expression 
assay procedure. The two alleles are shown in the axis and in different colours are shown the 
three different genotypes: blue colour – homozygous G allele - (Val/Val), red colour – 
homozygous A allele (Met/Met), green colour – Heterozygous -both alleles (Val/Met). 
 
4.5.2 Fragment analysis 
Fragment analysis is used to analyse microsatellites markers loci.  
Microsatellites are also called Short Tandem Repeats (STRs), Variable Number Tandem Repeats 
(VNTRs), Short Sequence Repeats (SSRs) and can span between 2 and 7 repeats (Figure 4.3). 
 




Figure 4.3 Graphic representation of a Microsatellite locus 
 
Microsatellites are amplified by Polymerase Chain Reaction (PCR) with Forward and Reverse 
primers, one of which is fluorescently labelled. Each sample contains multiple coloured dyes; one 
of the colours is used as size standard to extrapolate the base-pair sizes of the sample product peaks. 
After selecting the primers, 1ul of DNA product is loaded into the working plate and amplified 
using PCR. In order to achieve good results, each dye is mixed in different ratios to account for 
differences in fluorescent signal strength. The PCR product is then loaded into a 386 well plate and 
run in the Applied Biosystems 3130xl Genetic analyzer. Results are given in electropherogram form 
and analysed using the GeneMapper® software (Figure 4.3). 




Figure 4.4 Image representing an electropherogram of two different samples analysed with 
the GeneMapper® software. 
 
4.6 Power calculation 
Statistical power calculation was performed using Quanto (Gauderman et al., 2007). 
4.6.1 Gene Only 
A model assuming a population prevalence of 1% and a log additive effect of an allele was used. 
For a MAF of 0.1 and odds ratio of 1.2 around 4,000 cases and matched controls are needed for 
80% power at a two sided significance of 0.005 (to account for 10 alleles), similar numbers of 
samples (~6,000) are needed for a MAF of 0.5. For an odds ratio of 2.0, 245 and 121 cases and 
matched controls are required.   
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4.6.2 Gene x Environment interaction 
A model assuming a population prevalence of 1%, an environmental exposure of 0.4 (in this study 
cannabis ever use as mean value) and a log additive effect of an allele was used. For a MAF of 0.1 
and odds ratio of 1.2 around 65,000 cases and matched controls are needed for 80% power at a two 
sided significance of 0.005 (to account for 10 alleles), similar numbers of samples (~20,000) are 
needed for a MAF of 0.5.  
The 3 samples analysed in this thesis, as mentioned earlier, consisted of 3 ethnically different 
populations: the GAP Study sample Caucasian group with 174 cases and 45 controls; the GAP 
Study sample Black group with 113 cases and 95 controls and the PICOS Study sample with 347 
cases and 307 controls. Although the PICOS Study sample is large enough to detect an effect size 
of 2 in a gene only analysis for an allele frequency of 0.5; replicated true associations in complex 
disease typically have much smaller odds ratios. This can be considered the case especially for 
complex disorders like schizophrenia; it is therefore safe to assume that all statistical tests 
























The CNR1 gene and cannabis use in First Episode Psychosis 
 
5.1 Background information 
As reviewed and discussed in chapter 3 of this thesis, the endocannabinoid system plays an 
important role in brain maturation, function and possibly psychopathology. Over the years many 
studies have focused attention on 2 main areas of interest when analysing the endocannabinoid 
system, 1. fat metabolism and body weight mechanisms; 2. mental health and drug dependence.  
The seven transmembrane G coupled endocannabinoid receptor 1, in fact, is widely expressed 
throughout the brain and particularly abundant in brain regions associated with hunger, appetite and 
reward (Matias and Di Marzo, 2007) (Wood et al., 2007).  
Two CNR1 variants, namely rs6454674, rs806368 and the 2 haplotypes containing genotypes of 
them, have been reported to increase risk for cocaine dependence in 3 separate study samples. (Zuo 
et al., 2009). Furthermore, rs806368 was also associated with cocaine induced paranoia in the same 
study (Zuo et al., 2009). Two other polymorphisms were associated with cocaine induced paranoia 
in the same study, rs1049353 and rs2146274 in a family based cohort (Zuo et al., 2009). More 
recent findings come from Marcos et al., who found a haplotype containing rs6454674, rs1049353 
and rs806368 to be associated with alcohol dependence, with positive interaction also at the alleles 
of the last two polymorphisms of the haplotype (Marcos et al., 2012). A meta-analysis performed 
by Benyamina et al., however, only found only a marginal effect of the AAT repeat within the 
CNR1 gene and drug dependence (Benyamina et al., 2011). Finally Bienertova-Vaskus et al., found 
an effect of the CNR1 haplotype made up of rs6454674, rs1049353 and rs806368 on self reported 
number of cigarettes smoked (Bienertova-Vaskus et al., 2012). These finding were a part of a study 
on metabolic response and feeding control (Bienertova-Vaskus et al., 2012).  
Studies on the association between the CNR1 gene and metabolic measures also show positive 
association of various polymorphisms, with some overlapping markers. Tiwari et al., reported a 
polymorphism, rs806378, to be associated with weight gain in patients treated with olanzapine and 
clozapine, thus highlighting once again, the close relationship between the endocannabinoid system 
and the metabolic system (Tiwari et al., 2010). Park et al., however, found no significance between 
variation at 3 CNR1 loci (rs1049353, rs806368, and rs4707436) and olanzapine induced weight 
gain (Park et al., 2011). In a study of 2411 participants, rs806365 was found to be associated with 
Type 2 Diabetes, Coronary Heart Disease and insulin resistance (De Miguel-Yanes et al., 2011). 
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On the same line, findings of Jaeger et al., found a marginal association of the rs1049353-
rs12720071-rs806368 haplotype on waist to hip ratio, though association was not significant after 
multiple testing correction (Jaeger et al., 2009). In the same study, no association was found 
between rs104973, rs12720071 and measures of central obesity; only rs806368 returned significant 
p-value even after multiple testing correction on WTHR. (Jaeger et al, 2009). Other polymorphisms, 
namely rs6928499, rs1535255, and rs2023239 were also found to be associated with lower risk of 
metabolic syndrome in schizophrenic patients (Yu et al., 2013), whereas, in the same study, some 
others, namely rs806377, rs1049353, rs6454674, and rs806379 returned no positive results (Yu et 
al., 2013). Furthermore, rs1049353 has returned interesting results in 2 other studies, with A allele 
associated to a lack of improvement of leptin levels in obese subjects exposed to both high 
monounsaturated and polyunsaturated diet (De Luis et al., 2013) and the G allele associated to 
antipsychotic refractoriness but not psychosis (Hamdani et al., 2009). Indeed, rs806374 was found 
to predispose schizophrenic patients to Tardive Diskinesia, after treatment with antipsychotics 
(Tiwari et al., 2012).  
Several recent studies have also implicated markers at the CNR1 gene in anxiety, schizophrenia 
and other disorders. rs2180619 was found to have an additive effect on anxiety extinction in healthy 
subjects whereas rs1049353 had no effect (Heitland et al., 2012). The haplotype rs806368-
rs1049353-rs806371 was found to be associated with Major Depression, increasing significance 
after stratification for Melancholia and psychotic symptoms (Mitjans et al., 2013). Furthermore, 
rs806371 and rs806368 were found to be associated with Major depression, Melancholia and 
increased risk of non remission; there was also some evidence of a better response in rs806368 C 
allele carriers (Mitjans et al, 2013). Finally, rs1049353, rs7766029 and rs806366 were shown to 
increase risk of psychosis on a cohort of 150 schizophrenic patients and 350 healthy controls, even 
though not retaining significance after multiple testing correction (Costa et al., 2013). Fewer studies 
have reported associations with polymorphisms within the CNR1 gene and cannabis use, Schacht 
et al., reported rs2023239 to have a group by genotype interaction, where the G allele predicted 
lower volume of bilateral hippocampi in cannabis users (Schacht et al., 2012). Onwameze et al., 
suggested a diplotype effect of rs12720071 combined with rs12199654 in the MAPK14, interacting 
with cannabis use in white matter brain volumes (Onwameze et al., 2013).  In summary, several 
polymorphisms within the CNR1 gene have been investigated in relation to metabolic changes in 
the normal population as well as in anti psychotic treated schizophrenia patients with discordant 
results. In the same way, results differ within studies on drug dependence like cocaine or cannabis 
use and even more on main effect on psychosis. This could be related to the strength of the 
associations. As GWA Studies teach us, to achieve meaningfull results of statistical true relevance, 
samples need to be well characterised and in the range of thousands. These findings could therefore 
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be the consequence of false associations, which give the picture of heterogeneity of results whereas 
it could be a consequence of poor statistical power. 
 
There appear to be polymorphisms more widely studied than others, like, for example rs1049353, 
also included in the set of tag SNPs analysed in this thesis. It has been shown to return positive 
associations with cocaine induced paranoia (Zuo et al., 2009), lack of improvement in leptin levels 
(De Luis et al. 2012) and treatment resistance in psychotic patients (Hamdani et al., 2008); or as 
part of a 3 SNPs haplotype rs806368-rs1049353-rs806371 with Major Depression (Mitjans et al., 
2013), rs6454674, rs1049353 and rs806368 on self reported number of cigarettes smoked 
(Bienertova-Vaskus et al., 2012), rs1049353-rs806368 with alcohol dependence (Marcos et al., 
2010) with both alleles seemingly involved. This suggests a potential role in metabolism and/or 
drug abuse and even on psychosis (Costa et al., 2013). The polymorphism rs806368 has also been 
reported by several studies, as associated SNP or as part of a haplotype. This marker, as well as 
several others, reported by recent studies, has not been included in the selection of SNPs to be 
analysed in this thesis. In light of these recent contrasting, but interesting results, it would have been 
reasonable to include previously reported markers for the analysis, or even proceed with sequencing 
of the entire gene. SNPs selection, however, was performed in 2007, when the CNR1 gene was not 
widely studied and the all above mentioned studies were not yet available. I therefore, based on 
HapMap data available in 2007, tagged the whole length of the CNR1 gene in an attempt of getting 
the main signals from independent SNPs. By tagging the whole length of the gene, I choose not to 
start with a hypothesis a priori driven experiment. SNPs analysed in my thesis are aimed to give 
complete coverage of the gene which was achieved. Table 5.1 shows the selection of SNPs tagged 
and analysed in this thesis and whether they have been reported, with or without significance in 
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Table 5.1: Summary of recent studies reporting significant and non significant association of the SNPs analysed in this thesis and different disorders
in aetiology of 
MD/citolapra
m response 








(Yu et al., 
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5.2 Hypothesis under investigation  
In this chapter I will analyze the potential contribution of 15 polymorphisms, namely rs10485171, 
rs806365, rs806366, rs12189668, rs1049353, rs806369, rs806371, rs806374, rs12195101, 
rs806375, rs806377, rs806378, rs2023239, rs1535355, rs6454672 within the CNR1 gene to the 
increase in risk for psychosis. 
I hypothesise that genetic polymorphisms analysed will give an increase in risk for psychosis. 
I will then run an exploratory analysis to check for haplotypic association with psychosis. 
Haplotypes are analysed with window of 3. 
Finally, I will analyse Gene x Environment interaction between rs1049353 and lifetime cannabis 
use. 
I hypothesise that the multiplicative effect of lifetime cannabis use and rs1049353 gives an increase 
in risk for psychosis. 
5.3 SNPs selection 
Markers of the CNR 1 gene have been selected using the international HapMap data and  SNPs 
within the CNR1 gene are presented graphically in a linkage disequilibrium plot, so that only a 
subset of them needs to be genotyped (Figure 5.1). 
 
 
Figure 5.1 shows a linkage disequilibrium plot generated with Haploview for the CNR1 gene 
based on genotyping data available from the HapMap project (The International HapMap 
Consortium, 2005). 
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After choosing the gene, CNR1 in this study, the HapMap web page produces a diagram of the gene 
with all SNPs present in the exact area under investigation. Figure below shows the output of the 
webpage given after selection of the CNR1 gene (Figure 5.2) 
 
 
Figure 5.2 shows data obtainable from HapMap. In this case the gene illustrated is the CNR1 
gene with several of the validated SNPs based on genotyping data available from the HapMap 
project (The International HapMap Consortium, 2005) 
 
 
The GAP Black study population is West African and Afro Caribbean and it is genetically very 
close to the Yoruba population. When tagging SNPs it was decided to choose Yoruba and CEPH 
populations. 
Tag SNPs have been selected using the Haploview program with HW p-value cutoff=0.0010; min 
genotype=75%; minimum minor allele frequency=0.0010; r2 threshold 0.8; LOD threshold for 
multi-marker tests=3.0. Aggressive tagger with two or three marker haplotype was used. Non 
synonymous SNPs have been force included because of their importance in association studies. A 
list of SNPs and their chromosomal position can be seen in table 5.2. 
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Table 5.2 List of markers selected via Haploview within the CNR1 gene 
 
*MAF= Minor Allele Frequency as reported in NCBI search engine
Gene SNP Chr position MAF * Sequence 
CNR1 rs10485171 89261282 G=0.329 CAAAGACAGAGCAATCATCTGGAAAA[C/T]GGGAGCTAAAAACACAAGCTTTTGT 
CNR1 rs806365 89263841 T=0.397 TTCATAGCTAGCTCTTACTTTGTCTT[C/T]AGTGCTCTATTCAAGCATCACCTCT 
CNR1 rs806366 89265481 C=0.415 ACACACTTCTACATTTCCGCTACAAG[C/T]GGGTCTGCATCTACACAGCGGTAAT 
CNR1 rs12189668 89267257 C=0.001 AGTTAAAATCTTTAATGAAATAATGC[C/T]TTTTAAAGGTGTGGTGGCCTTTTCT 
CNR1 rs1049353 89271527 T=0.137 GCCGCAGAAAGCTGCATCAAGAGCAC[A/G]GTCAAGATTGCCAAGGTAACCATGT 
CNR1 rs806369 89274070 T=0.305 ATGGAGGAGGCCTCCTGATAGTCCCC[C/T]TCATGAGCAGGTTGGTGACACAAGT 
CNR1 rs806371 89274255 G=0.278 GAGAACTGATCTTACTATTTATAAAT[G/T]TTTGTTTAAAATGTGGGCTATTCAT 
CNR1 rs806374 89275212 C=0.402 AAGTAATTTGGAACAGGCATAAAGTG[C/T]TAAATGTGGCCCACCTTCCCACATT 
CNR1 rs12195101 89275717 G=0.002 TGCCACTTGGGCTACACCAGATGAAT[G/T]TTAGTTCCATAAACACAGCAAATTG 
CNR1 rs806375 89276413 T=0.373 TGGTGAACAGAGAAAGAGCCCTCAGC[A/T]CTAATGTGACAGGTAAGCCAGAAGG 
CNR1 rs806377 89276615 C=0.478 GGCTTCTGAACCAGTTCTGCACACCT[C/T]TCCTGCAACTGTCATAGAATAAAGC 
CNR1 rs806378 89277443 T=0.182 TCCCTCTATTACAGGCCTCATCACGT[C/T]GTATAATCAGGAGTTCACATATTTA 
CNR1 rs2023239 89278374 C=0.167 CTAGGTTTGTGGATGTGCCAGGACCA[C/T]GTAAGGAACAGCTCTCTCATATATT 
CNR1 rs1535255 89279100 G=0.168 TAAGCCTCAGTATTTCATCTGTAAAA[G/T]GGGGATGAGGATGATGACAATAATG 
CNR1 rs6454672 89279462 C=0.141 GTTATATCCAGCCATTTGAGAAACTT[C/T]ACATATATTCTATCATTAAATTGTC 
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5.4 SNPs Genotyping 
All samples of the Genetics and Psychosis research Study (GAP) and all samples of the PICOS 
research Study were extracted, diluted, prepared in 186 well plates and shipped to Prevention 
Genetics for genotyping. For detailed explanation of study sample characteristics, procedures on 
DNA extraction and sample preparation please see chapter 4 of this thesis (Materials and Methods). 
5.5 Statistical Analysis 
In this chapter samples analysed are from the GAP Study (both Caucasian and Black population 
included) and from the PICOS study. 
The GAP Study Caucasian population analysed consisted of 174 psychotic patients and 45 non 
psychotic subjects; 
The GAP Study Black population analysed consisted of 113 psychotic patients and 95 non 
psychotic subjects; 
The PICOS Study sample consisted of 347 psychotic patients and 307 non psychotic patients. 
The three main groups of samples were tested separately: Caucasian group (GAP); Black African 
group (GAP); Caucasian Italian group (PICOS). 
5.5.1 Statistical tests performed 
With the three sets of samples, namely the GAP study sample (including Caucasian subjects), the 
GAP study (including the black population) and the PICOS study sample (consisting of Caucasian 
population) the following statistical tests were performed: 
- Hardy Weinberg Equilibrium Test 
- Logistic regression test for allelic and genotype association analysis between each SNP and 
disease status 
- Haplotype association analysis with sliding window of 3 
- Haplotype Conditional test for independence effect of rs1049353 
- Bonferroni multiple testing correction 
- Logistic regression test for the Gene x Environment analysis (only the GAP Caucasian 
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5.5.2 Hardy Weinberg Equilibrium Test 
Hardy Weinberg Equilibrium Test was performed using PLINK software for genetic analysis 
throughout the thesis (Purcell et al., 2007).  
The command used for the HWE test is --hardy 
The full line of command used to run the HWE test in this thesis is: 
Plink --file mydata --hardy 
A file containing three entries for each SNP was then generated and saved as plink.hwe 
The file contains calculations of the HWE test for all, affected only or unaffected only subjects. 
In this thesis, only results of the unaffected group of subjects are discussed and reported in the 
tables. 
5.5.3 Allelic and genotype association analysis 
Statistical analysis carried out to establish association between allelic and genotype variation at 
each locus within the CNR1 and psychosis was performed using PLINK software for genetic 
analysis (Purcell et al., 2007). 
The main effect of each SNP on psychosis was tested with logistic regression. PLINK calculates a 
basic association of a disease trait by comparing allele frequencies between cases and controls 
(Purcell et al., 2007). The association commands used are --assoc --logistic. 
SNPs alleles and genotypes were treated as independent variables and disease outcome (psychosis) 
was treated as dependent variable. It was coded in the program as a binary disease status: 1=case 
0=control. Because the disease outcome was a binary value, --1 was added to the command line 
used. 
The complete set of commands used to calculate association in this thesis was: 
Plink –file mydata --1 --assoc --logistic 
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5.5.4 Haplotype analysis 
Linkage Disequilibrium between SNPs within the CNR1 gene was computed using Haploview 
version 3.32 (Barrett et al., 2005). All markers were within 500Kb which is the default value for 
distance. 
A graphical representation of linkage disequilibrium between markers was created with LD-Plus, a 
program that is freely available via a web interface (https://chgr.mc.vanderbilt.edu/ldplus). D’ and 
r2 values, were calculated using Haploview (Barrett et al., 2005). 
Haplotype analysis was then carried out using PLINK software for genetic analysis (Purcell et al., 
2007). 
In order to phase a set of SNPs for haplotypic analysis, both the --chap and the --hap--snp were 
used together.  
--mhf 0.05 was used to increase the minimum haplotype frequency 
--window 3 
The full line of command used in this thesis for haplotype analysis is: 
Plink --bfile mydata --1 --hap-window 3 --hap-assoc 
The output file generated by the program after this calculation is saved as plink.hap 
After some haplotypes returned significant p-value, I proceeded to a conditional test to check 
whether there was an independent of rs1049353. This SNP showed significant association with 
psychosis in the GAP study sample with Caucasian subjects (corrected p-value=0.03). The 
conditional test was run to check for independence of rs1049353 from haplotypic effects formed by 
the remaining SNPs. 
The full line of command used was 
Plink --file mydata --hap--snps rs1048517-rs6454672 --chap --independent-effect rs1049353 
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5.5.5 Gene x Environment analysis 
GxE analysis was performed with logistic regression test using HapStat version 3.0 (Lin et al., 
2008).  Hapstat is a user-friendly software that allows testing of single markers and haplotype-
disease association. The haplotype association is calculated by maximizing the observed data 
likelihood that accounts for phase uncertainty and study design (Lin et al., 2008).  
Environmental variable entered was: 
 cannabis use (variable modeled as binary trait: yes/no answer) 
Genetic variables entered were: 
 rs1049353 
5.5.6 Bonferroni Correction for multiple testing 
Bonferroni conservative correction for multiple testing was applied after allelic and genotype 
association analysis and after haplotype analysis was performed.  
For the logistic regression, the markers analysed were 13, Bonferroni corrected p-value calculated 
as 0.05/15 would be 0.003.  
When Bonferroni was applied to correct for the number of sliding windows generated with 
haplotype analysis, there were a total of 15 markers and 13 tests performed. Bonferroni corrected 
p-value calculated as 0.05/13 would be 0.003. 
In the tables, Bonferroni corrected p-value is reported as χ2 p-value * number of tests performed. 
5.6 Results 
5.6.1 Hardy Weinberg Equilibrium Test 
Hardy Weinberg Equilibrium was examined in non psychotic control groups of both the GAP Study 
and the PICOS Study separately. As mentioned earlier, the GAP Study is made of two main ethnic 
groups: the Caucasian and the Black group. In every statistical analysis performed in this thesis, 
they were analysed separately as 3 distinct populations. A HWE test was therefore performed for 
each group: Caucasian, Black and PICOS. The GAP Study Black population included participants 
from Black African, Black Caribbean origins as well as any other ethnicity mixed with black 
Caribbean or Black African. Deviation from equilibrium was checked for a total of 15 SNPs namely 
rs10485171, rs806365, rs806366, rs12189668, rs1049353, rs806369, rs806371, rs806374, 
rs12195101, rs806375, rs806377, rs806378, rs2023239, rs1535355, rs6454672 within the CNR1 
gene.  
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None of the markers failed the HWE test after accounting for multiple testing correction 
(0.05/15=0.003) in the GAP Black and Caucasian non psychotic groups (Complementary Tables 
C.1 and C.2).  
In the PICOS Study samples, 15 SNPs were tested with the Hardy Weinberg Equilibrium test: 
rs10485171, rs806365, rs806366, rs12189668, rs1049353, rs806369, rs806371, rs806374, 
rs12195101, rs806375, rs806377, rs806378, rs2023239, rs1535355, rs6454672 within the CNR1 
gene. Analysis confirmed that all SNPs in the non psychotic PICOS Study control group were in 
equilibrium (Complementary Table C.3). 
5.6.2 Association between allelic and genotype variation at each locus within the CNR1 gene 
and Psychosis 
The main effect of each SNP at each locus within the CNR1 gene on psychosis was tested with a χ2 
test in the 3 study samples separately. 
In the GAP Caucasian study sample 2 markers, namely rs806378 and rs1049353 returned higher 
significance values, p-value 0.004 and p-value 0.002 respectively. Significance was only retained 
by 1 marker rs1049353 with a p-value of 0.03 (0.002*15), for which the C allele seems to be over 
expressed in psychotic participants.  Bonferroni set threshold for significance for this set of test 
would be p-value=0.003 (Table 5.2). 
The higher values, however, probably relate to low MAFs at both loci in the population examined. 
The MAFs in the affected and non affected population are 0.12 and 0.26, 0.04 and 0.14, 
respectively; as it can be seen in table 4.5. I therefore had a very low statistical power to detect any 
true association as explained in detail later in the conclusions paragraph of this chapter. 
 In the GAP Black group no association was found (table 5.3).    
Genotype variation at the two loci did not show association with psychosis (Complementary 
Table C.4 and C.5).        
In the PICOS sample allelic variation was found to be associated with psychosis at rs806378 
locus (p-value=0.03 OR=0.77) and at rs806371 locus (p-value=0.047 OR=1.34). We also have to 
bear in mind, in this study sample, that 13 tests were performed, therefore the p-value reported are 
not adjusted for multiple testing. If we were, however, to adjust for multiple testing using the 
conservative Bonferroni, none of the observed p-value would have met criteria for significance 
(Bonferroni adjusted p-value= 0.003) (Table 5.4). 
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Genotype variation however did not show any significance at any of the loci (Complementary Table 
C.6). 
The MAFs of the affected and unaffected populations within the PICOS sample are low: 0.23 and 
0.28 respectively. It is thus possible that the higher value observed is due to a statistical false 
positive. I had, in fact, very low power to detect a true effect of a locus with a low MAF. The 
number of case-control pair should range in the thousand. This is further reviewed in the final 
paragraph of this chapter. Results are summarised in table 5.5. 
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TABLE 5.3: Association between allelic variation at each locus within CNR1 and psychosis in the GAP Caucasian sample 
 
























CNR1 rs10485171 C/T 0.43 153 0.50 35 1.19 0.275 0.75 
CNR1 rs806365 T/C 0.32 157 0.34 32 0.20 0.656 0.88 
CNR1 rs806366 C/T 0.27 152 0.39 35 3.71 0.054 0.59 
CNR1 rs12189668 C/T 0.01 156 0.04 35 2.87 0.090 0.29 
CNR1 rs1049353 A/G 0.04 156 0.14 35 9.32 0.002/0.03 0.28 
CNR1 rs806369 T/C 0.11 154 0.17 35 1.75 0.186 0.62 
CNR1 rs806371 G/T 0.29 157 0.22 32 1.23 0.268 1.44 
CNR1 rs806374 C/T 0.43 159 0.35 31 1.13 0.287 1.36 
CNR1 rs12195101 G/T 0.04 157 0.06 35 0.34 0.563 0.71 
CNR1 rs806375 A/T 0.45 155 0.43 34 0.14 0.706 1.11 
CNR1 rs806377 T/C 0.35 156 0.40 34 0.48 0.489 0.83 
CNR1 rs806378 C/T 0.12 155 0.26 35 8.23 0.004/0.06 0.40 
CNR1 rs2023239 C/T 0.36 157 0.34 35 0.07 0.788 1.08 
CNR1 rs1535255 G/T 0.32 159 0.24 35 1.52 0.218 1.45 
CNR1 rs6454672 C/T 0.31 154 0.23 35 1.62 0.203 1.48 
 
MAF= Minor allele frequency 
OR=Odd Ratio 
(a)= number of participants (Psychotic and non psychotic) for genotype groups at each locus  
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TABLE 5.4: Association between allelic variation at each locus within CNR1 and psychosis in the GAP Black sample 




















(DF=1)* P-Value OR 
CNR1 rs10485171 C/T 0.40 97 0.42 71 0.06 0.805 0.95 
CNR1 rs806365 T/C 0.43 96 0.37 71 1.48 0.224 1.32 
CNR1 rs806366 T/C 0.52 97 0.44 70 2.24 0.135 1.40 
CNR1 rs12189668 C/T 0.05 101 0.07 73 0.29 0.587 0.78 
CNR1 rs1049353 A/G 0.28 99 0.20 75 3.15 0.076 1.58 
CNR1 rs806369 T/C 0.26 95 0.19 70 2.73 0.099 1.57 
CNR1 rs806371 G/T 0.14 98 0.21 74 2.63 0.105 0.63 
CNR1 rs806374 C/T 0.36 96 0.37 74 0.00 0.972 0.99 
CNR1 rs12195101 G/T 0.03 100 0.05 74 0.33 0.564 0.73 
CNR1 rs806375 T/A 0.48 96 0.51 71 0.29 0.591 0.89 
CNR1 rs806377 C/T 0.45 99 0.53 74 1.87 0.172 0.74 
CNR1 rs806378 T/C 0.28 96 0.29 75 0.08 0.780 1.07 
CNR1 rs2023239 C/T 0.17 99 0.28 72 5.62 0.018 0.54 
CNR1 rs1535255 G/T 0.14 101 0.22 72 3.02 0.082 0.61 
CNR1 rs6454672 C/T 0.12 99 0.16 71 1.15 0.283 0.71 
 
 
MAF= Minor allele frequency 
OR=Odd Ratio 
(a)= number of participants (Psychotic and non psychotic) for genotype groups at each locus  
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CNR1 rs10485171 T/C 0.38 266 0.39 505 0.26 0.613 0.95 
CNR1 rs806365 T/C 0.47 273 0.49 510 0.45 0.502 0.93 
CNR1 rs806366 T/C 0.48 263 0.45 504 1.94 0.062 1.19 
CNR1 rs12189668 T/C 0.00 273 0.00 510 1.87 0.172 NA 
CNR1 rs1049353 G/A 0.23 267 0.22 502 0.20 0.652 1.06 
CNR1 rs806371 G/T 0.17 275 0.13 504 3.96 0.047/0.6 1.34 
CNR1 rs806369 T/C 0.34 270 0.35 509 0.03 0.869 0.98 
CNR1 rs806374 C/T 0.34 265 0.33 507 0.23 0.632 1.06 
CNR1 rs12195101 G/T 0.00 270 0.00 514 1.05 0.305 0.00 
CNR1 rs806375 A/T 0.38 264 0.43 501 3.50 0.061 0.81 
CNR1 rs806377 C/T 0.48 266 0.50 502 0.55 0.458 0.92 
CNR1 rs806378 C/T 0.23 269 0.28 507 4.46 0.035/0.45 0.77 
CNR1 rs2023239 T/C 0.18 268 0.17 510 0.89 0.345 1.14 
CNR1 rs1535255 G/T 0.18 267 0.17 504 0.63 0.428 1.12 
CNR1 rs6454672 C/T 0.14 271 0.11 511 1.76 0.185 1.24 
 
MAF= Minor allele frequency 
OR=Odd Ratio 
(a)= number of participants (Psychotic and non psychotic) for genotype groups at each locus  
* Degrees of freedom=1 
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TABLE 5.6 Summary of non corrected VS corrected p-values obtained with the allelic test across all 
population examined 
 
SNPs GAP samples  
(Caucasian group) 













































MAF AFF= 0.2 




MAF AFF= 0.14 




MAF AFF= 0.17 
MAF UN= 0.13 
 OR= Odds Ratio 
MAF AFF=Minor Allele Frequency in affected population 
MAF UN=Minor Allele Frequency in unaffected population 
 
The above table shows a summary of markers that have returned a significant non corrected p-value 
from the χ2 test. The point of the summary is to show the same markers with non corrected VS 
corrected p-value across the 3 different samples analysed in this chapter. As it can be seen rs1049353 
shows association with psychosis only in the GAP study sample with Caucasian subjects. rs806371 
shows association only in the PICOS Study samples, but changed to non significant after multiple 
testing correction. rs806378 shows association with psychosis in the GAP Caucasian Study sample and 
the PICOS Study sample but retained significance only in the GAP Caucasian Study sample. All the 
above mentioned significant p-values, however, are probably due to low MAFs that can be observed 
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5.6.3 Gene x Environment analysis 
As shown above in paragraph 5.6.2, rs1049353 has been found to have a main effect on psychosis 
in the Caucasian population. In order to explore the correlation between rs1049353 and cannabis 
use, I performed a logistic regression test in both the Caucasian and the Black samples. 
 There was no association between rs1049353 and cannabis use in either of the 2 study samples 
(Tables 5.7). rs1049353 did not seem to have any effect on cannabis use. 
 
Table 5.7 Correlation between cannabis use and rs1049353  
POPULATION GENE MARKER P-VALUE 
STANDARD 
ERROR Z SCORE 
Caucasian CNR1 rs1049353 0.5 0.2 -1.3 
Black CNR1 rs1049353 0.1 0.2 0.5 
 
 
Gene x Environment interaction was calculated with logistic regression test under additive model. 
No interaction was found between rs1049353 and cannabis use in either of the GAP Study sample 
groups (Table 5.8). 
 
Table 5.8 Gene x Environment interaction between rs1049353 and Cannabis use  
POPULATION GENE MARKER P-VALUE 
STANDARD 
ERROR Z SCORE 
Caucasian CNR1 rs1049353 0.32 0.25 1.2 
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5.6.4 Haplotype analysis 
I decided to further explore the data by performing haplotype analysis as it may reveal additional 
associations. The level of Linkage Disequilibrium (LD) for the SNPs within the CNR1 gene was 
assessed using haploview (Barrett et al., 2005) and haplotypic association analysis was carried out 
using PLINK version 1.7 (Purcell et al., 2007). 
For a better understanding of the level of correlation between the SNPs in the population examined 
in this chapter, I calculated the D’ and the r2 values with haploview (Table 5.9, Table 5.10 and 
Table 5.11). They are also displayed in figure 5.3, 5.4 and 5.5 representing LD blocks plots with 














The CNR1 and the COMT genes in First Episode of Psychosis Page 88 
 
Figure 5.3: Linkage Disequilibrium Plot computed with markers within the CNR1 gene in the 
GAP Caucasian sample  
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Table 5.9 D’ and r2 values calculated with Haploview in the GAP Caucasian sample (shown 
in bold markers with higher D’ and r2 scores further discussed in the conclusion paragraph 
of this chapter) 
 
MARKER 1 MARKER 2 D' VALUE r2 VALUE 
rs10485171 rs806365 0.817 0.248 
rs10485171 rs806366 0.177 0.01 
rs10485171 rs1049353 1 0.089 
rs10485171 rs806371 0.369 0.039 
rs10485171 rs806374 0.449 0.113 
rs10485171 rs806375 0.116 0.008 
rs10485171 rs806377 0.082 0.005 
rs10485171 rs806378 0.271 0.01 
rs10485171 rs2023239 0.231 0.038 
rs10485171 rs1535255 0.279 0.043 
rs10485171 rs6454672 0.246 0.031 
rs806365 rs806366 0.285 0.069 
rs806365 rs1049353 1 0.029 
rs806365 rs806371 0.144 0.004 
rs806365 rs806374 0.009 0 
rs806365 rs806375 0.195 0.014 
rs806365 rs806377 0.056 0.003 
rs806365 rs806378 0.458 0.078 
rs806365 rs2023239 0.04 0 
rs806365 rs1535255 0.222 0.01 
rs806365 rs6454672 0.196 0.007 
rs806366 rs1049353 1 0.027 
rs806366 rs806371 0.516 0.041 
rs806366 rs806374 0.293 0.025 
rs806366 rs806375 0.409 0.058 
rs806366 rs806377 0.155 0.017 
rs806366 rs806378 0.187 0.015 
rs806366 rs2023239 0.139 0.014 
rs806366 rs1535255 0.19 0.006 
rs806366 rs6454672 0.208 0.007 
rs1049353 rs806371 1 0.025 
rs1049353 rs806374 0.642 0.019 
rs1049353 rs806375 0.513 0.021 
rs1049353 rs806377 0.314 0.012 
rs1049353 rs806378 0.093 0.003 
rs1049353 rs2023239 0.416 0.006 
rs1049353 rs1535255 0.257 0.002 
rs1049353 rs6454672 0.22 0.001 
rs806371 rs806374 0.922 0.459 
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rs806371 rs806375 0.059 0.002 
rs806371 rs806377 0.04 0 
rs806371 rs806378 0.563 0.019 
rs806371 rs2023239 0.171 0.02 
rs806371 rs1535255 0.205 0.036 
rs806371 rs6454672 0.161 0.024 
rs806374 rs806375 0.114 0.008 
rs806374 rs806377 0.283 0.032 
rs806374 rs806378 0.467 0.026 
rs806374 rs2023239 0.133 0.014 
rs806374 rs1535255 0.25 0.039 
rs806374 rs6454672 0.182 0.019 
rs806375 rs806377 0.674 0.317 
rs806375 rs806378 1 0.134 
rs806375 rs2023239 0.8 0.294 
rs806375 rs1535255 0.754 0.199 
rs806375 rs6454672 0.817 0.213 
rs806377 rs806378 0.151 0.002 
rs806377 rs2023239 0.474 0.07 
rs806377 rs1535255 1 0.245 
rs806377 rs6454672 0.958 0.21 
rs806378 rs2023239 0.159 0.008 
rs806378 rs1535255 1 0.075 
rs806378 rs6454672 1 0.068 
rs2023239 rs1535255 0.942 0.691 
rs2023239 rs6454672 0.934 0.613 
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Figure 5.4: Linkage Disequilibrium Plot computed with markers within the CNR1 gene in the 
GAP Black sample 
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Table 5.10 D’ and r2 values calculated with haploview in the GAP Black sample (shown in 
bold markers with higher D’ and r2 scores further discussed in the conclusion paragraph of 
this chapter) 
MARKER 1 MARKER 2 D' VALUE r2 VALUE 
rs10485171 rs806365 1 0.48 
rs10485171 rs806366 0.299 0.064 
rs10485171 rs1049353 0.727 0.253 
rs10485171 rs806371 1 0.14 
rs10485171 rs806374 0.323 0.043 
rs10485171 rs12195101 1 0.03 
rs10485171 rs806375 0.114 0.009 
rs10485171 rs806377 0.1 0.007 
rs10485171 rs806378 0.206 0.012 
rs10485171 rs2023239 0.143 0.004 
rs10485171 rs1535255 0.194 0.011 
rs10485171 rs6454672 0.235 0.012 
rs806365 rs806366 0.49 0.157 
rs806365 rs1049353 1 0.22 
rs806365 rs806371 0.199 0.005 
rs806365 rs806374 0.008 0 
rs806365 rs12195101 0.311 0.005 
rs806365 rs806375 0.099 0.006 
rs806365 rs806377 0.107 0.008 
rs806365 rs806378 0.046 0.001 
rs806365 rs2023239 0.297 0.017 
rs806365 rs1535255 0.547 0.043 
rs806365 rs6454672 0.413 0.019 
rs806366 rs1049353 0.686 0.169 
rs806366 rs806371 0.505 0.054 
rs806366 rs806374 0.472 0.138 
rs806366 rs12195101 0.799 0.027 
rs806366 rs806375 0.17 0.028 
rs806366 rs806377 0.063 0.004 
rs806366 rs806378 0.205 0.018 
rs806366 rs2023239 0.391 0.045 
rs806366 rs1535255 0.138 0.004 
rs806366 rs6454672 0.081 0.001 
rs1049353 rs806371 1 0.069 
rs1049353 rs806374 0.134 0.004 
rs1049353 rs12195101 0.003 0 
rs1049353 rs806375 0.02 0 
rs1049353 rs806377 0.258 0.022 
rs1049353 rs806378 0.068 0.001 
rs1049353 rs2023239 0.073 0.005 
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rs1049353 rs1535255 0.031 0 
rs1049353 rs6454672 0.094 0.004 
rs806371 rs806374 0.724 0.187 
rs806371 rs12195101 0.609 0.079 
rs806371 rs806375 0.011 0 
rs806371 rs806377 0.133 0.003 
rs806371 rs806378 0.035 0 
rs806371 rs2023239 0.045 0.001 
rs806371 rs1535255 0.382 0.006 
rs806371 rs6454672 0.506 0.008 
rs806374 rs12195101 1 0.073 
rs806374 rs806375 0.213 0.026 
rs806374 rs806377 0.161 0.015 
rs806374 rs806378 0.074 0.001 
rs806374 rs2023239 0.19 0.006 
rs806374 rs1535255 0.377 0.017 
rs806374 rs6454672 0.495 0.022 
rs12195101 rs806375 1 0.042 
rs12195101 rs806377 0.383 0.006 
rs12195101 rs806378 0.642 0.041 
rs12195101 rs2023239 0.894 0.112 
rs12195101 rs1535255 0.828 0.006 
rs12195101 rs6454672 0.407 0.001 
rs806375 rs806377 0.711 0.493 
rs806375 rs806378 0.975 0.422 
rs806375 rs2023239 0.773 0.183 
rs806375 rs1535255 0.66 0.098 
rs806375 rs6454672 0.884 0.13 
rs806377 rs806378 0.558 0.139 
rs806377 rs2023239 0.316 0.031 
rs806377 rs1535255 1 0.218 
rs806377 rs6454672 0.945 0.144 
rs806378 rs2023239 0.139 0.013 
rs806378 rs1535255 1 0.091 
rs806378 rs6454672 1 0.07 
rs2023239 rs1535255 0.948 0.605 
rs2023239 rs6454672 0.964 0.448 
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Figure 5.5: Linkage Disequilibrium Plot computed with markers within the CNR1 gene in the 
PICOS Study  
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Table 5.11 D’ and r2 values calculated with haploview in the PICOS Study sample (shown in 
bold markers with higher D’ and r2 scores further discussed in the conclusion paragraph of 
this chapter) 
 
MARKER 1 MARKER 2 D' VALUE r2 VALUE 
rs10485171 rs806365 0.992 0.566 
rs10485171 rs806366 0.279 0.055 
rs10485171 rs1049353 0.978 0.45 
rs10485171 rs806371 0.888 0.085 
rs10485171 rs806374 0.49 0.074 
rs10485171 rs12195101 1 0.001 
rs10485171 rs806375 0.227 0.044 
rs10485171 rs806377 0.221 0.03 
rs10485171 rs806378 0.083 0.004 
rs10485171 rs2023239 0.354 0.042 
rs10485171 rs1535255 0.347 0.04 
rs10485171 rs6454672 0.511 0.06 
rs806365 rs806366 0.543 0.239 
rs806365 rs1049353 0.992 0.265 
rs806365 rs806371 0.922 0.13 
rs806365 rs806374 0.041 0.001 
rs806365 rs12195101 1 0.002 
rs806365 rs806375 0.212 0.03 
rs806365 rs806377 0.26 0.064 
rs806365 rs806378 0.088 0.003 
rs806365 rs2023239 0.664 0.086 
rs806365 rs1535255 0.633 0.077 
rs806365 rs6454672 0.613 0.05 
rs806366 rs1049353 0.993 0.32 
rs806366 rs806371 1 0.196 
rs806366 rs806374 0.654 0.249 
rs806366 rs12195101 1 0.002 
rs806366 rs806375 0.086 0.006 
rs806366 rs806377 0.091 0.007 
rs806366 rs806378 0.149 0.007 
rs806366 rs2023239 0.444 0.046 
rs806366 rs1535255 0.453 0.049 
rs806366 rs6454672 0.539 0.047 
rs1049353 rs806371 1 0.048 
rs1049353 rs806374 0.146 0.003 
rs1049353 rs12195101 1 0.001 
rs1049353 rs806375 0.138 0.008 
rs1049353 rs806377 0.068 0.001 
rs1049353 rs806378 0.347 0.012 
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rs1049353 rs2023239 0.289 0.06 
rs1049353 rs1535255 0.295 0.062 
rs1049353 rs6454672 0.485 0.116 
rs806371 rs806374 0.768 0.199 
rs806371 rs12195101 1 0.011 
rs806371 rs806375 0.052 0 
rs806371 rs806377 0.294 0.015 
rs806371 rs806378 0.027 0 
rs806371 rs2023239 0.129 0.014 
rs806371 rs1535255 0.129 0.013 
rs806371 rs6454672 0.212 0.001 
rs806374 rs12195101 1 0.004 
rs806374 rs806375 0.329 0.039 
rs806374 rs806377 0.268 0.036 
rs806374 rs806378 0.307 0.017 
rs806374 rs2023239 0.33 0.012 
rs806374 rs1535255 0.327 0.011 
rs806374 rs6454672 0.518 0.019 
rs12195101 rs806375 1 0.001 
rs12195101 rs806377 1 0.002 
rs12195101 rs806378 0.309 0.001 
rs12195101 rs2023239 1 0 
rs12195101 rs1535255 1 0 
rs12195101 rs6454672 1 0 
rs806375 rs806377 0.959 0.661 
rs806375 rs806378 0.98 0.474 
rs806375 rs2023239 0.421 0.051 
rs806375 rs1535255 0.411 0.048 
rs806375 rs6454672 0.762 0.113 
rs806377 rs806378 1 0.346 
rs806377 rs2023239 0.967 0.197 
rs806377 rs1535255 0.978 0.201 
rs806377 rs6454672 0.983 0.137 
rs806378 rs2023239 0.959 0.067 
rs806378 rs1535255 1 0.072 
rs806378 rs6454672 1 0.05 
rs2023239 rs1535255 0.977 0.934 
rs2023239 rs6454672 0.968 0.641 
rs1535255 rs6454672 0.974 0.66 
 
 
Disequilibrium values, D’ and r2, are measures of non random association of alleles at two or more 
loci. D’ values, in a given population, assess the probability for historical recombination (Mueller 
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J C, 2004), and refer to the rate at which the two alleles tend to be co-inherited. D’ value ranges 
from 0 to 1; when the value deviates from 1 there is evidence of historical recombination (Mueller 
J C, 2004). D’ values tend to be higher when they are calculated in small sample seizes and/or in 
the presence of rare alleles (Mueller J C, 2004), they tend to suffer from ceiling effect. R2 values 
measure the degree of independence; it is a preferred measure of a polymorphism given the other. 
R2 is, in fact, widely used in association studies. If 2 given polymorphisms have a high r2 value, 
they can act as proxies of each other. It is therefore very important to calculate both D’ and r2 value 
in order to better understand a given haplotype. 
As it can been seen in the LD plot generated with the GAP Study sample data Caucasian group, in 
block 1 at the far right of the figure, the 3 SNPs namely rs2023239, rs1535255 and rs6454672 have 
both a high D’ and r2 value. What the values suggest is that these 3 markers do not seem to be 
independent of each other. The high D’ value points out the fact that the above mentioned markers 
tend to be co-inherited 90% of the times and because the r2 value is also high, they can act as 
proxies. The haplotype made of rs2023239, rs1535255 and rs6454672 is therefore, not very 
informative.  
In the plot generated with the GAP Study sample Black group, there also is a visible block on the 
far right side of the picture. In it, rs2023239 rs1535255 rs6454672 have a D’ value of 0.94 and 0.96 
and r2 value of 0.4 and 0.6. Assuming that the D’ value is higher due to the sample size, the high 
r2 scores may indicate that we are not in the presence of independent signals from these 3 markers. 
The same interpretation can be safely made for rs10485171 and rs806365 which compose another 
block in the population analysed. 
 
In the PICOS Study sample we have a bigger pattern of LD. As it can be seen from the LD plot 
(Figure 5.5), there are 3 blocks in the population examined. In the first block rs10485171 rs806365 
have a D’ value of almost 1 and r2 score of 0.6, the same in the second block for rs2023239 
rs1535255 rs6454672, and in the third  a even higher dependence can be observed, where rs806375 
rs806377 have both D’ and r2 value of almost 1. 
This suggests a pattern of co-inheritance and a high dependence between all the mentioned markers. 
We are in the presence of a small sample with rarer allele (as discusses earlier with the MAFs), it 
is therefore important to pay attention to both measures, D’ and r2, even though, r2 is more 
informative in this case. Although we are in the presence of a small sample size compared, for 
example, to the recent GWAS studies done in psychosis, the number of case-control pairs is not as 
small as to influence very much the D’ scores.   
All haplotypes were tested for association with psychosis using a sliding window of 3. 
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In the GAP Caucasian sample, 9 haplotypes within 5 windows showed significant p-value (Table 
5.12). When corrected with the Bonferroni multiple testing correction (α value/number of 











rs806366|rs12189668|rs1049353 TTA 0.04572 0.1437 9.194 1 0.002/0.026 
rs806366|rs12189668|rs1049353 TTG 0.6822 0.4682 11.37 1 0.0007/0.009 
rs12189668|rs1049353|rs806369 TAC 0.03752 0.1303 9.364 1 0.002/0.026 
rs1049353|rs806369|rs806371 ACT 0.04295 0.1385 9.205 1 0.002/0.026 
 
 
In the GAP Black sample, 6 haplotypes within 4 windows showed significant p-values (Table 5.13), 
but none of them retained significance after Bonferroni multiple testing correction. 
In the PICOS group 6, haplotypes within 5 windows showed significant p-value (Table 5.14), 












rs806375|rs806377|rs806378 ACC 0.1162 0.0729 8.681 1 0.003/0.039 
 
All Haplotypes that retained a significant p-value after Bonferroni correction in the GAP Study 
sample Caucasian group, contain rs1049353 that incidentally have shown significance in the 
association analysis (Bonferroni corrected p-value=0.03). Although the GAP Study sample 
Caucasian group consists of a very low number of cases and controls and both the allelic and the 
haplotype associations found, have to be seen in light of a very statistically under powered study, I 
proceeded to perform a conditional test to check for an independent effect of rs1049353. Not 
surprisingly, the test showed an independent significant signal of rs1049353 from the remaining 
SNPs forming the other haplotypes (rs806366, rs806369, rs12189668 and rs806371) (df=2; p-value 
= 0.0289). These results have to be interpreted in light of the small sample size and the number of 
tests performed with the same markers within the same sample size. The issue is further discussed 
in the conclusions section. 
The ACC haplotype also showed significance in the PICOS Study sample. It contains rs806378, 
the SNP that was found to be associated with psychosis, although it did not retain significance after 
multiple testing correction (corrected p-value=0.45). Conditional test showed the presence of an 
independent significant signal of rs806378 (df=2; p-value=0.0432). 
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rs10485171|rs806365|rs806366 OMNIBUS NA NA 6.361 6 0.384 
rs10485171|rs806365|rs806366 CTC 0.0162 0.03427 0.9702 1 0.3246 
rs10485171|rs806365|rs806366 TTC 0.12 0.179 1.738 1 0.1873 
rs10485171|rs806365|rs806366 CCC 0.07828 0.1263 1.651 1 0.1988 
rs10485171|rs806365|rs806366 TCC 0.05896 0.04817 0.1232 1 0.7256 
rs10485171|rs806365|rs806366 TTT 0.1769 0.1261 1.05 1 0.3055 
rs10485171|rs806365|rs806366 CCT 0.3291 0.3368 0.0153 1 0.9014 
rs10485171|rs806365|rs806366 TCT 0.2206 0.1493 1.756 1 0.1851 
rs806365|rs806366|rs12189668 OMNIBUS NA NA 3.497 3 0.3211 
rs806365|rs806366|rs12189668 TCT 0.1363 0.2089 2.288 1 0.1304 
rs806365|rs806366|rs12189668 CCT 0.1319 0.1656 0.5256 1 0.4685 
rs806365|rs806366|rs12189668 TTT 0.1757 0.1279 0.9031 1 0.3419 
rs806365|rs806366|rs12189668 CTT 0.5561 0.4976 0.7606 1 0.3831 
rs806366|rs12189668|rs1049353 OMNIBUS NA NA 18.88 3 0.0002893 
rs806366|rs12189668|rs1049353 TTA 0.04572 0.1437 9.194 1 0.002/0.026 
rs806366|rs12189668|rs1049353 CCG 0.005951 0.0371 4.817 1 0.03/0.39 
rs806366|rs12189668|rs1049353 CTG 0.2661 0.3509 2.027 1 0.1546 
rs806366|rs12189668|rs1049353 TTG 0.6822 0.4682 11.37 1 0.0007/0.009 
rs12189668|rs1049353|rs806369 OMNIBUS NA NA 12.41 3 0.006 
rs12189668|rs1049353|rs806369 CGT 0.009429 0.02792 1.515 1 0.2183 
rs12189668|rs1049353|rs806369 TGT 0.09756 0.1319 0.7056 1 0.4009 
rs12189668|rs1049353|rs806369 TAC 0.03752 0.1303 9.364 1 0.002/0.026 
rs12189668|rs1049353|rs806369 TGC 0.8555 0.7099 8.34 1 0.004/0.052 
rs1049353|rs806369|rs806371 OMNIBUS NA NA 11.77 3 0.008 
rs1049353|rs806369|rs806371 GCG 0.2855 0.2251 1.046 1 0.3065 
rs1049353|rs806369|rs806371 GTT 0.1111 0.1672 1.689 1 0.1938 
rs1049353|rs806369|rs806371 ACT 0.04295 0.1385 9.205 1 0.002/0.026 
rs1049353|rs806369|rs806371 GCT 0.5605 0.4691 1.917 1 0.1662 
rs806369|rs806371|rs806374 OMNIBUS NA NA 2.904 5 0.7148 
rs806369|rs806371|rs806374 CGC 0.2756 0.2321 0.5411 1 0.462 
rs806369|rs806371|rs806374 TTC 0.01025 0.01849 0.3291 1 0.5662 
rs806369|rs806371|rs806374 CTC 0.1416 0.1254 0.1226 1 0.7262 
rs806369|rs806371|rs806374 CGT 0.01398 0.003143 0.5519 1 0.4575 
rs806369|rs806371|rs806374 TTT 0.1027 0.158 1.719 1 0.1899 
rs806369|rs806371|rs806374 CTT 0.4558 0.4628 0.011 1 0.9164 
rs806371|rs806374|rs12195101 OMNIBUS NA NA 2.01 5 0.8478 
rs806371|rs806374|rs12195101 GCC 0.02902 0.0396 0.2094 1 0.6472 
rs806371|rs806374|rs12195101 TCC 0.01258 0.01922 0.1824 1 0.6693 
rs806371|rs806374|rs12195101 GCT 0.2441 0.1923 0.8378 1 0.36 
rs806371|rs806374|rs12195101 TCT 0.1369 0.1228 0.0952 1 0.7577 
rs806371|rs806374|rs12195101 GTT 0.01414 0.003134 0.5629 1 0.4531 
rs806371|rs806374|rs12195101 TTT 0.5633 0.623 0.8161 1 0.3663 
rs806374|rs12195101|rs806375 OMNIBUS NA NA 2.175 4 0.7037 
rs806374|rs12195101|rs806375 CTA 0.1865 0.153 0.4258 1 0.5141 
rs806374|rs12195101|rs806375 TTA 0.2655 0.2735 0.0184 1 0.8922 
rs806374|rs12195101|rs806375 CCT 0.04246 0.05882 0.3469 1 0.5559 
rs806374|rs12195101|rs806375 CTT 0.1983 0.146 1.003 1 0.3166 
rs806374|rs12195101|rs806375 TTT 0.3072 0.3687 0.9791 1 0.3224 
rs12195101|rs806375|rs806377 OMNIBUS NA NA 1.947 5 0.8564 
rs12195101|rs806375|rs806377 TAT 0.3012 0.2956 0.0084 1 0.9268 
rs12195101|rs806375|rs806377 CTT 0.02122 0.04132 0.9571 1 0.3279 
rs12195101|rs806375|rs806377 TTT 0.03044 0.05055 0.7049 1 0.4011 
rs12195101|rs806375|rs806377 TAC 0.1512 0.1254 0.3064 1 0.5799 
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rs12195101|rs806375|rs806377 CTC 0.02048 0.01582 0.0646 1 0.7994 
rs12195101|rs806375|rs806377 TTC 0.4754 0.4713 0.004 1 0.9498 
rs806375|rs806377|rs806378 OMNIBUS NA NA 9.647 5 0.08589 
rs806375|rs806377|rs806378 TTT 0.04183 0.1048 4.502 1 0.03/0.39 
rs806375|rs806377|rs806378 TCT 0.07788 0.1524 3.831 1 0.05/0.65 
rs806375|rs806377|rs806378 ATC 0.2962 0.2826 0.0511 1 0.8212 
rs806375|rs806377|rs806378 TTC 0.01342 0.004024 0.4369 1 0.5086 
rs806375|rs806377|rs806378 ACC 0.1555 0.1356 0.1763 1 0.6745 
rs806375|rs806377|rs806378 TCC 0.4151 0.3206 2.137 1 0.1438 
rs806377|rs806378|rs2023239 OMNIBUS NA NA 8.899 4 0.06367 
rs806377|rs806378|rs2023239 TTC 0.03654 0.09214 3.99 1 0.05/0.65 
rs806377|rs806378|rs2023239 CCC 0.3208 0.2507 1.32 1 0.2506 
rs806377|rs806378|rs2023239 CTT 0.08678 0.165 3.867 1 0.05/0.65 
rs806377|rs806378|rs2023239 TCT 0.315 0.3037 0.0342 1 0.8533 
rs806377|rs806378|rs2023239 CCT 0.2409 0.1885 0.8869 1 0.3463 
rs806378|rs2023239|rs1535255 OMNIBUS NA NA 8.418 4 0.0774 
rs806378|rs2023239|rs1535255 CCG 0.3075 0.2314 1.58 1 0.2088 
rs806378|rs2023239|rs1535255 TCT 0.03625 0.08765 3.441 1 0.0636 
rs806378|rs2023239|rs1535255 CCT 0.01951 0.029 0.2454 1 0.6204 
rs806378|rs2023239|rs1535255 TTT 0.08535 0.1623 3.751 1 0.05277 
rs806378|rs2023239|rs1535255 CTT 0.5514 0.4896 0.8679 1 0.3515 
rs2023239|rs1535255|rs6454672 OMNIBUS NA NA 4.548 4 0.3369 
rs2023239|rs1535255|rs6454672 CGC 0.2857 0.2143 1.476 1 0.2244 
rs2023239|rs1535255|rs6454672 TGC 0.01728 0.01429 0.0313 1 0.8595 
rs2023239|rs1535255|rs6454672 CGT 0.02296 0.01429 0.2065 1 0.6495 
rs2023239|rs1535255|rs6454672 CTT 0.05419 0.1143 3.415 1 0.0646 
rs2023239|rs1535255|rs6454672 TTT 0.6199 0.6429 0.1292 1 0.7192 
 
 
Analysis conducted using PLINK with a sliding window of three. 
 Significant p-values are shown in Bold. 















The CNR1 and the COMT genes in First Episode of Psychosis Page 101 
 
Table 5.13 Haplotype association analysis of markers within the CNR1 gene in the 











rs10485171|rs806365|rs806366 OMNIBUS NA NA 6.406 5 0.2687 
rs10485171|rs806365|rs806366 TTT 0.1095 0.08652 0.4915 1 0.4832 
rs10485171|rs806365|rs806366 CCT 0.2935 0.246 0.9492 1 0.3299 
rs10485171|rs806365|rs806366 TCT 0.1213 0.1135 0.04877 1 0.8252 
rs10485171|rs806365|rs806366 TTC 0.3186 0.288 0.3671 1 0.5446 
rs10485171|rs806365|rs806366 CCC 0.1094 0.1759 3.108 1 0.07789 
rs10485171|rs806365|rs806366 TCC 0.04766 0.09013 2.456 1 0.1171 
rs806365|rs806366|rs12189668 OMNIBUS NA NA 5.531 5 0.3546 
rs806365|rs806366|rs12189668 TTC 0.0257 0.01723 0.2789 1 0.5974 
rs806365|rs806366|rs12189668 CCC 0.0308 0.05248 1.029 1 0.3105 
rs806365|rs806366|rs12189668 TTT 0.1086 0.07987 0.7945 1 0.3727 
rs806365|rs806366|rs12189668 CTT 0.3902 0.3493 0.6001 1 0.4385 
rs806365|rs806366|rs12189668 TCT 0.2937 0.2687 0.2573 1 0.612 
rs806365|rs806366|rs12189668 CCT 0.1511 0.2323 3.674 1 0.05528 
rs806366|rs12189668|rs1049353 OMNIBUS NA NA 4.415 5 0.4913 
rs806366|rs12189668|rs1049353 TTA 0.248 0.1642 3.557 1 0.05931 
rs806366|rs12189668|rs1049353 CTA 0.03608 0.03514 0.0022 1 0.9626 
rs806366|rs12189668|rs1049353 TCG 0.01376 0.009027 0.1633 1 0.6861 
rs806366|rs12189668|rs1049353 CCG 0.03754 0.05577 0.6515 1 0.4196 
rs806366|rs12189668|rs1049353 TTG 0.2643 0.2716 0.02271 1 0.8802 
rs806366|rs12189668|rs1049353 CTG 0.4003 0.4643 1.417 1 0.2338 
rs12189668|rs1049353|rs806369 OMNIBUS NA NA 9.018 4 0.06066 
rs12189668|rs1049353|rs806369 CGT 0.0219 0.01032 0.6834 1 0.4084 
rs12189668|rs1049353|rs806369 TGT 0.2405 0.178 1.981 1 0.1593 
rs12189668|rs1049353|rs806369 TAC 0.2869 0.2027 3.208 1 0.07326 
rs12189668|rs1049353|rs806369 CGC 0.03352 0.05824 1.234 1 0.2666 
rs12189668|rs1049353|rs806369 TGC 0.4171 0.5508 6.095 1 0.013/0.13 
rs1049353|rs806369|rs806371 OMNIBUS NA NA 9.828 3 0.02009 
rs1049353|rs806369|rs806371 GCG 0.1431 0.2044 2.273 1 0.1316 
rs1049353|rs806369|rs806371 GTT 0.2664 0.1802 3.577 1 0.05857 
rs1049353|rs806369|rs806371 ACT 0.2847 0.2017 3.142 1 0.07629 
rs1049353|rs806369|rs806371 GCT 0.3057 0.4137 4.358 1 0.04/0.52 
rs806369|rs806371|rs806374 OMNIBUS NA NA 4.494 5 0.4807 
rs806369|rs806371|rs806374 CGC 0.1292 0.1616 0.7174 1 0.397 
rs806369|rs806371|rs806374 TTC 0.03414 0.01576 1.112 1 0.2917 
rs806369|rs806371|rs806374 CTC 0.2084 0.1943 0.1047 1 0.7462 
rs806369|rs806371|rs806374 CGT 0.02011 0.03994 1.184 1 0.2765 
rs806369|rs806371|rs806374 TTT 0.2288 0.1728 1.613 1 0.2041 
rs806369|rs806371|rs806374 CTT 0.3793 0.4156 0.462 1 0.4967 
rs806371|rs806374|rs12195101 OMNIBUS NA NA 3.322 5 0.6504 
rs806371|rs806374|rs12195101 GCC 0.02469 0.03278 0.2051 1 0.6507 
rs806371|rs806374|rs12195101 TCC 0.01031 0.01424 0.1116 1 0.7383 
rs806371|rs806374|rs12195101 GCT 0.09924 0.1368 1.186 1 0.2762 
rs806371|rs806374|rs12195101 TCT 0.2313 0.1934 0.729 1 0.3932 
rs806371|rs806374|rs12195101 GTT 0.02094 0.04173 1.279 1 0.2581 
rs806371|rs806374|rs12195101 TTT 0.6135 0.581 0.3767 1 0.5394 
rs806374|rs12195101|rs806375 OMNIBUS NA NA 0.8157 4 0.9363 
rs806374|rs12195101|rs806375 CCT 0.03571 0.04795 0.3188 1 0.5723 
rs806374|rs12195101|rs806375 CTT 0.08773 0.1021 0.2018 1 0.6532 
rs806374|rs12195101|rs806375 TTT 0.3562 0.3686 0.05598 1 0.813 
rs806374|rs12195101|rs806375 CTA 0.2457 0.2199 0.3099 1 0.5777 
rs806374|rs12195101|rs806375 TTA 0.2747 0.2615 0.07401 1 0.7856 
rs12195101|rs806375|rs806377 OMNIBUS NA NA 5.158 4 0.2714 
rs12195101|rs806375|rs806377 TTC 0.4109 0.4206 0.03234 1 0.8573 
rs12195101|rs806375|rs806377 TAC 0.05037 0.1069 3.894 1 0.05/0.065 
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rs12195101|rs806375|rs806377 CTT 0.03009 0.03416 0.04509 1 0.8318 
rs12195101|rs806375|rs806377 TTT 0.0359 0.04665 0.249 1 0.6178 
rs12195101|rs806375|rs806377 TAT 0.4728 0.3917 2.23 1 0.1353 
rs806375|rs806377|rs806378 OMNIBUS NA NA 7.833 4 0.09791 
rs806375|rs806377|rs806378 TCT 0.2329 0.2032 0.43 1 0.512 
rs806375|rs806377|rs806378 TTT 0.06962 0.08645 0.3337 1 0.5635 
rs806375|rs806377|rs806378 TCC 0.1696 0.2227 1.516 1 0.2182 
rs806375|rs806377|rs806378 ACC 0.04763 0.1073 4.375 1 0.04/0.52 
rs806375|rs806377|rs806378 ATC 0.4803 0.3804 3.395 1 0.06541 
rs806377|rs806378|rs2023239 OMNIBUS NA NA 6.828 4 0.1453 
rs806377|rs806378|rs2023239 TTC 0.05752 0.07514 0.4373 1 0.5085 
rs806377|rs806378|rs2023239 CCC 0.1241 0.2053 4.232 1 0.04/0.52 
rs806377|rs806378|rs2023239 CTT 0.2502 0.2182 0.486 1 0.4857 
rs806377|rs806378|rs2023239 CCT 0.08249 0.111 0.8129 1 0.3673 
rs806377|rs806378|rs2023239 TCT 0.4857 0.3904 3.157 1 0.07562 
rs806378|rs2023239|rs1535255 OMNIBUS NA NA 4.122 3 0.2486 
rs806378|rs2023239|rs1535255 CCG 0.1411 0.2129 3.074 1 0.07956 
rs806378|rs2023239|rs1535255 TCT 0.05625 0.07787 0.6492 1 0.4204 
rs806378|rs2023239|rs1535255 TTT 0.2486 0.2188 0.4166 1 0.5186 
rs806378|rs2023239|rs1535255 CTT 0.554 0.4904 1.372 1 0.2414 
rs2023239|rs1535255|rs6454672 OMNIBUS NA NA 4.748 3 0.1912 
rs2023239|rs1535255|rs6454672 CGC 0.1138 0.1487 0.9221 1 0.3369 
rs2023239|rs1535255|rs6454672 CGT 0.02987 0.05727 1.599 1 0.2061 
rs2023239|rs1535255|rs6454672 CTT 0.05561 0.08942 1.488 1 0.2226 
rs2023239|rs1535255|rs6454672 TTT 0.8007 0.7046 4.289 1 0.04/0.52 
 
Analysis conducted using PLINK with a sliding window of three. 
 Significant p-values are shown in Bold. 
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rs10485171|rs806365|rs806366 OMNIBUS NA NA 8.049 4 0.08978 
rs10485171|rs806365|rs806366 TTT 0.09929 0.1031 0.06023 1 0.8061 
rs10485171|rs806365|rs806366 CCT 0.2354 0.2277 0.1274 1 0.7212 
rs10485171|rs806365|rs806366 TCT 0.1615 0.1179 6.207 1 0.012/0.156 
rs10485171|rs806365|rs806366 TTC 0.3704 0.3881 0.5055 1 0.4771 
rs10485171|rs806365|rs806366 CCC 0.1334 0.1632 2.607 1 0.1064 
rs806365|rs806366|rs12189668 OMNIBUS NA NA 4.499 3 0.2124 
rs806365|rs806366|rs12189668 TTT 0.101 0.1025 0.009276 1 0.9233 
rs806365|rs806366|rs12189668 CTT 0.3939 0.3456 3.824 1 0.05/0.65 
rs806365|rs806366|rs12189668 TCT 0.3663 0.3875 0.7213 1 0.3957 
rs806365|rs806366|rs12189668 CCT 0.1388 0.1644 1.904 1 0.1677 
rs806366|rs12189668|rs1049353 OMNIBUS NA NA 4.348 2 0.1137 
rs806366|rs12189668|rs1049353 TTA 0.2242 0.2211 0.02006 1 0.8874 
rs806366|rs12189668|rs1049353 TTG 0.2708 0.2278 3.761 1 0.05246 
rs806366|rs12189668|rs1049353 CTG 0.505 0.551 3.194 1 0.07393 
rs12189668|rs1049353|rs806369 OMNIBUS NA NA 0.004099 2 0.998 
rs12189668|rs1049353|rs806369 TGT 0.3461 0.3464 0.0001647 1 0.9898 
rs12189668|rs1049353|rs806369 TAC 0.224 0.2227 0.003939 1 0.95 
rs12189668|rs1049353|rs806369 TGC 0.4299 0.4309 0.001636 1 0.9677 
rs1049353|rs806369|rs806371 OMNIBUS NA NA 4.165 3 0.2442 
rs1049353|rs806369|rs806371 GCG 0.1631 0.1295 3.505 1 0.06117 
rs1049353|rs806369|rs806371 GTT 0.348 0.3473 0.0007561 1 0.9781 
rs1049353|rs806369|rs806371 ACT 0.215 0.2199 0.05385 1 0.8165 
rs1049353|rs806369|rs806371 GCT 0.274 0.3032 1.575 1 0.2094 
rs806369|rs806371|rs806374 OMNIBUS NA NA 4.716 5 0.4515 
rs806369|rs806371|rs806374 CGC 0.1427 0.1131 3.066 1 0.07992 
rs806369|rs806371|rs806374 TTC 0.05017 0.06104 0.8397 1 0.3595 
rs806369|rs806371|rs806374 CTC 0.148 0.1559 0.181 1 0.6705 
rs806369|rs806371|rs806374 CGT 0.02495 0.02069 0.3179 1 0.5729 
rs806369|rs806371|rs806374 TTT 0.2948 0.2852 0.1696 1 0.6804 
rs806369|rs806371|rs806374 CTT 0.3394 0.3641 1.012 1 0.3143 
rs806371|rs806374|rs12195101 OMNIBUS NA NA 4.038 3 0.2574 
rs806371|rs806374|rs12195101 GCT 0.141 0.1108 3.215 1 0.07297 
rs806371|rs806374|rs12195101 TCT 0.199 0.2182 0.8378 1 0.36 
rs806371|rs806374|rs12195101 GTT 0.02564 0.02072 0.4153 1 0.5193 
rs806371|rs806374|rs12195101 TTT 0.6345 0.6503 0.4157 1 0.5191 
rs806374|rs12195101|rs806375 OMNIBUS NA NA 2.836 3 0.4176 
rs806374|rs12195101|rs806375 CTT 0.08864 0.09521 0.1931 1 0.6604 
rs806374|rs12195101|rs806375 TTT 0.302 0.3378 2.208 1 0.1373 
rs806374|rs12195101|rs806375 CTA 0.2492 0.2332 0.5272 1 0.4678 
rs806374|rs12195101|rs806375 TTA 0.3602 0.3337 1.17 1 0.2793 
rs12195101|rs806375|rs806377 OMNIBUS NA NA 8.965 2 0.01131 
rs12195101|rs806375|rs806377 TTC 0.3825 0.4303 3.528 1 0.06033 
rs12195101|rs806375|rs806377 TAC 0.1162 0.07547 7.536 1 0.006/0.07 
rs12195101|rs806375|rs806377 TAT 0.5013 0.4942 0.07536 1 0.7837 
rs806375|rs806377|rs806378 OMNIBUS NA NA 12.93 3 0.0048 
rs806375|rs806377|rs806378 TCT 0.2203 0.278 6.517 1 0.01/0.13 
rs806375|rs806377|rs806378 TCC 0.1599 0.1523 0.1641 1 0.6854 
rs806375|rs806377|rs806378 ACC 0.1162 0.0729 8.681 1 0.003/0.039 
rs806375|rs806377|rs806378 ATC 0.5035 0.4968 0.06782 1 0.7945 
rs806377|rs806378|rs2023239 OMNIBUS NA NA 8.026 3 0.04547 
rs806377|rs806378|rs2023239 CCC 0.1857 0.1562 2.373 1 0.1234 
rs806377|rs806378|rs2023239 CTT 0.2194 0.2785 6.929 1 0.008/0.1 
rs806377|rs806378|rs2023239 CCT 0.08348 0.07204 0.7034 1 0.4016 
rs806377|rs806378|rs2023239 TCT 0.5114 0.4933 0.4961 1 0.4812 
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rs806378|rs2023239|rs1535255 OMNIBUS NA NA 6.875 2 0.03214 
rs806378|rs2023239|rs1535255 CCG 0.1854 0.1612 1.556 1 0.2123 
rs806378|rs2023239|rs1535255 TTT 0.2232 0.281 6.535 1 0.01/0.13 
rs806378|rs2023239|rs1535255 CTT 0.5914 0.5578 1.735 1 0.1878 
rs2023239|rs1535255|rs6454672 OMNIBUS NA NA 2.328 2 0.3123 
rs2023239|rs1535255|rs6454672 CGC 0.1396 0.115 2.098 1 0.1475 
rs2023239|rs1535255|rs6454672 CGT 0.04895 0.04507 0.1276 1 0.7209 
rs2023239|rs1535255|rs6454672 TTT 0.8114 0.8399 2.159 1 0.1417 
 
 
Analysis conducted using PLINK with a sliding window of three. 
 Significant p-values are shown in Bold. 
*DF= Degrees of Freedom 
 
 
5.7 Summary of results 
The summarized results of statistical analyses performed in this chapter are as follow: 
 15 tag SNPs within the CNR1 gene were analysed for main effect on psychosis in 3 
different study samples (GAP Caucasian; GAP Black and PICOS) 
 A χ2 test was performed to check for allelic as well as genotypic association of each SNPs 
and psychosis. rs1049353 showed positive association in the GAP Caucasian sample, also 
after conservative Bonferroni correction (p-value=0.03). rs806378 showed marginal 
positive association in the GAP Caucasian sample and in the PICOS sample, it only retained 
significance after multiple testing correction in the GAP Caucasian sample (p-value=0.05). 
Finally, rs806371 showed positive association in the PICOS sample but not after 
Bonferroni correction. 
 After haplotype analysis with window of 3, 4 haplotypes (rs806366-rs12189668-
rs1049353) TTA; (rs806366-rs12189668rs1049353) TTG; (rs12189668-rs1049353-
rs806369) TAC; (rs1049353-rs806369-rs806371) ACT showed positive association also 
after multiple testing correction (p-value=0.03, 0.009, 0.03 and 0.03 respectively; target 
Bonferroni p-value=0.005). In the PICOS group, 1 haplotype showed positive association 
(rs806375-rs806377-rs806378) ACC after Bonferroni multiple testing correction (p-
value=0.003). 
 The 4 haplotypes found significant in the GAP Caucasian sample all contained rs1049353. 
I therefore performed a conditional test to check for independent signal from the SNP. 
Results showed that indeed there was significance (p-value=0.02). 
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 The ACC haplotype found significant in the PICOS Study sample contained rs806378. I 
therefore performed a conditional test to check for independent signal from the SNP. 
Results showed significance (p-value=0.04). 
 No association was found between rs1049353 and cannabis use. The SNP did not seem to 
have a moderating effect on cannabis use. 
 No gene x environment interaction was observed between rs1049353 and cannabis use. 
5.8 Conclusions 
It is of a great importance to interpret the results shown on the basis of many limitations of this 
study. First and foremost, one of the biggest obstacles resides in the sample size with the GAP 
Study sample Caucasian group consisting of 174 psychotic patients and 45 controls. This sample 
size seems to be more relevant because of the association found for rs1049353 with psychosis, a 
similar effect also seen in the haplotype analysis. Small sample size, does not only limit statistical 
power of discovery, which is very low in this study. A small sample size, may also give a false 
estimation of MAFs, this is to say that some alleles could be under represented, also because of the 
number of subjects genotyped. For example, rs1049353 is a common polymorphisms of which the 
minor A allele frequency is 0.23 in the CEU population of HapMap. In this study the MAF of 
affected Vs unaffected individuals is 0.04/0.14 respectively. Such difference may indeed reflect 
disease status and normal genetic frequency variation across different Caucasian populations, but 
could also be due to the very low number of subjects genotyped. This, in turn, may generate false 
positives with p-values retaining significance even after the strictest multiple testing correction. 
Low MAFs and sample size also influence the values of D’ calculated in a given population, 
therefore it is important to also pay attention to the r2 values calculated in order to check for the 
presence of proxy SNPs. In the GAP Caucasian group rs1049353 do not seem to however; be 
closely related to any of the neighbouring SNPs as can be seen in the table below. In particular, 
rs1049353-rs806371 show a D’ value of 1 and a r2 score of 0.025. This is very likely due to the 
ceiling effect of D’ value due, as mentioned earlier, to a very small sample size. Therefore, although 
D’ is high, r2 is very low and it can be concluded that these 2 SNPs are not in strong LD. The same 
consideration can be made for SNPs rs1049353-rs806374 and rs1049353-rs806375 and others that 
can be fully seen in table 5.7. This could give the confidence that the signal, if not a statistical false 
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MARKER 1 MARKER 2 D' VALUE r2 VALUE 
rs1049353 rs806371 1 0.025 
rs1049353 rs806374 0.642 0.019 
rs1049353 rs806375 0.513 0.021 
rs1049353 rs806377 0.314 0.012 
 
The positive association shown in the haplotype analysis in the GAP Study sample Caucasian group 
and the PICOS Study sample can also be interpreted in the same way as allelic association. It is in 
fact very important to note that the haplotype frequency is low, being in the psychotic and non 
psychotic population within the GAP Caucasian group of 0.4 and 0.14 respectively (CTA 
haplotype) and 0.05 and 0.14 (TAT haplotype). The markers were not in high LD with  r2 score 
below 0.2, but the low frequency together with a very small sample size, have probably generated 
a statistical false positive result. The same considerations can be made for the haplotype that 
survived the Bonferroni correction in the PICOS Study sample: rs806375|rs806377|rs806378 
(ACC). The haplotype frequency in psychotic patients and non psychotic controls was low (0.12 
and 0.07 respectively) and the markers scored in the high range for D’ and r2 values: 
 
MARKER 1 MARKER 2 D' VALUE r2 VALUE 
rs806375 rs806377 0.959 0.661 
rs806375 rs806378 0.98 0.474 
rs806377 rs806378 1 0.346 
 
Bonferroni multiple testing correction is very strict, it is common place to use other type of tests 
like permutation tests. Surviving Bonferroni correction though, does not equal true association; it 
is still possible to be in the presence of a false positive. Indeed, many SNPs in the PICOS Study 
sample do not show a completely independent signal from each others, although they are tag SNPs. 
This is, in turn, also partly explained by low haplotype frequency and small sample size.  
In the literature, there are conflicting reports of these SNPs being associated with metabolic 
disorder, schizophrenia, anxiety and drug abuse. Among all markers found in literature, rs1049353 
seem to be the most studied. It is a A/G base change located in the coding region of the Cannabinoid 
Receptor 1 gene (Exon 4) with both alleles described as risk alleles by different studies (Hadmani 
et al., 2008) (De Luis et al., 2012). Rs1049353 has been found to be associated with cocaine 
dependence (Zuo et al., 2009), major depression (Mitjans et al., 2013), lack of improvement in 
leptin levels (De Luis et al., 2012) and very recently with schizophrenia, although it did not pass 
the multiple correction (Costa et al., 2013). Rs1049353 has been reported associated with cigarette 
intake (Bienertova-Vaskus et al., 2012), but no evidence of association was found with other main 
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stream drugs of abuse (Benyamina et al., 2011). Incidentally, rs1049353 is the SNP that returned 
lower p-values in this thesis. It showed a main effect on psychosis in the GAP Caucasian population 
but no evidence of association with cannabis use or gene x environment interaction.  
In light of the limitations highlighted earlier, but also in light of many evidences presented in the 
literature; results of this work are not seen as a striking positive association. However, neither 
should they be treated as certain false positive. They are interpreted as indication of a possible 
involvement of the CNR1 gene in the risk for psychosis. Further work needs to be done if the role 
of rs1049353 and more in general on the CNR1 gene needs to be elucidated in the pathophysiology 
of schizophrenia.  The first suggestion would be increasing the sample size to many more case-
control matched pairs. This is in order to obtain a power of at least 80%, diminishing therefore the 
possibility of statistical error. As shown in the power calculation (Materials and Methods chapter) 
in order to detect an effect size of 1.2 in a model assuming a population prevalence of 1% and allelic 
log additive effect for a MAF of 0.1 and, around 4,000 cases and matched controls are needed. A 
smaller number of samples is needed if the effect size is bigger, but it is plausible that schizophrenia 
is a polygenic disorder with multiple genes of small size all playing a role in the pathophysiology. 
Another consideration would be on the genotyping methods used; in light of recent sequencing 
techniques being easier to perform and cheaper, it is only logical to move towards that new field 
with whole exome sequence of pairs of cases and controls ranging in the thousands. Increasing the 
sample size would limit the possibility of type 1 error and maximize the likelihood of finding a true 
association. Most recent GWAS have failed to report any association of the rs1049353 
polymorphism in schizophrenia. One of the latest GWAS analysis performed is the one by Ripke 
et al., who analysed more than 11,000 population-based samples from Sweden and re-analysed data 
using 1000 genome imputation in over 20,000 samples, excluding the Swedish ones. No markers 
within the CNR1 or the COMT gene were found to be significantly associated with schizophrenia 
(Ripke et al., 2013). This suggests that we are in the presence of a false positive association that 


















The Catechol-O-Methyltransferase gene in First Episode of Psychosis 
 
6.1 Background information 
 
Catechol-O-Methyltransferase (COMT) catalyses the O-methylation of catecholamines including 
dopamine, adrenaline and noradrenalin. It was discovered by Axelrod and Tomchick in 1958 
(Axelrod and Tomchick, 1958). COMT is expressed throughout the brain but it plays a particularly 
important role in the prefrontal cortex for dopamine flux, where inactivation of dopamine is 
preferentially performed by catabolic enzymes. The COMT gene is located on the short arm of 
chromosome 22: 22q11.2 and encodes two main isoforms: S-COMT, soluble and mostly found in 
human peripheral tissues (Jeffery and Roth, 1984) and MB-COMT, a longer membrane found 
mainly in the brain (Tenhunen et al., 1994). MB-COMT has much higher affinity for dopamine and 
noradrenaline than S-COMT. 
Over the years, many polymorphisms within the COMT gene have been reported associated with 
schizophrenia; however, the evidence is still inconsistent. Meta-analysis studies in 2003 and 2005 
reported no or very minimal association of COMT rs4680 polymorphism with schizophrenia in a 
case-control and family based cohort (Glatt et al., 2003) and Asian and European case-control 
population (Fan et al., 2005). A further meta-analysis investigating 4 more markers within the 
COMT gene (rs737865, rs165599, rs2075507, rs165849) also found no evidence of association 
with schizophrenia in a Japanese case-control population (Okochi et al., 2009). Interestingly 
though, Costas et al., found significant association between rs4680 and schizophrenia in a meta-
analysis of 51 studies, under an over dominant model; where having too low as well as too high 
levels of Dopamine signaling seemed to be a risk factor for the disease (Costas et al., 2011). More 
recently, rs4680 has been associated with an increase in violent behavior among schizophrenic 
patients (Bhakta et al., 2012) and among schizophrenic male patients in a meta-analysis (Singh et 
al., 2012). An effect of rs4680 on schizophrenia was also described by Lo Bianco, who found 
evidence of a main effect in the striatum and an interaction between the Val/Val genotype and brain 
activity in prefrontal cortex during emotion processing (Lo Bianco et al., 2012). rs4680 was also 
associated with schizophrenia, together with rs4646315 and rs9332377, in a North Indian case-
control study (Kukshal et al., 2013). Other studies, however failed to replicate any association 
(Lajin et al., 2011) (Zhang et al., 2012) (Chen et al., 2012) (Tovilla-Zarate et a., 2013). A number 
of studies have also implicated rs4680 in neuropsychological performances and brain structure, 
with evidences in temporal regions, frontal areas, lateral ventricles and thalamus (reviewed in Ira 
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et al., 2013). This review suggested a link between rs4680 and 2 neuropsychological and 2 brain 
structural endophenotypes.  
Certainly, rs4680 is the most studied polymorphism within the COMT gene to date and, although 
conflicting, evidence suggests a possible role in the pathophysiology of schizophrenia. Rs4680 is a 
common polymorphism located in the coding region of the COMT gene, resulting in a 
valine/methionine substitution at codon 158 in the MB-COMT isoform (Met158Val). This 
substitution affects the thermostability of the enzyme resulting in reduction of COMT activity in 
the Met allele carriers and an increase of function in Val allele carriers (Lachman et al., 1996) with 
38% reduction of COMT activity in PFC tissue in human post mortem studies, with no change in 
mRNA transcription (Chen et al., 2004).  This leads to reduced degradation and therefore higher 
levels of catecholamines in the Met allele carriers. As reviewed in chapter 3 of this thesis, rs4680 
has been implicated widely as having a possible role in the interaction with environment, 
particularly drug abuse. The first study to highlight the possible interaction between rs4680 and 
cannabis use was that of Caspi in 2005, who found that Val carriers had a five fold increased risk 
in developing schizophreniform disorder (Caspi et al., 2005). These findings were supported by the 
work of Henquet et al, in 2006, Estrada et al., 2011 and by mice models (O’Tualthaigh et al., 2012). 
Some conflicting evidence however, has come from the recent studies of Okochi and Zammit 
(Okochi et al., 2011) (Zammit et al., 2011). Furthermore, Sanders et al., found no evidence of 
association between the rs4680 polymorphism and schizophrenia in a large sample of over 3.500 
subjects (Sanders et al., 2008). 
In light of the reviewed evidence, rs4680 seemed to be one of the logical candidates to be analyzed 
in this chapter. Rs4680 is also part of a haplotype formed with 3 other polymorphisms, namely 
rs6269, rs4633 and rs4818. This haplotype seems to be a better index of COMT enzymatic activity 
than the single polymorphism. Nackley et al. analyzed the three different haplotypes made by 
rs6269, rs4633 and rs4818 within the COMT gene; they were named after their ability to influence 
sensitivity to pain: Low Pain Sensitivity (LPS) haplotype, Average Pain Sensitivity (APS) 
haplotype and High Pain Sensitivity (HPS) haplotype. The three haplotypes contain two 
synonymous and 1 non synonymous variations and both the HPS and the LPS contain the Val allele 
whereas the APS contained the Met allele at position 158 (Nackley et al., 2006). Both haplotypes 
containing the Val allele showed higher enzymatic activity (Nackley et al., 2006).  
Rs165599 is located in the COMT 3’- untraslated region (UTR) and it is a G to A change. It has 
been found to be positively associated with Schizophrenia (Shifman et al., 2002) (Allen et al., 2008). 
Furthermore, rs165599 has been found to be preferentially transmitted to affected individuals and 
to account for a later onset of the disease in a family study of Tawanese schizophrenic population 
(Chien et al., 2009).  The same study found no association with rs4680 and rs737865 and 
schizophrenia (Chien et al., 2009), with rs737865 being located in intron 1 of the gene. Jugurnauth 
and colleagues found rs165599 as part of a haplotype with rs4680 to be over represented in 
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Methamphetamine users but not in schizophrenia patients (Jugurnauth et al., 2011). Indeed Maria 
et al., showed a higher frequency of a haplotype made of rs4680, rs737865 and rs165599 in Greek 
schizophrenic patients (Maria et al., 2012). The same polymorphism was also found to be positively 
associated in a cohort of African patients (Wright et al., 2012). Rs2075507 is located in the promoter 
region 2 of the COMT gene and has been investigated in schizophrenia by several studies.  
There is however no supporting evidence of a role in the increase of the risk of the disease 
(Nunokawa et al., 2007) (Okochi et al., 2009), although it showed significant association as part of 
the rs4680-rs165599-rs2075507 haplotype in a group of female group of schizophrenic patients 
with sensory gating deficits (Ancin et al., 2011). 
The interaction between the COMT gene, particularly rs4680 and cannabis use, has been explored 
widely during the last decade. Since the publication of Caspi et al., in 2005 showed that the Val 
allele moderated the effect of cannabis in a schizophrenic population with a 5 fold increase of risk 
of the disease, replications have showed a mix of positive and negative findings (reviewed in 
chapter 3). As mentioned earlier, the LPS haplotype can represent better the enzymatic activity of 
the COMT gene and therefore may show a stronger interaction with cannabis use. Furthermore, 
consumption before or after adolescence seems to play an important role in the pathophysiology of 
the disorder, with earlier start of use posing a greater risk (Arsenault et al., 2002) (Stefanis et al., 
2004) (Dragt et al., 2010) (Estrada et al., 2011). 
 
6.2 Hypothesis under investigation 
This chapter aims to investigate whether 7 SNPs within the COMT gene namely rs737865, rs6269, 
rs4633, rs4818, rs165599, rs4680 and rs2075507 have a main effect on psychosis.  
I hypothesise that the analysed SNPs and the LPS haplotype within the COMT gene have a main 
effect on psychosis.  
The LPS haplotype (a priori hypothesis) is also investigated in search for evidence of interaction 
with cannabis use. I hypothesise that the LPS haplotype moderates the risk of psychosis following 
use of cannabis. 
Furthermore I will conduct exploratory analyses to examine the role of the LPS haplotype in 
moderating the risk of psychosis following high VS low frequent use of cannabis and use in 
adolescence. 
Table 6.1 shows all markers analysed in this chapter with their chromosomal position, minor allele 
frequency as reported in NCBI database and base pairs sequence. 
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POSITION MAF SEQUENCE 
COMT rs6269 3801154 G=0.37 GCATTTCTGAACCTTGCCCCTCTGC[G/A]AACACAAGGGGGCGATGGTGGCACT 
COMT rs4633 3801437 T=0.39 CCAAGGAGCAGCGCATCCTGAACCA[C/T]GTGCTGCAGCATGCGGAGCCCGGGA 
COMT rs4818 3802409 G=0.32 GCCTGCTGTCACCAGGGGCGAGGCT[C/G]ATCACCATCGAGATCAACCCCGACT 
COMT rs4680 3802473 A=0.39 CCAGCGGATGGTGGATTTCGCTGGC[A/G]TGAAGGACAAGGTGTGCATGCCTGA 
COMT rs2075507 3779368 G=0.35 CTGGACTGTGAGTATGGGAAGGGGAA[A/G]CTTTTCTGTCTGTTGTCCCCACTAC 
COMT rs165599 3807982 G=0.46 TGTTAGCCCCATGGGGACGACTGCC[A/G]GCCTGGGAAACGAAGAGGAGTCAGC 
COMT rs737865 3781397 G=0.23 GCTTTTTGGATTTTTCCAGCCAGGG[A/G]TTTTTGTGTCCTGTTGCTTTTTATT 
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6.3 SNPs Genotyping 
Primers used to genotype were ordered through Applied Biosystems as follow: 
 
rs6269 (Chr. 22 - 18329952 ) - Context-Sequence VIC/FAM 
GCATTTCTGAACCTTGCCCCTCTGC[G/A]AACACAAGGGGGCGATGGTGGCACT 
 
rs4633 (Chr. 22 - 18330235 ) - Context-Sequence VIC/FAM 
CCAAGGAGCAGCGCATCCTGAACCA[C/T]GTGCTGCAGCATGCGGAGCCCGGGA 
 
rs4818 (Chr. 22 – 18331207) - Context-Sequence VIC/FAM 
GCCTGCTGTCACCAGGGGCGAGGCT[C/G]ATCACCATCGAGATCAACCCCGACT 
 
rs4680 (Chr. 22 – 18331271) - Context-Sequence VIC/FAM 
CCAGCGGATGGTGGATTTCGCTGGC[A/G]TGAAGGACAAGGTGTGCATGCCTGA 
 
rs737865 (Chr. 22 – 19930121) - Context-Sequence VIC/FAM 
GCTTTTTGGATTTTTCCAGCCAGGG[A/G]TTTTTGTGTCCTGTTGCTTTTTATT 
 
rs165599 (Chr. 22 – 19956781) - Context-Sequence VIC/FAM 
TGTTAGCCCCATGGGGACGACTGCC[A/G]GCCTGGGAAACGAAGAGGAGTCAGC 
 
rs2075507 (Chr. 22) (Information  obtained from Okochi and colleagues as reported in Okochi et 
al., 2009. The same set of Applied Biosystems Custom Assays was used) 
 
 
rs2075507 (Assay-by-Design )   
RS2075507-SNP1F CGTGTCTGGACTGTGAGTATGG 
RS2075507-SNP1R GGGTTCAGAATCACGGATGTGA 
RS2075507-SNP1V2 (VIC) ACAGAAAAGTTTCCCC 
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Primers are at 900 nM final concentration. 
 
PCR followed standard procedure as per Applied Biosystems TaqMan® SNP Genotyping Assays 








expression assay 20X 
Assay Mix  
1X 0.1 μl 
cDNA Template 10ηg 2. μl 
ddH2O  0.9 μl 
TaqMan® Universal 
PCR 
Master Mix, No 
AmpErase® 
UNG (2X) 
1X 1 μl 
 
PCR reaction was carried out in the Applied Biosystems 7900HT Fast Real-Time PCR System 
machine. as per manufacturer protocol with the following conditions:  
STEP 1 - hold at 50C for 2 minutes 
STEP 2 - denature at 92C for 15 seconds 
STEP 3 - anneal/extend at 60C for 1 minute 
STEP 4 - repeat step 2 and 3 for 40 cycles.  
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6.4 Statistical Analysis 
In this chapter samples analysed are from the GAP Study (both Caucasian and Black population 
included) and from the PICOS study. 
The GAP sample was genotyped for 7 SNPs within the COMT gene: rs737865, rs6269, rs4633, 
rs4818, rs165599, rs4680 and rs2075507. 
The PICOS samples were only genotyped for rs4680 within the COMT gene. 
The GAP Study Caucasian population analysed consisted of 174 psychotic patients and 45 non 
psychotic subjects; 
The GAP Study Black population analysed consisted of 113 psychotic patients and 95 non 
psychotic subjects; 
The PICOS Study sample consisted of 347 psychotic patients and 307 non psychotic patients. 
The three main groups of samples were tested separately: Caucasian group (GAP); Black group 
(GAP); Caucasian Italian group (PICOS). 
Gene-environment interaction was only calculated for the GAP Caucasian and the GAP Black study 
samples because of lack of environmental data (Cannabis use) for the PICOS study sample. They 
were analysed as 2 separate samples. 
The GAP Study Caucasian population analysed consisted of 174 psychotic patients (68 non 
cannabis users, 106 cannabis users) and 45 non psychotic subjects (20 non cannabis users, 25 
cannabis users).  
The GAP Study Black population analysed consisted of 113 psychotic patients (39 non cannabis 
users, 63 cannabis users, 11 excluded with no information) and 95 non psychotic subjects (29 non 
cannabis users, 56 cannabis users, 10 excluded with no information). 
6.4.1 Statistical tests performed  
With the three sets of samples, namely the GAP study sample (including Caucasian subjects), the 
GAP study (including the black population) and the PICOS study sample (consisting of Caucasian 
population) the following statistical tests were performed: 
- Hardy Weinberg Equilibrium Test 
- Logistic regression test for allelic and genotype association analysis between each SNP and 
disease status 
- Logistic regression test for haplotype association analysis (only the GAP Caucasian and 
Black study sample) 
- Logistic regression test for the Gene x Environment analysis (only the GAP Caucasian and 
Black study sample) 
- Bonferroni multiple testing correction 
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6.4.1.1 Hardy Weinberg Equilibrium Test 
Hardy Weinberg Equilibrium Test was performed using PLINK software for genetic analysis 
throughout the thesis (Purcell et al., 2007).  
The command used for the HWE test is --hardy 
The full line of command used to run the HWE test in this thesis is: 
Plink --file mydata --hardy 
A file containing three entries for each SNP is then generated and saved as plink.hwe 
The file contains calculations of the HWE test for all, affected only or unaffected only subjects. 
In this thesis, only results of the unaffected group of subjects is discussed are reported in the tables. 
6.4.1.2 Allelic and genotype association analysis 
Statistical analysis carried out to establish association between allelic and genotype variation at 
each locus within the COMT and psychosis was performed using PLINK software for genetic 
analysis (Purcell et al., 2007). 
The main effect of each SNP on psychosis was tested with logistic regression. PLINK calculates a 
basic association of a disease trait by comparing allele frequencies between cases and controls 
(Purcell et al., 2007). The association commands used are --assoc --logistic. 
SNPs alleles and genotypes were treated as independent variables and disease outcome (psychosis) 
was treated as dependent variable. It was coded in the program as a binary disease status: 1=case 
0=control. Because the disease outcome was a binary value, --1 was added to the command line 
used. 
The complete set of commands used to calculate association in this thesis was: 
Plink –file mydata --1 --assoc 
A file containing both allelic and genotype association calculation is then created and saved as 
plink.assoc. 
6.4.1.3 Haplotype analysis 
Linkage Disequilibrium between SNPs within the COMT gene was computed using Haploview 
version 3.32 (Barret et al., 2005).  
A graphical representation of linkage disequilibrium between the 4 markers constituting the LPS 
haplotype was created with LD-Plus, a program that is freely available via a web interface 
(https://chgr.mc.vanderbilt.edu/ldplus). D’ and r2 values, were calculated using Haploview (Barrett 
et al., 2005). 
A graphical representation of linkage disequilibrium between all 7 analysed markers within the 
COMT was created with haploview (Barrett et al., 2005). 
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Haplotype analysis was then carried out using PLINK software for genetic analysis (Purcell et al., 
2007). 
In order to phase a set of SNPs for haplotypic analysis, both the --chap and the --hap--snp were 
used together.  
--window 4 command was used to include all 4 SNPs in the haplotype 
The full line of command used in this thesis for haplotype analysis is: 
Plink --bfile mydata --1 --hap-window 4 --hap-assoc 
The output file generated by the program after this calculation is saved as plink.hap 
6.4.1.4 Gene x Environment analysis 
GxE analysis was performed with logistic regression test using HapStat version 3.0 (Lin et al., 
2008).  Hapstat is a user-friendly software that allows testing of single markers and haplotype-
disease association. The haplotype association is calculated by maximizing the observed data 
likelihood that accounts for phase uncertainty and study design (Lin et al., 2008).  
Environmental variable entered was: 
 cannabis use (variable modeled as binary trait: yes/no answer) 





 LPS haplotype chosen a priori. 
For the exploratory analysis the environmental variables entered were: 
  frequency of cannabis use (variable modeled as binary trait: high frequency users Vs low 
frequency use) 
 Age of first use (variable modeled as binary trait: before and after the age of 15yrs) 
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6.4.1.4.1 Cannabis use data 
Cannabis use data were collected as part of the Cannabis Experience Questionnaire explained in 
detail in chapter 4 and chapter 7 of this thesis. 
Subjects were asked if they ever used cannabis, frequency of use and age of first use. All data are 
retrospectively based. 
For the GxE analysis I used the data on cannabis use (yes/no) and excluded all individuals with no 
data. For the exploratory analysis I used the frequency of cannabis use modeled as before or after 
15 years of age. This cut off is in line with the literature on the subject (Arsenault et al., 2002) 
(Stefanis et al., 2004) and offers an arbitrary mark of adolescence. Frequency of use was classified 
as frequent VS non frequency, where the first refers to use of 3 or more times per week.  
6.4.1.5 Bonferroni Correction for multiple testing 
Bonferroni conservative correction for multiple testing was applied after allelic and 
genotype association analysis. For the logistic regression, the markers analysed were 7, 
Bonferroni corrected p-value calculated as 0.05/7 would be 0.007.  




6.5.1 Hardy Weinberg Equilibrium Test 
Hardy Weinberg Equilibrium test was examined in non psychotic control groups of the 
GAP Study Caucasian group, the GAP Study Black group and the PICOS Study separately. 
The PICOS group was only genotyped for rs4680. In every statistical analysis performed 
in this thesis, they were analysed separately as 3 distinct populations. Deviation from 
equilibrium was checked for a total of 7 SNPs namely rs6269, rs4633, rs4818, rs4680, 
rs2075507, rs165599 and rs737865 within the COMT gene. One SNP namely rs165599 
was found to differ from Hardy Weinberg expected values in the GAP Caucasian group: p-
value=0.048 (Complementary Table C.7), but was still included in the subsequent analysis 
after accounting for multiple testing correction (Bonferroni multiple testing threshold is 
0.05/7=0.007).  
In the GAP Black group none of the markers failed the HWE test (Complementary Table C.8).  
The PICOS Study sample was only genotyped for rs4680 which was found to be in equilibrium 
after performing HWE test (p-value=0.45). 
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6.5.2 Association between allelic and genotype variation at each locus within the COMT gene 
and Psychosis 
The main effect of each SNP at each locus within the COMT gene on psychosis was tested with a 
χ2 test in the 3 study samples separately. 
No association was found in the GAP Study sample Caucasian or Black group for any of the 
markers analysed within the COMT gene.  
Moreover, no association was found with rs4680 and psychosis in the PICOS Study sample. 
Chi square and p-values could not be calculated for rs737865, rs6269, rs4818 and rs2075507 in the 
GAP Caucasian group for genotype association because 1 genotype at each locus, G/G, G/G, G/G 
and G/G respectively had a very low frequency in the psychotic or non psychotic group of subjects 
(Table 6.5). 
Frequency of 1 genotype (rs737865 G/G) was also too low for chi square and p-value calculation 
in the GAP Black group (Table 6.6). 
All results are shown in Tables 6.2 to 6.6. 
As mentioned in section 6.4.1.4 Bonferroni correction in this analysis is applied by dividing p-
values by number of SNPs analysed: 0.05/7=0.007. This is the threshold for significance in this 
particular test. No association however was observed, Bonferroni correction is therefore not needed. 
Frequencies of minor alleles are, for some of the COMT markers analysed, differ to the ones 
reported by NCBI that can be seen in Table 6.1. For example rs6269 has a MAF of 0.29 in the non 
psychotic Caucasian group, and of 0.43 in the non psychotic Black group, whereas NCBI reports a 
MAF of 0.37. MAF of rs4680 seem to differ between the 2 Caucasian groups analysed in this study, 
the GAP and the PICOS, 0.38 and 0.46 respectively. NCBI reports a MAF of 0.39 for rs4680, thus 
closer to the one observed in the GAP Caucasian group. This difference in values could reflect 
ethnic differences present within European populations of different countries or indeed a reflection 
of low numbers in the population analysed. In the presence of a positive association, this 
observation would be more important, because, as observed in chapter 5 of this thesis, it could lead 
to statistical false positive. In this case, however, no association was found and it is unlikely a false 
negative result, even in the presence of many limitations, discussed further in the conclusion 
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TABLE 6.2: Association between allelic variation at each locus within COMT and Psychosis in the GAP Caucasian sample 
 
MAF= Minor allele frequency 
OR=Odd Ratio 
(a)= number of participants (Psychotic and non psychotic) for genotype groups at each locus  





TABLE 6.3: Association between allelic variation at each locus within COMT and Psychosis in the GAP Black sample 
 
MAF= Minor allele frequency 
OR=Odd Ratio 
(a)= number of participants (Psychotic and non psychotic) for genotype groups at each locus  
* Degrees of freedom=1 
 
Gene rs number 
Minor Allele/ 
Other allele psychotic participants (MAF) 
psychotic 
participants (N) 





(DF=1)* P-Value OR 
COMT rs737865 G/A 0.16 155 0.12 43 1.06 0.303 1.46 
COMT rs6269 G/A 0.38 168 0.29 41 1.94 0.164 1.45 
COMT rs4633 T/C 0.34 148 0.41 43 1.26 0.262 0.75 
COMT rs4818 G/C 0.20 167 0.18 41 0.09 0.764 1.10 
COMT rS4680 A/G 0.34 154 0.38 32 0.33 0.567 0.85 
COMT rs2075507 G/A 0.34 150 0.38 23 0.30 0.585 0.86 
COMT rs165599 A/G 0.38 166 0.4 41 0.07 0.77 0.93 
Gene rs number 
Minor 
Allele/ 
Other allele psychotic participants (MAF) 
psychotic 
participants (N) 





(DF=1)* P-Value OR 
COMT rs737865 G/A 0.30 105 0.28 89 0.17 0.680 1.10 
COMT rs6269 G/A 0.40 105 0.43 88 0.38 0.539 0.88 
COMT rs4633 T/C 0.48 97 0.46 91 0.21 0.650 1.10 
COMT rs4818 G/C 0.37 109 0.39 89 0.20 0.658 0.91 
COMT rs4680 A/G 0.51 92 0.46 72 0.72 0.397 1.21 
COMT rs2075507 G/A 0.39 95 0.33 71 1.42 0.233 1.32 
COMT rs165599 A/G 0.33 109 0.34 94 0.04 0.82 0.95 
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MAF= Minor allele frequency 
OR=Odd Ratio 
(a)= number of participants (Psychotic and non psychotic) for genotype groups at each locus  






TABLE 6.5: Association between genotype variation at each locus within COMT and Psychosis in the GAP Caucasian sample 
 
Gene rs number 
Minor Allele/ 
Other allele psychotic participants (a) 
psychotic 





COMT rs737865 G/A 7/36/112 155 1\8\34 43 NA NA 
COMT rs6269 G/A 26/74/68 168 4/16/21 41 NA NA 
COMT rs4633 T/C 17/67/64 148 8/19/16 43 1.59 0.452 
COMT rs4818 G/C 9/48/110 167 0/15/26 41 NA NA 
COMT rs4680 A/G 15/74/65 154 5/14/13 32 0.97 0.615 
COMT rs2075507 G/A 18/67/65 150 4/17/12 23 NA NA 














(a)= number of participants for genotype groups at each locus presented as homozygous for the minor allele, heterozygous and homozygous for the major allele 
(b)= number of participants (Psychotic and non psychotic) for genotype groups at each locus 




 COMT rs4680 A/G 















participants (N)(a) CHISQ (DF=1)* P-Value OR 
 The Endocannabinoid and the Dopaminergic Systems in First Episode Psychosis Page 121 
 
 
TABLE 6.6: Association between genotype variation at each locus within COMT and Psychosis in the GAP Black sample 
 
Gene rs number 
Minor Allele/ 
Other allele psychotic participants (a) 
psychotic 





COMT rs6269 G/A 18/47/40 105 19/37/32 88 0.61 0.736 
COMT rs4633 T/C 24/45/28 97 22/39/30 91 0.39 0.821 
COMT rs4818 G/C 18/45/46 109 15/40/34 89 0.35 0.839 
COMT rs4680 A/G 24/45/23 92 15/36/21 72 0.74 0.691 
COMT rs2075507 G/A 10/55/30 95 11/25/35 71 8.39 0.015 
COMT rs165599 A/G 11/50/48 109 14/36/44 94 1.714 0.4244 
COMT rs737865 G/A 9/45/51 105 4/42/43 89 NA NA 
 
(a)= number of participants for genotype groups at each locus presented as homozygous for the minor allele, heterozygous and homozygous for the major allele 
(b)= number of participants (Psychotic and non psychotic) for genotype groups at each locus 
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6.5.3 Haplotype analysis 
 
I decided to further explore the data by performing haplotype analysis testing the main effect of the 
LPS, a priori set as the risk haplotype, on psychosis. I calculated Linkage Disequilibrium (LD) for 
the SNPs within the COMT gene using haploview and carried out the association analysis using 
PLINK version 1.7 (Purcell et al., 2007). 
All analyses were carried out in the GAP Study sample Caucasian and Black group separately. 
For a better understanding of the level of correlation between the 6 COMT SNPs in the populations 
examined in this chapter, I calculated the D’ and the r2 values with haploview (Table 6.7, Table 
6.8). D’ and r2 scores for the 4 SNPs of the LPS haplotype (rs6269, rs4633, rs4818 and rs4680)are 
displayed in figure 6.3 and 6.4. LD blocks plots with r2 values in the Caucasian and the Black 
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Figure 6.1 Linkage Disequilibrium Plot computed with markers within the COMT gene in 




Figure 6.2 Linkage Disequilibrium Plot computed with markers within the COMT gene in 
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Figure 6.3 Linkage Disequilibrium Plot computed of the LPS haplotype within the COMT 





Table 6.7 D’ and r2 values calculated with Haploview in the GAP Caucasian sample (shown 
in bolt markers with higher D’ and r2 scores further discussed in the conclusion paragraph 
of this chapter) 
 
MARKER 1 MARKER 2 D' VALUE r2 VALUE 
rs6269 rs4633 1 0.338 
rs6269 rs4818 0.856 0.327 
rs6269 rs4680 0.893 0.227 
rs4633 rs4818 0.942 0.137 
rs4633 rs4680 0.96 0.774 
rs4818 rs4680 0.841 0.09 
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Figure 6.4 Linkage Disequilibrium Plot computed of the LPS haplotype within the COMT 





Table 6.8 D’ and r2 values calculated with Haploview in the GAP  Black sample (shown in 




MARKER 1 MARKER 2 D' VALUE r2 VALUE 
rs6269 rs4633 1 0.629 
rs6269 rs4818 1 0.893 
rs6269 rs4680 0.98 0.582 
rs4633 rs4818 1 0.553 
rs4633 rs4680 0.933 0.828 
rs4818 rs4680 1 0.536 
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When analysing haplotypes, it is important to interpret results in light of D’ and r2 scores. D’ values 
refer to the rate at which analysed SNPs tend to be co-transmitted, the higher the D’ score, the lower 
the probability of historical recombination. D’ scores though tend to be higher in the presence of a 
small sample, like the one analysed in this chapter. It is generally a very informative value, but in 
this case, sample size plays a big role in its calculation. R2 values represent the degree of 
independence between SNPs, the higher the value, the less independent from each other 2 signals 
will be. It is therefore a very useful score to take into consideration when interpreting results from 
association studies. The LPS haplotype accounts for more than 90% of genetic variation at that site 
in the population, as reported by Diatchenko and colleagues (Diatchenko et al., 2006). The same 
frequencies can be seen in both the GAP Caucasian and the GAP Black group analysed in this 
chapter (Tables 6.9 and 6.10). D’ scores are therefore high and close to 1 within the 4 SNPs that 
make the LPS/APS/HPS haplotypes (Tables 6.7 and 6.8). R2 values are higher between rs4633 and 
rs4680 in both the GAP Caucasian and Black group r2=0.77 and r2=0.82 respectively (Tables 6.7 
and 6.8). These 2 SNPs therefore seem to act as proxies in the sample analysed, which indicates 
that we are not in the presence of independent signals from these 3 markers.  
The LPS susceptibility haplotype consists of 4 SNPs within the COMT gene: rs6269, rs4633, 
rs4818 and rs4680 (GCGG) was analyzed against all other haplotypes in a window 4 type analysis 
in PLINK (Purcell et al., 2007) in the GAP Caucasian and the GAP Black group separately. 
No main effect of LPS on risk of psychosis was found in either group: OMNIBUS p-value=0.59 
LPS P-value=0.61 and OMNIBUS p-value=0.7 LPS P-value=0.5 respectively (Tables 6.9 and 
6.10). 
These results show no main effect of the LPS or any other haplotype on risk of psychosis. Although 
both study samples are small, type 2 error can be safely excluded. 
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psychotics CHISQ DF P-value 
rs6269|rs4633|rs4818|rs4680 OMNIBUS   NA NA 2.992 5 0.7012 
rs6269|rs4633|rs4818|rs4680 GCGG LPS 0.365 0.3978 0.4448 1 0.5048 
rs6269|rs4633|rs4818|rs4680 ACCA   0.01796 0.002355 2.245 1 0.134 
rs6269|rs4633|rs4818|rs4680 ATCA APS 0.4732 0.4453 0.3052 1 0.5806 
rs6269|rs4633|rs4818|rs4680 ATCG   0.01224 0.01942 0.3258 1 0.5681 
rs6269|rs4633|rs4818|rs4680 GCCG   0.02498 0.02525 0.000291 1 0.9864 







non psychotics CHISQ DF P-value 
rs6269|rs4633|rs4818|rs4680 OMNIBUS   NA NA 3.738 5 0.5878 
rs6269|rs4633|rs4818|rs4680 GCGG LPS 0.1822 0.1581 0.2586 1 0.6111 
rs6269|rs4633|rs4818|rs4680 ATCA  APS 0.3155 0.37 0.8793 1 0.3484 
rs6269|rs4633|rs4818|rs4680 ACGG   0.01186 0.02702 1.022 1 0.3121 
rs6269|rs4633|rs4818|rs4680 ATCG   0.05103 0.05261 0.00333 1 0.954 
rs6269|rs4633|rs4818|rs4680 GCCG   0.1851 0.1161 2.176 1 0.1401 
rs6269|rs4633|rs4818|rs4680 ACCG  HPS 0.2543 0.2762 0.1615 1 0.6878 
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6.5.4 Gene x Environment Analysis 
In order to explore the correlation between the LPS haplotype and cannabis use, I performed a 
logistic regression test. Firstly I tested all markers forming the LPS haplotype, namely rs6269, 
rs4633, rs4818 and rs4680 and then the a priori hypothesis: the LPS haplotype under additive 
model. 
There was no association between any of the 4 markers within the COMT gene or the LPS 
haplotype and cannabis use in either of the 2 study samples (Tables 6.11). Variations within the 
COMT gene analysed in this study did not seem to have any effect on cannabis use. 
 
Table 6.11 Correlation between cannabis use and COMT  







Caucasian COMT rs6269 0.1 0.2 -1.5 
Caucasian COMT rs4633 0.8 0.2 0.2 
Caucasian COMT rs4818 0.07 0.2 -1.7 
Caucasian COMT rs4680 0.2 0.2 1.2 
Caucasian COMT LPS 0.06 0.2 1.8 
Black COMT rs6269 0.06 0.2 -2.1 
Black COMT rs4633 0.1 0.2 -1.6 
Black COMT rs4818 0.06 0.2 -1.8 
Black COMT rs4680 0.3 0.2 -1 
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Gene x Environment interaction was calculated with logistic regression test under additive 
model. No interaction was found between any of the COMT markers analysed in this study or 
the LPS haplotype and cannabis use in either of the GAP Study sample groups (Table 6.12). 
 
Table 6.12 Gene x Environment interaction between the COMT gene and Cannabis use  







Caucasian COMT rs6269 0.58 0.23 -0.55 
Caucasian COMT rs4633 0.5 0.26 -0.6 
Caucasian COMT rs4818 0.09 0.3 -1.6 
Caucasian COMT rs4680 0.77 0.25 0.28 
Caucasian COMT LPS 0.09 0.3 1.6 
Black COMT rs6269 0.06 0.3 -1.8 
Black COMT rs4633 0.1 0.3 1.3 
Black COMT rs4818 0.3 0.3 -1.03 
Black COMT rs4680 0.5 0.3 0.6 
Black COMT LPS 0.3 0.3 1 
 
6.5.5 Exploratory analysis 
An explorative analysis to test whether use of cannabis during adolescence could have a higher 
impact in the interaction, data on adolescent cannabis use was modeled as binary trait and divided 
in two groups: 1. first use before the age of 15; 2. first use at or after the age of 15. Non cannabis 
users were excluded from the analysis.  
Analysis could only be carried out in the GAP group including all ethnic groups due to limited 
number of adolescent cannabis use available. The additive model for the LPS was the a priori   
hypothesis and the only tested in this analysis. 
Results showed no interaction between the LPS haplotype and age of first use in Caucasian or 
Black populations (p-values of 0.3 and 0.09 respectively).  
 
6.6 Summary of results 
In this chapter I have tested the main effect of 7 markers within the COMT gene, namely rs6269, 
rs4633, rs4818, rs4680, rs2075507, rs165599 and rs737865 and 3 haplotypes formed by 4 of the 
markers (rs6269, rs4633, rs4818, rs4680), namely the LPS, APS and HPS.  
 
 
 Results showed no presence of main effect on psychosis at any of the loci nor the 
haplotypes. 
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 Exploring correlation between each of the markers, the LPS (a priori hypothesis) and 
lifetime cannabis use showed that genetic variants examined did not have any effect on 
cannabis use.  
 Genetic x environment analysis also showed no interaction. Moreover, exploratory 
analysis on interaction between use of cannabis before or after adolescence and the LPS 
haplotype on risk of psychosis also returned no positive results. 
 
6.7 Conclusions 
The COMT gene is among those most studied in association with psychosis, also because of its 
reported interaction with cannabis use. It seems to be a good candidate because of its role in 
dopamine catabolism in the prefrontal cortex. Indeed many studies have shown positive 
association, even stronger when cannabis use started before adolescence or when the type of 
cannabis smoked was of the strongest (Skunk, Sinsemilla). Other studies however, have failed 
to identify any association. Findings of the association studies therefore remain conflicting for 
the COMT gene, whereas the most recent findings of the GWAS are very clear and do not 
mention it among the most promising genes for schizophrenia. The role of COMT though may 
be more apparent in the presence of a well characterised cohort also offering environmental data 
such as drug abuse. In this chapter I have tried to replicate findings of interplay between lifetime 
use of cannabis and psychosis. Results were unanimously negative. It is very important though 
to look at these results in light of many limitations present in this study. First and foremost the 
sample size is small to detect an interaction of polymorphisms that may only account for a very 
little effect in the aetiology of a complex disorder. To detect an effect of a common 
polymorphism (MAF>5%) on a common disorder, numbers should equal those of the latest 
GWAS performed. This study also analysed environmental risks, adding more power to the 
analysis, but a sample size of less than 200 cases and 100 controls has no power to detect any 
interaction or association unless in the presence of a rare variant (MAF<1%) with a substantial 
effect size. As shown in the power analysis (Materials and Methods chapter), in order to achieve 
80% of power for detecting a true association between a frequent allele (MAF>0.5) with an effect 
size of 1.2 for a population risk of disease of 1%, there is the need of 6000 case-controls pairs. 
Adding environmental effects to the model to calculate a gene x environment interaction, 
assuming an exposure of 40% and an effect size of 1.2, there is the need of 20,000 case-control 
pairs. Combining the two groups, Caucasian and Black within the GAP study sample would have 
added no power to the analysis as the bias of ethnic stratification in such different populations 
would have been too great. Of note there is also the possible discrepancy between self-reported 
frequency/amount of cannabis used and the real figures. Furthermore, in this study, all cannabis 
data are collected retrospectively. This may pose a potential bias within the group of psychotic 
subjects due to possible cognitive impairments. One of the future directions would be to certainly 
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increase the sample size within both groups of the GAP study sample. This would ensure more 
power to the analyses, therefore increasing accuracy. One of the strengths of the GAP study is 
the recruitment of ethnically different populations at the same time; this allows analysing the 
comparison of findings in different groups. They will however have to be of a bigger number in 
future studies. Overall, from the analyses performed it can be concluded that the markers and the 
haplotype within the COMT gene in this chapter do not exert an effect on psychosis, or lifetime 

























Psychological Experiences in Cannabis Use: The Mediating role of the 
COMT gene 
 
7.1 Background information 
Cannabis is one of the most abused drugs among young people. Many of them report a calming, 
pleasurable experience, but many report feeling anxious and paranoid. It has long being 
discussed whether some personality trait leads to consumption of cannabis in an attempt to self 
medicate (Chackroun et al., 2004) (Howes et al., 2004) (Howes and Kapur, 2009). Impulsivity 
and schizotipy both seem to play a role in initiating drug abuse behaviour. Impulsivity is 
characterised by a motor component and an attention component (as reviewed in Barkus et al., 
2006) and it has been associated with cannabis use but findings are conflicting (Boden et al., 
2006) (Adams et al., 2003) (Crawford et al., 2003). Schizotypy is a trait that is normally 
distributed in the general population. It is characterised by an unusual belief system, anxiety, 
depression, social withdrawn and attenuated psychotic symptoms (Barkus et al., 2008). Whether 
individuals with schizotypy use more cannabis, use it to self medicate and will develop 
schizophrenia later in life has long been studied but with conflicting conclusions. Henquet et al, 
showed that subjects with psychosis liability were more likely to suffer from long term effect of 
cannabis use than those who did not (Henquet et al., 2005b).  Assessing psychological 
experiences during and after drug self administration is thus very important. This chapter is based 
on an adapted version of the Cannabis Experience Questionnaire (CAQ) developed by Barkus et 
al. to test the likelihood of non psychotic subjects who scored high in schizotypal personality, of 
experiencing more psychosis like symptoms upon use of cannabis (Barkus et al., 2006). They 
found that indeed, subjects that scored high in the schizotypal personality test were also more 
likely to experience more psychotic like experience and unpleasant effects after smoking (Barkus 
et al., 2006). Findings later confirmed by a follow up study in 2008 (Stirling et al., 2008). 
Furthermore, Henquet et al., in a double blind, placebo controlled cross over study with psychotic 
patients, relatives and healthy controls showed that carriers of the Val158Met allele of the COMT 
gene were more sensitive to psychotic experience induced by the compound and to worst results 
in memory and attention tasks; the same subjects showed prior psychometric psychosis liability 
(Henquet et al., 2006). The COMT gene may therefore play a role in the complex puzzle of 
psychosis liability, cannabis use, pleasurable VS unpleasant experiences upon cannabis use and 
development of schizophrenia later in life. 
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7.2 Hypothesis under investigation 
In this chapter I will analyse self reported experiences during and after cannabis consumption. I 
will reduce the items to be analysed by combining them using Principal Component Analysis. I 
will then explore the relationship between cannabis use with the perceived experiences. I 
hypothesise that:  
1. psychotic subjects will experience more anxiety/paranoia or perception abnormality 
response 
2. healthy subjects will experience more pleasurable response 
I will also explore the role of the rs4680 polymorphism and the LPS haplotype within the COMT 
gene in mediating the role of cannabis. I hypothesise that: 
1. subjects with more copies of the risk Val allele will report more anxiety or hallucinatory 
response 
2. people with more copies of the LPS haplotype will report more anxiety or hallucinatory 
response 
I will conduct further analysis to elucidate the role of a) frequency of drug abuse b) age of first 
use c) type of cannabis used. I hypothesise that: 
1. heavier consumers are those who experience more pleasurable response 
2. having more copies of the risk Val allele and using cannabis more often predisposes 
subjects to experience more anxiety/paranoia and or perception abnormalities 
3. having more copies of the risk LPS haplotype and using cannabis more often predisposes 
subjects to experience more anxiety/paranoia and or perception abnormalities 
7.3 Statistical analysis 
For this chapter I only used the GAP Study sample, Caucasian and Black group. As this chapter 
focuses on the self reported experiences during and after cannabis consumption, the population 
used includes cannabis smokers only (present and past) from the case and the control group. Non 
cannabis smokers are excluded. Moreover, the population includes subjects from both ethnic 
backgrounds analysed together, as it was not possible to stratify for ethnicity due to low number 
of patients with cannabis data. 
All analysis refers to the Caucasian and Black group together as the GAP Study sample. 
The total sample size used for this chapter is summarised in Table 7.1. 
In this chapter statistical tests performed were: 
- Principal Component Analysis (SPSS version IBM 19) 
 The CNR1 and the COMT genes in First Episode of Psychosis Page 134 
 
- Linear regression test for association analysis 
- Bonferroni correction for multiple testing 
 








Black case 34 28 29 
Black control 34 21 16 
Caucasian case 26 20 12 
Caucasian control 20 12 9 
 
7.3.1 The Cannabis Experience Questionnaire 
Cannabis data were obtained by a screening questionnaire used for both cases and controls. The 
questionnaire is the revised version of the Cannabis Experience Questionnaire (Barkus et al., 
2006) and it includes date of first use, preferred mode of use, frequency as well as data on self 
reported feelings before and after consumption (Appendix).  The Cannabis experience 
questionnaire contains 19 items with multiple choice answers as well as an open answer. From 
item 14 onwards it collects perceived experiences while smoking and after. It also establishes 
type of cannabis used and quantity smoked during adolescence and adulthood. The questionnaire 
also collects information on other drugs used in combination or during the same period of time 
as cannabis consumption, this helps to correct for possible confounders. 
For the factor analysis reported in this chapter, section 15.14 and 15.15 of the cannabis 
questionnaire were used. Section 15.14 addresses the question of self reported experiences during 
cannabis consumption whereas section 15.15 refers to experience occurred after the effect of 
cannabis has worn off. Participants are given a list of experiences (9 for section 15.14 and 5 for 
section 15.15) for which they have to rate the frequency (a) rarely or never; b) from time to time; 
c) sometimes; d) more often than not; e) almost always) and how they felt about it (a) good; b) 
bad and c) neutral). 
The Cannabis Experience Questionnaire was administered to patients and control by the group 
of clinical researchers of the GAP team. I was part of this group for the whole first year of my 
PhD, before starting laboratory work. I was assigned to the group of researchers recruiting non 
psychotic volunteers. Subjects included in this chapter were also, but not all, recruited by the 
team of which I was part. My contribution can be estimated to be of a total of 40% of the non 
psychotic population included in this chapter. 
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7.3.2 Principal Component Analysis 
Principal Component Analysis (PCA) with Varimax rotation was conducted using IBM SPSS 
version 19. PCA is a factorial technique that allows analysing correlation among variables which 
occurs when they measure the same underlying dimension. It is possible therefore to group 
correlated variables into factors independent of each other. I will use the term factor analysis to 
describe PCA and factors to refer to components. Factors were extracted using PCA and rotated 
using Varimax with Kaiser Normalisation. Rotation maximises the load of each variable into a 
factor while, at the same time, minimising the load on the other factors. Orthogonal rotation was 
chosen because I expected the factors to be independent from each other. Scores were calculated 
under the Anderson-Rubin method. Factors can only be calculated if the percentage of data 
missing is low in any of the variables. Low frequency variables 15.14 g) hearing voices and 
15.15 b) being suspicious without reason were excluded from the analysis. An experience-factor 
loading cut off point of >0.4 was used to interpret the factors. Finally, Keiser-Meyer-Olkin test 
and Barlett’s test of sphericity were used to assess adequacy of sample size. 
Variables included were from section 15.14 and 15.15 of the adapted Cannabis Experience 
Questionnaire as follow: 
 Section 15.14 (self reported experiences during cannabis consumption) 
a Fearful 
b Feel like going crazy/mad 
c Nervy 
d Suspicious 
e Feeling happy 
f Full of plans/ideas 
g Able to understand the world better 
h Seeing visions 
 Section 15.15 (self reported experiences after cannabis consumption) 
a Not wanting to do anything 
b Slowed down thinking 
c Difficulty in concentrating 
d Not able to think clearly 
Subjects were also asked to rate the extent to which they thought the experience was enjoyable, 
but this measure was not used for this analysis. 
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7.3.3 Association analysis 
Stepwise linear regression analysis was carried out to test association between each cannabis-
response factor score, rs4680 and the LPS haplotype within COMT, and frequency of cannabis 
use. I used SPSS version 19. 
For the main correlation analyses each factor score was entered in the regression models as a 
dependent variable. The following variables were entered as independent variables: 
 Disease status: psychotic subjects VS non psychotic subjects (variable modelled as 
binary trait: 1,0) 
 Rs4680 genotype was coded as number of copies (0,1,2) of the risk Val allele. 
 LPS the a priori risk haplotype (variable was coded in number of copies of LPS 
haplotype for each subject: values are 0, 1 and 2). Haplotype pairs for each subject were 
obtained using PHASE package for Windows version 2.1 (Stephens et al., 2001) and 
only pairs that exceeded probability of 80% were considered.  
 Frequency of cannabis use (data were coded in a binary variable: people reporting to 
have used cannabis between less than once a week and few times per year were grouped 
as light smokers – group 1 -; people reporting to have used cannabis twice a week or 
more were grouped as heavy smokers – group 2-). 
 Age of first cannabis use (data were coded in a binary variable: before or after the age 
of 15) 
 Finally, type of cannabis used (dichotomised as strong Vs non-strong) was an 
exploratory variable added to the model. Strong type of cannabis refers to the 
hypothetical higher content of Δ9-THC, the psychoactive component; and lower 
concentration of CBD, which is thought to exert anti-psychotic activity. 
7.3.4 Bonferroni Correction for multiple testing 
Bonferroni conservative correction for multiple testing was applied after logistic regression 
analysis. Factor analysed were 4, Bonferroni corrected p-value calculated as 0.05/4 would be 
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7.4 Results 
7.4.1 Principal Component Analysis 
Results showed that all 14 variables could be grouped by 4 independent dimensions or factors, 
each mainly exploring a different response to cannabis use. 
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Table 7.2 Factors loading obtained from the Principal Component Analysis conducted on sections 
15.14 and 15.15 of the Cannabis Experience Questionnaire (CEQ). Samples are of the GAP group 



















fearful .676 .150 -.025 -.034 
feel like going 
crazy 
.436 .185 .090 .410 
nervy .756 .164 .035 .057 
suspicious .709 .227 .027 .193 
not wanting to do 
anything 
.211 .572 .088 .079 
slowed down 
thinking 
.218 .707 .059 .202 
difficulty in 
concentrating 
.255 .733 .090 .091 
feeling happy -.231 .109 .431 -.022 
Full of plans or 
ideas 
.187 .133 .816 .082 
able to understand 
world better 
.077 .001 .465 .142 
hearing voices .293 .116 .101 .566 
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Figure 7.1 Scree plot with results of the Factor Analysis 
 
As it can be seen from the plot highlighted inside of the circle, there are 4 factors clearly visible 
before the curve starts its plateau. However, after factor 6 (marked with an arrow), another 
plateau is visible. I could therefore choose to run the factorial analysis force including 6 factors, 
but because of the small sample size and possible error, I decided that it was safe to assume the 








 The CNR1 and the COMT genes in First Episode of Psychosis Page 140 
 
The 4 factors clearly describe a range of different dimensions of experiences. Experiences during 
and after consumption of cannabis were pooled together in this analysis in an attempt to get a 
better idea of the whole experience of the use of the drug. As suggested by Barkus et al., after 
use experiences appear to identify the “amotivational syndrome” frequently reported by people 
with daily use of cannabis (Barkus et al., 2006). Analysing self reported experiences during and 
after abuse also gives a wider insight into the motivation behind perpetuation of the behaviour. 
If a subject experiences pleasurable effects during consumption and no “amotivational 
syndrome” afterwards, he or she is more likely to continue abusing the drug than a subject 
experiencing paranoia or anxiety upon use and amotivation afterwards, especially if this 
interferes with daily tasks. Pooled experience factor analysis show that each factor can be related 
to features observed in psychotic disorder.  
Factor 1 includes items: a) fearful, b) feel like going crazy, c) nervy and d) suspicious, a group 
of experiences that refers to an anxiety or paranoid response to cannabis consumption. 
Factor 2 includes: a) not wanting to do anything, b) slowed down thinking and c) difficulty in 
concentrating thus exploring an inhibitory and depressive response to cannabis consumption. 
Factor 3 includes: a) feeling happy, b) full of plans and ideas, c) able to understand the world 
better and seems to highlight the most pleasurable response to cannabis consumption. 
Factor 4 includes: a) hearing voices and b) seeing visions and seems to refer to perception 
abnormalities in response to cannabis consumption. 
Keiser-Meyer-Olkin sample adequacy value of 0.754, exceeded the recommended of 0.5 and 
Barlett’s test reached significance with a p-value=0.004. It is therefore safe to assume that, in 
light of sample adequacy, that the clear load of the variables into 4 factors and their independence 
between each other, the results of the analysis are an indication of the range of experiences 
reported in the questionnaire. 
7.4.2 Association analysis 
I decided to further explore the results of the factorial analysis by analysing factors correlation 
with psychosis and cannabis use. I firstly analysed the correlation between experiences (factor1-
4), disease status and genetic data (copies of the Val allele at rs4680 locus and copies of the LPS 
haplotype).  
I subsequently run exploratory analyses by adding 3 further variables to the model: frequency of 
cannabis use (dichotomised high Vs low), age of first use (dichotomised before or after 15 years 
of age) and type of cannabis use (dichotomised Stong Vs weak). 
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Results of the linear regression analysis showed no correlation between disease status and any 
of the factors (Table 7.3). Moreover, it showed no correlation between number of risk allele Val 
copies at the rs4680 locus and any of the factors (Table 7.4). In this sample, being a patient or a 
control did not predict the type of experiences the subject was going to have upon cannabis 
consumption. Furthermore, having more or less copies of the Val risk allele at the rs4680 locus 
did not make subjects more likely to have more or less pleasurable experiences with cannabis 
use. 
Copies of the LPS haplotype were however positively associated with the inhibitory/depressive 
response (Factor 2) (p-value=0.02). Having less or no copies of the LPS risk haplotype 
predisposes individuals to experience a more inhibitory/depressive response upon consumption 
of cannabis. Results also showed that having more copies of the LPS haplotype predisposes 
individuals to experience more perception abnormalities (Factor 4) upon cannabis consumption 
(p-value=0.04). This however did not retain significance after Bonferroni correction for multiple 
testing (adjusted p-value=0.08 and 0.16 respectively) (Table 7.5), it is therefore not a true 
association. Associations were independent of disease status (p-value=0.4 and p-value=0.8 
respectively) and ethnicity (p-value=0.36 and p-value=0.53 respectively). 
64.8% of our sample of users reported they had used cannabis 3 or more times per week (high 
frequency users) and 35.2% reported to have used it less than twice a week/sometimes/once a 
month (low frequency users). 48% started to use cannabis before the age of 15, whereas 52% 
started afterwards.  
Association analysis showed that frequency of cannabis use was associated with Factor 1 (Table 
7.6). Subjects that used cannabis 3 or more times per week, tended to have more anxiety and 
paranoia response to the drug (adjusted p-value=0.004). This suggests that people that use 
cannabis more than 3 times per week are more likely to respond with anxiety and or paranoia to 
the drug. Interestingly, frequency of cannabis use was also associated with the pleasurable 
response (Factor 3) although only marginally (p-value=0.05). Adding number of copies of the 
LPS haplotype, age of first use and type of cannabis used did not show significance. Effect was 
independent of disease status (p-value=0.6) and ethnicity (p-value=0.5). 
No association was observed when number of copies of the Val risk allele, frequency of cannabis 
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Table 7.3 Association between psychosis and factors 
VARIABLE CASES CONTROLS BETA VALUE Std. Error 
P-VALUE/CORRECTED 
P-VALUE 
Anxiety/Paranoia response 60 53 0.09 0.16 0.31 
 Inhibitory/depressive response 60 53 0.07 0.16 0.45 
Pleasurable response 60 53 0.19 0.15 0.05 
Perception abnormalities 
response 60 53 0.06 0.143 0.4 
 




Table 7.5 Association between number of copies of the LPS haplotype and factors 
VARIABLE CASES CONTROLS BETA VALUE Std. Error 
P-VALUE/CORRECTED 
P-VALUE 
Anxiety/Paranoia response 48 34 -0.12 0.16 0.2 
Inhibitory/depressive response 48 34 -0.23 0.14 0.02/0.08 
Pleasurable response 48 34 0.18 0.14 0.9 
Perception abnormalities 
response 48 34 0.21 0.12 0.04/0.16 
 
Table 7.6 Association between frequency of cannabis use and factors 
VARIABLE CASES CONTROLS BETA VALUE Std. Error 
P-VALUE/CORRECTED 
P-VALUE 
Anxiety/Paranoia response 60 53 0.32 0.16 0.001/0.004 
Inhibitory/depressive response 60 53 -0.01 0.17 0.9 
Pleasurable response 60 53 0.19 1.16 0.05/0.2 
Perception abnormalities 




VARIABLE CASES CONTROLS BETA VALUE Std. Error P-VALUE 
Anxiety/Paranoia response  41  25 -0.09 0.15 0.4 
Inhibitory/depressive response  41  25 -0.1 0.13 0.4 
Pleasurable response  41  25 0.04 0.13 0.7 
Perception abnormalities response  41  25 -0.22 0.09 0.11 
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7.5 Summary of results 
Cannabis experience Questionnaire was administered to psychotic patients and healthy 
volunteers. Complete data were collected for 113 subjects, 60 patients and 53 controls. 19 items 
from the questionnaires were taken into consideration for analysis in this chapter, sections 15.14 
and 15.15, recording perceived retrospective experiences during and after use of cannabis. 
Results of factorial analysis showed that the 19 variables could be explained by 4 factors, each 
referring to a dimension of experience: 
- FACTOR 1: Anxiety/paranoia response 
- FACTOR 2: Inhibitory/depressive response 
- FACTOR 3: Pleasurable response 
- FACTOR 4: Perception abnormality response 
Further analysis to explore the role of genetic background and a) frequency of cannabis use b) 
age of first use showed: 
- Subjects with no copies or 1 copy of the LPS risk haplotype experienced a more 
inhibitory/depressive response upon consumption of cannabis. Moreover, subjects with 
2 copies of the LPS haplotype seemed to experience more perception abnormalities. This 
however did not retain significance after Bonferroni correction for multiple testing 
(adjusted p-value=0.08 and p-value= 0.16 respectively). It is therefore not a true 
association. 
- Subjects using cannabis more than 3 times per week were more likely to respond with 
anxiety and or paranoia to the drug (adjusted p-value=0.004). 
- Subjects using cannabis more than 3 times per week were also more likely to have a 
pleasurable experience upon cannabis consumption. This did not however retain 
significance after multiple testing correction (adjusted p-value=0.2). 
- Associations observed were not disease group or ethnicity dependent. 
No other association was found. 
7.6 Conclusions 
This chapter explores the relationship between perceived experiences during and after 
consumption of cannabis and genetic factors, namely number of copies of the LPS haplotype and 
number of copies of the risk Val allele at rs4680 locus. Furthermore, it attempts to elucidate the 
role of early start of cannabis use, such as before adolescence, frequency of use and type of 
cannabis used. The cannabis experiences questionnaire used for this chapter is a revised version 
of the CEQ created by Barkus et al., in 2006. The questionnaire used in this chapter was 
elaborated by the Genetics and Psychosis Study at the Institute of Psychiatry and is enriched in 
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many items. The GAP CEQ, in fact was designed to obtain data on a wide range of cannabis 
related events. It prompts subjects to answer questions on age of first use, reason behind the first 
use and the perpetuation of the behaviour, pattern of use and type of self administration, 
dose/amount used and relation to money spent, information on any other drug used. This provides 
our study with a realistic, self perceived report on a range of aspects of cannabis use in psychotic 
subjects and healthy volunteers. Variables analysed in this chapters are from sections 15.14 and 
15.15 of the GAP CEQ (Appendix) and refer to experiences during and after consumption. 19 
variables were taken into consideration and reduced to 4 factors with a Principal Component 
Analysis. The 4 factors clearly show the 4 different dimensions of perceived experiences during 
drug abuse. Factors were independent between each other and measured 1) anxiety/paranoia 
response 2) inhibitory/depressive response 3) pleasurable response and 4) perception distortion 
response. As discussed in the results, the KMO test value of more than 0.5 indicated the adequacy 
of the sample size. It is therefore safe to assume that the GAP CEQ data analysed in this study 
addresses with competency all domains of experiences upon drug use. Experiences are of 
particular interest as they help with the understanding of the mechanisms of action of cannabis. 
Barkus and colleagues, after administering the CEQ and the Schizotypal Personality 
Questionnaire (SPQ), showed that the higher subjects scored in the SPQ, the more likely to be 
experience psychotic like experiences during cannabis use and negative effects afterwards 
(Barkus et al., 2006).  Findings in this chapter are not in line with the literature, in that patients 
seem to be more likely to experience increase in perception distortion experiences. It is well 
known that cannabis use tends to result in experiences similar to the positive symptoms observed 
in schizophrenia. Findings also supported by experimental studies on the effects of Δ9-THC (De 
Souza et al., 2004) (Morrison et al., 2009) (Morrison and Stone, 2011). In this chapter, there was 
no significant difference in perceived experiences among the group of patients and controls.  
Subjects using cannabis 3 or more times per week though, were more likely to experience 
negative symptoms such as anxiety and or paranoia (Factor 1) (adjusted p-value=0.004), but also 
pleasurable effect (although not statistically significant after Bonferroni correction). 
Experimental studies showed that CBD can exert anti-psychotic properties and it is able to 
moderate the psychoactive properties of Δ9-THC (Englund et al., 2013). It is possible that results 
observed in this study are due to Δ9-THC-CBD ratio content of cannabis consumed by subjects. 
Subjects that reported a marked increase in paranoia and/or anxiety could be consuming stronger 
type of cannabis with higher Δ9-THC content, whereas subjects experiencing a pleasurable effect 
could be consuming cannabis with a higher CBD content. 
Di Forti and colleagues (Di Forti et al., 2009) demonstrated that patients were more likely to use 
cannabis more frequently (3 or more times per week) and to use stronger types of cannabis 
(Skunk, Sinsemilla). Δ9-THC is found in higher concentration in stronger types of cannabis 
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(Sinsemilla) and in the flower part of the plant (Skunk). The ratio of the 2 compounds in the 
plant, gives the strength of the drug and it is usually linked to exacerbation of symptoms in 
patients and positive like symptoms in controls. Our results however showed that the association 
between frequency of cannabis use and anxiety/paranoia and/or pleasurable effect were 
independent of disease status. 
The fact that self reported perceived experienced during and after consumption were pooled 
together in an attempt to catch a better glimpse of the whole cannabis use phenomena may have 
lead to confused results where the real effect is diluted because of the merging. Barkus et al., 
measured experiences during and after cannabis use separately to investigate the “amotivational 
syndrome” or negative after effects and indeed found an association with high schizotypal 
scoring subjects. (Barkus et al., 2006). It would be interesting to analyse the two parts of the 
GAP CEQ separately to see whether there is a replication of the findings in literature. This 
however was not possible because of the sample size and because the number of tests already 
performed in this chapter. Analysing the same data in too many different ways would have made 
results more prone to type 1 error.  
This chapter also focuses on the question of whether subjects with a particular genetic 
background experience different responses to cannabis consumption and whether this helps 
perpetuate drug abuse behaviour. The question of whether genetic variants moderate the effect 
of cannabis in the brain has been widely discussed in literature with conflicting results. One of 
the most representative studies on this subject was conducted by Henquet and colleagues. They 
found subjects with the Val COMT allele to be more likely to experience psychotic like effect 
after cannabis use, although subjects scored high for psychosis liability (Henquet et al., 2006). 
Other studies though found no evidence of interaction between polymorphisms within the 
COMT gene and cannabis use (Munafo et al., 2005) (Costas et al., 2011) (Zammit et al., 2011).  
In this chapter I found evidence that subjects with no copies or 1 copy of the LPS, the a priori 
set risk haplotype, experienced a more inhibitory/depressive response upon consumption of 
cannabis. Interestingly, results also showed that subjects with 2 copies of the LPS haplotype tend 
to experience perception abnormalities upon consumption of the drug (p-value=0.04). These 
associations were not dependent on disease status or ethnicity, but however did not retain 
significance after Bonferroni correction for multiple testing (adjusted p-value=0.08 and p-
value=0.16 respectively). The LPS haplotype contains rs4680 Val allele, so in line with the 
observations done by Henquet and colleagues; having more copies predisposes subjects to 
experience more perception abnormalities upon cannabis use, although in this study psychosis 
liability was not analysed. There are also similarities with the study of Caspi and colleagues that 
found subjects with the Val allele having a five-fold increase of risk for psychosis if they smoked 
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cannabis (Caspi et al., 2005). Furthermore, Estrada et al., found that carriers of the Val allele 
who used cannabis had an earlier onset of psychiatric disorders (Estrada et al., 2010). Finding 
supported by animal studies (O’Tualthaigh et al. 2012) and by experimental studies on Δ9-THC, 
the psychoactive component of cannabis. Although results in this study did not retain 
significance after Bonferroni correction for multiple testing, they can be seen as indication of the 
involvement of the Val allele in moderating the effect of cannabis and certainly have biologic 
plausibility. Having more copies of the Val risk allele at the rs4680 locus, in this study, was not 
associated with any of the experiences or other measures. Age of first use and type of cannabis 
were not associated with genetic factors or with any of the experiences. As mentioned earlier, 
LPS haplotype is made of 4 SNPs, namely rs6260, rs4818, rs4633 and contains the Val allele at 
the rs4680 locus. It has been shown to be associated with greater enzymatic activity (Nackley et 
al., 2006), and it is therefore argued to be a better measure of the COMT gene enzymatic activity. 
This could explain the lack of association at the rs4680 locus and the trend towards significance 
of the LPS haplotype. It can also be explained by lack of statistical power, because of the sample 
size. As shown in the previous chapters of this thesis, MAF and frequency of haplotypes were 
very low, and analysed in this chapter, is only a subset of the total sample. Because of low 
numbers, subjects in this chapter were pooled together independent of ethnicity. MAF and 
frequency of haplotypes were different in the 2 sets of samples and although combining the 
samples does not necessarily increase statistical power, this subset of samples is very well 
characterised with several cannabis measures and co-varing for ethnicity showed no significance.  
The novelty of this chapter resides in the fact that it can analyse together very detailed self 
reported experiences perceived during and after cannabis use, candidate genetic variants and 
other aspects of cannabis consumption such as frequency, consumption in adolescence and type 
of cannabis used.  
It is however, advisable to collect a bigger sample size, ethnically characterise it and then analyse 
again cannabis experiences and genetic factors. Results of this chapter therefore, should be 
interpreted in light of many limitations. Together with the above described limitations, it is 
important to mention the nature of the data collected. They are all self reported, self perceived 
experiences described retrospectively, thus prone to error. Furthermore, type of cannabis was 
dichotomised in strong VS non-strong, according to the supposed content of Δ9-THC, which is 
the main psycho-active component. Subjects were not asked to bring a specimen of the drug used 
for analysis or biological specimen tested for drug metabolites (urine, hair, blood). This would 
have been unlikely to enhance accuracy of the data as reported experiences were based on past 
experiences with the inclusions of subjects who are not current users but were able to give an 
account of perceived past experiences. Overall, these finding do not clearly implicate the role of 
the LPS haplotype or the frequency of cannabis use in giving more anxiety, depression and or 
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paranoia response to the drug. There is the need of a much larger sample for this. They can 
however be seen as an indication of involvement of the COMT gene in moderating the effects of 



























The (AAT)n microsatellite of the Cannabinoid Receptor 1 gene in 
First Episode of Psychosis 
 
8.1 Background information 
The Human Cannabinoid receptor 1 gene (CNR1) is located at chromosome 6q14-q15 and has a 
length of 5.9kb. It consists of 2 isoforms (CNR1a and CNR1b) both containing 4 exons, 3 of 
which were identified by Zhang et al., in 2004. The AATn microsatellite polymorphism is a 
trinucleotide short-tandem repeat with 9-10 alleles, ranging from 7 to 18 repeats, with their 
frequencies being different across different populations. It is located 18,086 bp 3’ to the exon 4 
(Zhang et al., 2004) and has been studied in association with schizophrenia in 6 studies with 
conflicting results. The first study to investigate the role of the AATn microsatellite was in 2000, 
by Tsai and colleagues, on 127 Chinese schizophrenic patients and 146 controls. No evidence of 
association with schizophrenia was found (Tsai et al., 2000). Subsequently, Ujike and colleagues 
found the AATn microsatellite (MS) to be associated with schizophrenia and especially the 
hebephrenic subtype in a Japanese population (Ujike et al., 2002), findings partially replicated 
by Chavarria-Siles et al. in a family based association study of Central Valley and Costa Rica 
population (Chavarria-Siles et al., 2008). The AATn MS was associated with hebephrenic 
schizophrenia but not with a wider definition of the disorder (Chavarra-Siles et al., 2008). 
Martinez-Gras et al., found  allele 4 of the AATn MS (10 repeats) to be protective against 
schizophrenia (Martinez-Gras et al., 2006) in a sample of 113 schizophrenic patients and 111 
healthy controls (Martinez-Gras et al., 2006), whereas Siefert and colleagues failed to find any 
association of the AATn microsatellite and schizophrenia (Seifert et al., 2007). Moreover, Zhang 
et al., found the AATn MS not to be associated with schizophrenia in a sample of European-
American, African-American and Japanese schizophrenic patients and healthy volunteers 
(Zhang et al., 2004). Difference in allele frequencies across populations was confirmed (Zhang 
et al., 2004). The AATn MS has also been studied in other disorders including Parkinson’s 
disease (Barrero et al., 2005); Multiple sclerosis (Ramil et al., 2010) (Rossi et al., 2011); 
Anorexia nervosa (Siegfried et al., 2004) (Muller et al, 2008); Tourette’s syndrome (Gadziki et 
al., 2004), all with conflicting results. Furthermore, many studies have been conducted to analyse 
the role of the AATn microsatellite in drug addiction. Benyamina and colleagues in a recent 
meta-analysis of 11 studies, found that the AATn microsatellite within the CNR1 gene showed 
association with substance abuse in Caucasian population (Benyamina et al, 2011). The three 
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main areas of investigation of the AATn microsatellite are in schizophrenia, drug abuse and 
multiple sclerosis. The latest is being increasingly investigated because of the substantial role 
CNR1 and CNR2 play within the immune system. This chapter will investigate the role of the 
AATn microsatellite in 2 of the main areas of research: psychosis and cannabis use. Furthermore, 
it will try to explore its role in the perception of the experience that follows consumption of the 
drug, based on self reported data. 
8.2 Hypothesis under investigation 
This chapter will analyse the main effect of the AATn microsatellite on psychosis in the GAP 
Caucasian and Black populations and in the PICOS Caucasian population. I hypothesise that the 
AATn microsatellite will have a main direct effect on psychosis with some alleles being over 
represented in patients. 
Furthermore, I will analyse the role of the AATn microsatellite in relation to lifetime cannabis 
use and depressive/inhibitory perceived experience while consuming cannabis, in order to 
explore its role. 
8.3 AATn Microsatellite genotyping 
8.3.1 Custom made primers 
Primers used to genotype were computed with Primer3 (Rozen and Skaletsky, 2000; Untergasser 
et al., 2007) and ordered through Applied Biosystems as follow:  
Forward primer: 5’ – Fam – AACATGCAGCACACCAACAT – 3’ 
Reverse primer 5’ –GTTTCTTCCTTCTCCCAGCACAATCAT – 3’ 
DNA was amplified using PCR. The total length of the fragment is of 226 base pairs. Underlined 
are 19 AAT repeats reported by the online source: UCSC in-silico PCR. The total length of the 








 The CNR1 and the COMT genes in First Episode of Psychosis Page 150 
 
8.3.2 Sample preparation and Polymerase Chain Reaction 
DNA was diluted at 10ng/μl for all samples and stored in 96-well plates at 4°C. All DNA from 
cases and controls were mixed randomly between the plates to allow for PCR and fragment 
analysis to be carried out in a blinded fashion. Plates underwent a 1 minute spinning cycle in an 
ALC multispeed refrigerated centrifuge. 1 microlitre (μl) of each sample was then transferred to 
two 384-well plates and DNA left to dry overnight.  
Primers were lyophilized and prepared with 146μl dd H2O for the forward primer, and 175μl dd 
H2O for the reverse primer. Deoxynucleotide Triphosphate (dNTP) was mixed using 4μl each of 











Reagents Volume needed for 5μl reaction 
Forward Primer 0.5  μl 
Reverse Primer 0.5  μl 
Gold Buffer 0.5  μl 
dNTP 0.5  μl 
AmpliTaq Gold DNA polymerase 0.025  μl 
MgCl2 0.4  μl 
dd H2O 2.575 μl 
DNA dried  
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To establish optimum annealing temperature for the primers, a gradient PCR of 50 – 60 °C was 
performed in a BIO-RAD MJ Peltier Thermal Cycler. Gradient program as follow:  
 
1 Incubate at 95°C for 10 minutes 
2 Incubate at 95°C for 10 seconds 
3 Gradient from 50 – 60 °C for 10 seconds 
4 Incubate at 72°C for 30 seconds 
5 Go to line 2 for 30 more times 
6 Incubate at 72°C for 5 minutes 
7 Incubate at 4°C forever 
 
Samples were then loaded on agarose gel (1.5g UltraPure Agarose, 100 ml of 1xTBE buffer, and 
2μl 100 x Gel Red dye) and run at 115 Volts for 40 minutes. Gel was observed under ultraviolet 
light and compared to a 100 base pair ladder (1.5 μl loaded). Annealing temperature chosen was 
61°C, PCR program was therefore set as follow: 
 
1 Incubate at 95°C for 10 minutes 
2 Incubate at 95°C for 10 seconds 
3 Incubate at 61 °C for 10 seconds 
4 Incubate at 72°C for 30 seconds 
5 Go to line 2 for 30 more times 
6 Incubate at 72°C for 5 minutes 
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8.3.3 Fragment Analysis 
Samples were loaded into 384 well plates in a 11.5μl reaction volume as follow: 
 
Reagents Volume needed for 11.5μl reaction 
PCR product (DNA) 1 μl 
HiDi  Formamide 10 μl 
GeneScan 500 ROX size standard 0.5 μl 
 
The reaction was denatured at 95°C for 2 minutes in the BIO-RAD MJ Peltier Thermal Cycler. 
The plates were then run in an Applied Biosystems 3130xl Genetic analyzer.. Results from 
fragment analysis were viewed using GeneMapper v4.0 software, and the size of each allele in 
base pairs was recorded from electropherographs.  
Each plate included duplicate samples for quality control. No discrepancies were found in any 
of the plates. 
8.4 Statistical Analysis 
In this chapter, the samples analysed are from the GAP Study (both Caucasian and Black 
population included) and from the PICOS study. 
The GAP Study Caucasian population analysed consisted of 174 psychotic patients and 45 non 
psychotic subjects; 
The GAP Study Black population analysed consisted of 113 psychotic patients and 95 non 
psychotic subjects; 
The PICOS Study sample consisted of 347 psychotic patients and 307 non psychotic patients. 
The three main groups of samples were tested separately: Caucasian group (GAP); Black African 
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8.4.1 Statistical tests performed  
8.4.1.1 Calculation of main effect on Psychosis 
With the three sets of samples, namely the GAP study sample (including Caucasian subjects), 
the GAP study (including the black population) and the PICOS study sample (consisting of 
Caucasian population) the following statistical tests were performed: 
- Logistic regression test for allelic association analysis between the AATn microsatellite 
and disease status 
Linear regression test for correlation between the AATn microsatellite and cannabis use  
- Power calculation 
Exploratory analysis was performed in the GAP Caucasian and Black samples separately: 
- Linear regression test for the Gene x Environment analysis (only the GAP Caucasian 
and Black study sample) to asses correlation between the AATn microsatellite and a) 
cannabis use b)Factor 2 (depressive/inhibitory response to cannabis use) 
 
8.4.1.2 Allelic association analysis 
Statistical analysis carried out to compare allelic distribution between cases and controls using 
CLUMP software for genetic analysis (Sham and Curtis, 1997). CLUMP is software that uses 
the Monte Carlo approach to assess significance by performing repeated simulations of 
contingent tables with the same marginal totals as the one under consideration (Sham and Curtis, 
1997). The significance level is therefore unbiased independently of continuity correction or 
small expected values. The χ2 value is calculated by summing all cells and dividing the difference 
between observed and expected value by expected values (Sham and Curtis, 1997). CLUMP 
generates 3 statistics: T1 with χ2 from original table; T3 with χ2 obtained by comparing each 
column against the rest and T4 with χ2 calculated from a 2x2 table with clumped alleles to 
maximise χ2 value. This is the statistical test considered in this study. The procedure of clumping 
is obtained by dividing the columns into those with higher than expected values in the first row 
from those with lower values (Sham and Curtis, 1997). The full command line used to perform 
analysis was: 
CLUMP inputfilename outputfilename 
CLUMP produces an outputfile with χ2 values from each of the 3 statistics together with the 
number of times such value was reached in the simulation table, the less simulations reached, the 
more significant the result will be (Sham and Curtis, 1997). 
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8.4.1.3 Exploratory analysis 
Correlation between clinical variables and the copies of the AATn microsatellite was calculated 
with linear regression using IBM SPSS version 19.  
In line with literature I decide to further explore my data by adding to the model 
a) Cannabis use 
b) Factor 2 (depressive/inhibitory response to cannabis use)  
As mentioned in the background information, 2 studies (Ujike et al., 2002) (Chavarria-Siles et 
al., 2008) found the AATn microsatellite to be associated with hebephrenic schizophrenia.  
To diagnose hebephrenic schizophrenia Ujike et al., referred to the ICD-10 whereas Chavarria-
Siles et al., used the Lifetime Dimension of Psychosis (LDPS) as the DSM-IV does not include 
this diagnosis. Hebephrenic schizophrenia is largely characterised by predominance of 
disorganised and negative symptoms, although this is not formally included in the classification 
of the disorder by the ICD-10 (Ujike et al., 2002). As noted by Solowij and Michie, in 2007 and 
by Chavarria-Siles in 2008, the hebephrenic type of schizophrenia closely resembles the 
cognitive dysfunctions observed in schizophrenic patients abusing cannabis. My sample does not 
consist of individuals with the diagnosis of hebephrenic schizophrenia but does include patient 
and control data on cannabis use. Furthermore, individual experiences while and after taking 
cannabis were measured with the GAP Cannabis Experience Questionnaire, adapted from 
Barkus et al., 2006. As illustrated in chapter 7, experiences can be grouped in 4 factors, one of 
which (Factor 2 labelled as depressive/inhibitory response) can resembles some of the features 
seen in hebephrenic schizophrenia. I therefore decided to run an exploratory analysis to assess 
better the role of the AATn microsatellite in drug abuse (cannabis) and particularly in subjects 
that have reported a negative experience while self administering the drug.  
Alleles were collapsed into 2 groups, short alleles with less than 12 repeats and long alleles with 
more than 12 repeats, as reported in previous studies on association of the AATn microsatellite 
and drug abuse (Coming et al., 1997) (Li et al., 2000). This was performed also in light of the 
possible role played by the length of the repeats in gene regulation as illustrated by Li and 
colleagues in 2004. 
Individuals were divided into 3 different groups depending on their genotype:  
1. Homozygous individuals (genotype of <12repeats,<12repeats) 
2. Heterozygous individuals (genotype of <12repeats,>12repeats) 
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3. Homozygous individuals (genotype of >12repeats, >12repeats) 
Association was then assessed using a linear regression test with IBM SPSS version 19. 
Factor 2 was entered in the regression models as a dependent variable. The following variables 
were entered as independent variables: 
 Cannabis use: yes VS no (variable modelled as binary trait: 1,0) 
 AATn microsatellite genotype (3 groups: homozygous short allele, heterozygous, 
homozygous long allele) 
 
8.5 Results 
8.5.1 Association analysis 
In the GAP sample, after fragment analysis, 12 alleles were found at the AATn microsatellite 
locus, ranging from 5 to 17 repeats, with 6 repeats being absent and 5, 7, 8, 15 repeats being rare 
and 16, 17 repeats being very rare (Table 8.1). 
In the PICOS sample, after fragment analysis, 14 alleles were found at the AATn microsatellite 
locus, ranging from 3 to 19 repeats, with 8, 17 and 18 repeats being absent. 4, 6 and 19 repeats 
alleles were rare (Table 8.2). 
These finding are in line with literature on the subject, except for the 19 repeats allele which has 
never been observed before and has been only found in 3 patients of the PICOS study. 
As it can be seen from tables 8.1 and 8.2, there are marked allele frequency differences among 
the 3 samples examined, this is most likely due to ethnic difference among samples. 
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 (AAT)5 (AAT)7  (AAT)8  (AAT)9  (AAT)10  (AAT)11  (AAT)12  (AAT)13  (AAT)14  (AAT)15  (AAT)16  (AAT)17  
Caucasian cases 0 1.11% 1.80% 17.10% 29.80% 19% 11.50% 7.80% 10.44% 0.70% 0.37% 0 
Caucasian controls 1.47% 0 0 20.50% 33.80% 10.29% 13.20% 7.35% 13.20% 0 0 0 
Black cases 0.50% 1.13% 0.50% 8.50% 26.10% 3.90% 14.70% 22.70% 20.45% 0.50% 0 0.50% 
Black controls 0 0 0 5.19% 24% 8.40% 15.58% 18.80% 26.60% 1.29% 0 0 
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Table 8.2 Frequency percentage distribution of the AAT microsatellite alleles in the PICOS Study Sample 
 
 (AAT)3  (AAT)4  (AAT)5  (AAT)6  (AAT)7  (AAT)9  (AAT)10  (AAT)11  (AAT)12  (AAT)13  (AAT)14  (AAT)15  (AAT)16  (AAT)19  
PICOS cases 0.23% 0.11% 0.11% 0.23% 1% 2.10% 26.90% 3.50% 13.20% 20.60% 27.87% 3.30% 0.11% 0.35% 
PICOS controls 0.10% 0 0.50% 0 2.80% 1% 26.30% 5% 16.40% 18% 25.50% 3.30% 0.70% 0 
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Association analysis between the AATn microsatellite and disease status returned no positive 
association in any of the 3 groups, the AATn MS did not have a significant main effect on psychosis. 
 
GAP Study Caucaisan sample: 
Chi-square from 2x2 table clumped to produce maximum (T4) was 3.555573 
This was reached 54 times in 100 simulations (empirical p=0.544554) 
 
GAP Study Black sample: 
Chi-square from 2x2 table clumped to produce maximum (T4) was 4.300313 
This was reached 34 times in 100 simulations (empirical p=0.346535) 
 
PICOS Study sample: 
Chi-square from 2x2 table clumped to produce maximum (T4) was 13.148986 
This was reached 226 times in 10000 simulations (empirical p=0.242698) 
 
8.5.2 Exploratory analysis 
Exploratory analysis was carried out only in the GAP Study sample, in both Caucasian and Black 
group. There was no cannabis information on the PICOS Study sample. 




Frequencies of the 3 genotypes in the GAP Caucasian and Black samples can be seen in Table 8.3. 
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Correlation analysis between the AATn microsatellite and cannabis use did not return positive 
results. The polymorphism did not seem to have an effect on consumption of cannabis. 
When Factor 2 (depressive/inhibitory response) was added to the model, it also showed no 
significant association. 
Results can be seen in Table 8.4 
 











Caucasian cases 46% 51.70% 11.90% 
Caucasian 
controls 45.40% 39.30% 15% 
Black cases 18.60% 43% 38.30% 
Black controls 11.50% 52.50% 35.80% 
VARIABLE BETA VALUE Std. Error P-VALUE 
Lifetime cannabis use 
 
0.19 0.21 0.3 
Inhibitory/depressive response 
Factor 2 0.15 0.16 0.4 
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8.6 Summary of results 
In this chapter I analysed the main effect of the AATn microsatellite within the CNR1 gene on 
psychosis. The samples analysed were the GAP Study sample Caucasian and Black group and the 
PICOS sample. After initial association tests, I decided to further explore my data by testing the 
association of the AATn microsatellite with cannabis use and with a depressive/inhibitory response 
experienced by individuals during and after cannabis use. This analysis was only run in the GAP 
Caucasian and Black group as cannabis data were not available in the PICOS sample. 
 Monte Carlo test showed no association of the AATn microsatellite and psychosis in any 
of the 3 samples analysed. 
 Exploratory analysis did not show any significant association between the AATn 
microsatellite and lifetime cannabis use and depressive/inhibitory response. 
 
8.7 Conclusions 
Results of this chapter failed to show any significant association between the AATn microsatellite 
within the CNR1 gene and psychosis or cannabis use. Alleles observed in the 3 samples analysed 
(the GAP sample Caucasian and Black group and the PICOS sample) are mainly in line with 
literature. Different studies report different number of alleles, with the most frequent of them being 
the ones from 11 to 15 repeats. The literature also shows difference in allele frequency across 
ethnically different populations. The closest match to the Caucasian Italian PICOS population can 
be found in the study of Rossi and colleagues. In a study on Multiple Sclerosis (MS), they analysed 
a cohort of 350 MS patients of central-southern Italy origins. Frequencies reported in their study 
vary significantly with those observed in the PICOS sample. The 10 repeats allele for example 
seems to be rare (1%) in the MS study but rather frequent in the PICOS sample (26%), on the other 
hand, the 15 repeats allele seems to be more frequent in the MS study (25.7%) than in the PICOS 
sample (3%). These differences are most probably explained by methodological differences in 
genotyping and calling of repeat sizes, to correctly compare sizes in different studies ideally 
representative samples should be exchanged between centres.   Differences in frequency can also 
be observed between the GAP Study Caucasian and Black groups. The GAP Black group can be 
compared to the sample analysed by Ballon et al, which consisted of a cohort of African-Caribbean 
schizophrenic patients and controls with cocaine addiction co-morbidity. Although not as striking 
as differences between the 2 Italian samples mentioned above, the Afro-Caribbean cohort and the 
GAP Black group had some differences in allele frequency. These observed discrepancies in 
number of alleles found and frequency of them can be due to ethnic diversity where, for example, 
even individuals from the same Country share only partial genetic background. In light of such 
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differences within samples in this chapter and between samples analysed in other studies, I decided 
not to merge the Caucasian and the Black GAP populations. Although merging would have 
increased the sample size, it most definitely would not have increased the power of the analysis.  
The most positive results in literature, are from studies that have analysed the role of the AATn 
microsatellite, in hebephrenic schizophrenia. As mentioned earlier in this chapter, hebephrenic 
schizophrenia is not currently diagnosed with the DSM-IV, but is included in the ICD-10. This sub-
type of schizophrenia is characterised mainly by negative symptoms such as blunted affect or 
emotion, avolition and asociality as described in Ujike et al., 2002). This is what can be also 
observed in chronic cannabis abuse. Being a cohort of first episode of psychosis, the GAP study 
does not have diagnosis of schizophrenia or schizophrenia sub-types available. To explore further 
the relationship between the AATn microsatellite and cannabis abuse in the GAP sample, I opted 
to analyse the role of the polymorphism in relation to one of the 4 factors analysed in chapter 7 of 
this thesis. After factor analysis of 19 components of the GAP Cannabis Experience Questionnaire, 
a revised form of the CEQ (Barkus et al., 2006), 4 factor were highlighted as the ones that could 
explain the 4 different dimensions of perceived experiences during and after cannabis consumption. 
Factor 2 was associated with the depressive/inhibitory response. Individuals scoring higher for 
factor 2, were among those having a less pleasurable and a more similar experience of chronic 
cannabis abuse. This type of experience can possibly be compared to the features observed in 
hebephrenic schizophrenia, with the limitation of being a self reported, retrospective perceived 
experience while taking a drug. Grouping alleles of the AAT microsatellite have also been reported 
in literature with nearly all studies reporting analysis carried out with groups of alleles. Li and 
colleagues pointed out a possible role in gene regulation of the length of the repeats of a given 
microsatellite (Li et al., 2004). For this reason, many studies now report a division of less than 12 
or more than 12 repeats of the AATn microsatellite. A recent meta-analysis, however, reported an 
association of the AATn microsatellite and drug abuse only in Caucasian and only for 16 repeats 
and above (Benyamina et al., 2010). This division was not possible in this analysis, because alleles 
with more than 16 repeats, were very rare. I, therefore, decided to align my analysis with literature 
and divide the genotypes in 2 groups: short <12 and long >12 alleles. There was no significance 
reached in any of the analysis. 
Results reported in this chapter must be read in light of many limitations. First and foremost, as for 
all the other experimental chapters of this thesis, the sample size is very small and needs to be 
increased. Power calculation reported in the Materials and Methods chapter, indicates numbers than 
need to be much higher in order to achieve reasonable power. This can be considered a limitation 
for all experimental chapters in this thesis. Numbers in the GAP study are further reduced by the 
need to divide the sample into different groups according to different ethnic origins. This is very 
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important as the MAF of the polymorphism analysed in the previous experimental chapter and 
AATn allele frequency shown in this chapter differ consistently across different populations.  
Although there were no convincing results in this chapter, further work on this polymorphism is 
warranted, also in light of the fact that microsatellites have been shown to be able to influence gene 


























9.1 Summary of findings  
9.1.1 The Cannabinoid Receptor 1 Gene 
9.1.1.1 Hypotheses under investigation 
Chapters 5 and 8 addressed the research question of whether common polymorphisms within the 
CNR1 gene contribute to the pathophysiology of psychosis. In total I analysed 15 tag SNPs covering 
the complete CNR1 gene and the AATn microsatellite, close to the 3’ end of the gene. 
All markers were analysed in the GAP Study sample, Caucasian and Black groups, and in the 
PICOS Study sample. 
I hypothesized that: 
 Genetic polymorphisms analysed within the CNR1 gene increase risk for psychosis. 
 The multiplicative effect of lifetime cannabis use and rs1049353 increases risk for 
psychosis. 
 The AATn microsatellite has a main direct effect on psychosis with some alleles being over 
represented in patients. 
Exploratory analysis was run to: 
 Check for haplotypic association with psychosis. Haplotypes were analysed with a sliding 
window of 3. 
 Understand the role of the AATn microsatellite in association with lifetime cannabis use 
and depressive/inhibitory perceived experience while consuming cannabis. 
 
9.1.1.2 Findings 
Results showed that: 
 rs1049353 was associated with psychosis in the GAP Caucasian group (corrected p-
value=0.03). 
 rs806378 was marginally associated with psychosis in the GAP Caucasian group (corrected 
p-value=0.05). 
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 No association of any of the markers analysed and psychosis was found in the PICOS Study 
sample. 
 4 haplotypes were associated with psychosis in the GAP Caucasian group, there was 
however the presence of an independent significant signal from rs1049353 (p-value=0.02). 
 The ACC haplotype was associated with psychosis in the PICOS study, there was however 
the presence of an independent significant signal from rs806378 (p-value=0.04). 
 No Gene environment interaction was found. 
 No association of the AATn microsatellite with psychosis was found. 
 No association of the AATn microsatellite with lifetime cannabis use or the 
depressive/inhibitory response to cannabis consumption was found. 
 
9.1.2 The Catechol-O-Methyltransferase gene 
9.1.2.1 Hypotheses under investigation 
Chapters 6 and 7 addressed the research question of whether candidate polymorphisms within the 
COMT gene conferred an increase in risk for psychosis. 7 SNPs namely rs737865, rs6269, rs4633, 
rs4818, rs165599, rs4680 and rs2075507and the LPS haplotype were analysed. The LPS haplotype 
(a priori) and rs4680 was also investigated in search for evidence of interaction with cannabis use.  
Cannabis use data were collected with a variation of the Cannabis Experience Questionnaire. 
Variable used in the analysis included: 
 Lifetime cannabis use 
 Frequency of use 
 Age at first use 
 Type of cannabis used 
 Self reported experiences during and after cannabis use 
Experiences during and after cannabis consumption were grouped into 4 factors by Principal 
Component Analysis. Each of them described a different self reported dimension of symptoms 
experienced: 
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- FACTOR 1: Anxiety/paranoia response 
- FACTOR 2: Inhibitory/depressive response 
- FACTOR 3: Pleasurable response 
- FACTOR 4: Perception abnormality response 
 I therefore analysed the relationship between cannabis use, perceived experiences and the 
mediating role of genetic factors (LPS haplotype and rs4680). 
I hypothesised that: 
 The analysed SNPs and the LPS haplotype within the COMT gene have a main effect on 
psychosis.  
 The LPS haplotype moderates the risk of psychosis following use of cannabis. 
Exploratory analysis was run to: 
 Examine the role of the LPS in moderating the risk of psychosis following frequent VS 
non-frequent use of cannabis, use in adolescence and type of cannabis use. 
In regard to the perceived experiences upon cannabis use I hypothesised that:  
 Psychotic subjects will experience more anxiety/paranoia or perception abnormality 
response 
 Healthy subjects will experience more pleasurable response 
 Subjects with more copies of the risk Val allele will report more anxiety or hallucinatory 
response 
 People with more copies of the LPS haplotype will report more anxiety or hallucinatory 
response 
 Heavier consumers are those who experience more pleasurable response 
 Having more copies of the risk Val allele and using cannabis more often predisposes 
subjects to experience more anxiety/paranoia and or perception abnormalities 
 Having more copies of the risk LPS haplotype and using cannabis more often predisposes 
subjects to experience more anxiety/paranoia and or perception abnormalities 
Rs4680 was the only marker analysed in 3 populations: GAP Caucasian, GAP Black and PICOS 
Study sample. 
All other markers were only analysed in the GAP Caucasian and the GAP Black Study samples. 
 
 




 No presence of main effect on psychosis at any of the loci nor the haplotypes. 
 No effect of the LPS haplotype on cannabis use.  
 No evidence of Gene x Environmental interaction. 
Analysis of the perceived experiences upon cannabis consumption showed that: 
- Subjects with no copies or 1 copy of the LPS risk haplotype experienced a more 
inhibitory/depressive response upon consumption of cannabis. Moreover, subjects with 2 
copies of the LPS haplotype experienced more perception abnormalities. This however did 
not retain significance after Bonferroni correction for multiple testing (adjusted p-
value=0.08 and p-value= 0.16 respectively). 
- Subjects using cannabis more than 3 times per week were more likely to respond with 
anxiety and or paranoia to the drug (adjusted p-value=0.004). 
- Subjects using cannabis more than 3 times per week were also more likely to have a 
pleasurable experience upon cannabis consumption. This did not however retain 
significance after multiple testing correction (adjusted p-value=0.2). 
- Associations observed were not disease group or ethnicity dependent. 
 
9.2 Final conclusions 
To analyse the role of the Cannabinoid Receptor 1 gene, I selected 15 SNPs covering the complete 
length of the gene with an aggressive tag method. A good coverage of the region of interest 
increases statistical power (Evans and Purcell, 2012), this is what I tried to achieve as only having 
a small study sample. Samples have been further reduced in size as I decided to analyse the GAP 
Caucasian and the GAP Black groups separately. The Caucasian sample included 
Caucasian/European subjects whereas the Black population included Black African, Black 
Caribbean subjects, but also all individuals that reported one of the parents being either Black 
African or Black Caribbean. Minor Allele frequency (MAF) was in fact different between the two 
groups. If The 2 samples were to be analysed together, ethnic difference would have been a 
confounder. Difference in MAFs though, can also be explained by the small sample size. rs1049353 
showed significant association with psychosis in the GAP Caucasian group,  but not in the GAP 
Black group or in the PICOS Study sample. Differences in allele frequency are possibly due to 
ethnicity and are expected to differ between the GAP Caucasian and Black group. The PICOS Study 
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sample, however, included individuals of Italian Caucasian origins and was therefore expected to 
resemble the GAP Caucasian sample, although difference in frequency in these two study samples 
can still be due to natural ethnic difference between Caucasian populations within Europe. 
Rs1049353 is the polymorphism that has attracted most attention in research; it is a synonymous 
SNP located in exon 4 of the CNR1 gene, at 1359 base pairs from the start of the translational site 
at the codon for Thr 453 (Zhang et al., 2004). The rs1049353 A/G base change had both alleles 
described as risk alleles by different studies (Hadmani et al., 2008) (De Luis et al., 2012), moreover 
it has been found to be associated with cocaine dependence (Zuo et al., 2009), major depression 
(Mitjans et al., 2013), lack of improvement in leptin levels (De Luis et al., 2012) and very recently 
with schizophrenia, although it did not pass multiple correction (Costa et al., 2013). Other 
polymorphisms within the CNR1 gene have been reported as interesting in literature. Rs806366 
was very recently reported to be associated with schizophrenia (Costa et al., 2013), rs806371 with 
melancholia (Mitjans et al., 2013), rs806374 with Tardive Diskinesia in schizophrenic patients 
(Tiwari et al., 2012), rs806378 with weight gain in olanzapine and clozapine treated psychotic 
patients (Tiwari et al., 2010). Rs806378 showed marginal association with psychosis in this study 
(p-value=0.05). No other association was found with psychosis or cannabis use. 
I also analysed the AATn microsatellite within the CNR1 gene, but failed to replicate any findings. 
To date six studies have focused on the association between the AAT microsatellite and 
schizophrenia, two of which reporting significant association with the hebephrenic subtype. 
Hebephrenic schizophrenia is classified as definite and sustained incongruity or inappropriateness 
of affect or behaviour which is aimless and or disjointed rather than goal directed (ICD-10). Ujike 
and colleagues defined it as characterised predominantly by negative symptoms, resembling 
chronic cannabis use (Ujike et al., 2002) and found it to be associated with the AATn microsatellite; 
these findings were partially replicated by Chavarria-Siles and colleagues in 2008. Because of the 
resemblance in symptoms between hebephrenic schizophrenia and chronic cannabis abuse, I 
decided to analyse the role of the AATn microsatellite in relation to Factor 2 derived from the 
Cannabis Experience Questionaire, which describes experience of depressive/inhibitory type self 
reported by subjects upon cannabis use, but found no significant association. The hebephrenic 
subtype of schizophrenia is not stable over time, the positive results showed by Ujike et al. and 
Chavarria-Siles et al. could be related to methodology such as multiple testing. The same 
considerations regarding sample size can be made for the analysis of the AATn microsatellite, for 
which significant differences in alleles frequency were observed across samples analysed in this 
study but also with frequencies reported by prior published studies. Discrepancies observed could 
possibly be due to ethnic difference across samples, but are more likely due to methodological 
differences in genotyping and calling of repeat sizes or indeed related to inaccurate estimation of 
frequency. 
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The second gene analysed in this thesis is the Catechol-O-Methyltransferase (COMT) gene. 
Markers within the COMT gene have been chosen, because they were already reported to be 
associated with schizophrenia, in previous studies. Rs4680 is with no doubt the most studied 
polymorphisms within the COMT gene, in relation to schizophrenia and cannabis use. This type of 
research increased after it was found to interact with cannabis use in moderating the risk for 
psychosis by Caspi et al., in 2005. Rs4680 is also a biological plausible candidate as it is located in 
the coding region of the COMT gene, resulting in a valine/methionine substitution at codon 158 in 
the MB-COMT isoform (Met158Val). This substitution affects the thermostability of the enzyme 
resulting in reduction of COMT activity in the Met allele carriers and an increase of function in Val 
allele carriers (Lachman et al., 1996). Rs4680 was not found to be significantly associated with 
psychosis or cannabis use in this study. Other markers analysed within the COMT gene, namely 
rs6269, rs4633 and rs4818 have been chosen as part of three different haplotypes named after their 
ability to influence sensitivity to pain: Low Pain Sensitivity (LPS) haplotype, Average Pain 
Sensitivity (APS) haplotype and High Pain Sensitivity (HPS) haplotype. The LPS contains the Val 
allele of rs4680, the allele considered to be risk and showed higher enzymatic activity (Nackley et 
al., 2006). The LPS haplotype has been analysed in this study in relation to psychosis, to cannabis 
use and to the different self reported experiences upon cannabis consumption. No association was 
found to be statistically significant after Bonferroni Correction. Although not significant after 
multiple testing correction and therefore not statistically relevant, results showed that subjects with 
no copies or 1 copy of the LPS, the a priori set risk haplotype, experienced a more 
inhibitory/depressive response upon consumption of cannabis and that subjects with 2 copies of the 
LPS haplotype tend to experience perception abnormalities upon consumption of the drug (adjusted 
p-values=0.08, 0.16 respectively). These associations can however be seen as an indications of 
possible involvement of the COMT gene in moderating the effect of cannabis. The LPS in fact, 
contains the Val at risk allele, involved in the degradation of dopamine and therefore a logic 
biological candidate for moderating the effects of cannabis seen in psychosis. Evidences of the 
involvement of the Val allele in moderating the effect of cannabis come from several studies (Caspi 
et al., 2005) (Henquet et al., 2006) (Estrada et al., 2010). 
Furthermore, another association that lost significance after Bonferroni correction was between 
amount of cannabis used and two different dimensions of experiences. Subjects using cannabis 
three or more times per week were more likely to experience negative symptoms such as anxiety 
and or paranoia (Factor 1) but also pleasurable effects (Factor 3), association was not dependent on 
disease status or ethnicity, but not however statistically relevant. If we were instead in the presence 
of a true statistical positive association, these findings could be the result of subjects using different 
types of cannabis with different Δ9-THC-CBD ratio content and could therefore be experiencing a 
different response upon use, independently of whether their illness. For example consuming 
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cannabis mainly containing Δ9-THC everyday it is not comparable to consuming Hash like 
substances at the same frequency. This is largely addressed in the GAP group by asking subjects to 
state which type of cannabis they mainly use, but the terms Skunk or Herbal Cannabis only refer to 
the part of the plant being consumed, not to the potency of it. We could therefore have data from 
subjects consuming everyday skunk from a plant of medium potency (Δ9-THC content around 10-
12%) and from subjects using instead a very potent strain of the plant (Δ9-THC content around 18-
20%) in the same category group, thus generating biases. The same applies for terms like Herbal 
cannabis or Pollen or “Chocolate Hash”, but also “Sinsemilla” which refers to a particular method 
of cultivation of cannabis sativa but that very often is used as synonymous with Skunk. It has been 
shown, however that patients are more likely to use cannabis more frequently and of a stronger type 
(Di Forti et al., 2009). I tried to address this issue of conflicting results by including type of cannabis 
in the analysis, but no significant association was observed. 
These contrasting findings could be due to the small sample size but also to the fact that self reported 
perceived experienced during and after consumption were pooled together in an attempt to catch a 
better glimpse of the whole cannabis use phenomena, possibly confounding results.  
These difficulties can all be considered limitations that arose because of the naturalistic nature of 
the GAP study. 
 All results have to be interpreted in light of many limitations widely discussed in the experimental 
chapters. First and foremost, this study is underpowered; study samples available are too small to 
correctly detect any significant association. As mentioned in the power calculation paragraph, to 
achieve 80% power, sample analysed should be in the range of thousands in the presence of 
common polymorphisms with a small effect size in a complex disorder. This study lacks the ability 
to detect main genetic effect on psychosis and genetic x environment interaction, it therefore does 
not provide enough evidence of the involvement of the CNR1 or the COMT gene in the aetiology 
of psychosis. Subjects, although analysed in separate groups have been pooled together for the 
analysis on the cannabis experiences, thus causing ethnic stratification. Furthermore, as mentioned 
earlier, the GAP Caucasian group includes all individuals of Caucasian European background and 
the GAP Black group includes all individuals of Black African, Black Caribbean and Black African 
or Black Caribbean mixed ethnicity. This creates a bias as even within Europeans and within Black 
African/Caribbean descendants there is ethnic difference that can account for genetic difference. 
Furthermore, ethnicity is self reported, making data prone to biases. A better approach could be to 
analyse ancestry informative markers on samples before proceeding to association analysis. 
Another possible limitation lays in the fact that cannabis consumption and experiences are reported 
retrospectively, and can therefore be subjected to many biases, such as higher or lower consumption 
rate. 
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Heterogeneity of the study samples in terms of diagnosis can also be considered a limitation. There 
are several advantages on having a cohort of first episode psychosis, but one of the disadvantages 
is probably the inclusion in the study sample of several different phenotypes. A first episode cohort 
may include subjects with any of the psychotic disorders and also with affective disorders and 
although there has been shown that there is genetic overlap to some extent, such heterogeneity of 
diagnosis may lead to a dilution of the effect size of the markers analyzed. 
On the other hand, finding of an association of rs1049353 and rs806378 within the CNR1 gene and 
the LPS haplotype within the COMT gene with inhibitory/depressive response to cannabis use 
(although not significant after Bonferroni correction) has plausible biological relevance. The 
Endocannabinoid Receptor 1 gene is the main binding site of Δ9-THC which is the main 
psychoactive component of cannabis. Moreover the COMT gene plays a crucial role in the 
catabolism of dopamine, which has been implied in the pathophysiology of schizophrenia by many 
studies.  
The CNR1 gene is part of the endocannabinoid system and it is widely expressed in human brain. 
It is highly expressed in the frontal cortex, the basal ganglia, the hippocampus and the cerebellum. 
All these regions have been proposed as a locus for the pathophysiology of schizophrenia. The 
CNR1 gene has mainly been studied in regard to fat metabolism, mental health and drug abuse, also 
because of its localisation within the human brain.  
It has been shown that CNR1 knockout mice show D2 receptor hyperactivation and phenotypically 
resemble schizophrenia (Fritzsche et al., 2001), possibly due to co-localisation of CNR1 with D2 
receptors. Furthermore, CNR1 agonists reduce the rate of firing of neurons in hippocampus 
(Hampson et al., 2000) and impair long term potentiation and execution of working memory tasks 
(Hill et al., 2004), also observed in prefrontal cortex (Jentsch et al., 1997). It is not surprising that 
the role of the CNR1 gene has been investigated mainly in substance abuse (Comings et al., 1997) 
(Li et al., 2000) (Covault et al 2001) (Ballon et al., 2006) (Hoenicka et al., 2007) (Lopez-Moreno 
2010) and schizophrenia with conflicting but interesting results. A very recent study has proposed 
involvement of the CNR1 AATn microsatellite in working memory performance (Ruiz-Conteras et 
al., 2013), which can be disrupted in acute and chronic cannabis intoxication.  Endocannabinoids 
could therefore modulate the excitatory and inhibitory inputs to dopaminergic neurons. On the other 
hand the COMT Val allele (present in the rs4680 polymorphisms and in the LPS haplotype) 
increases dopamine synthesis in VTA neurons. Carriers of the Val allele present with an increase 
of function of the COMT activity due to reduced enzymatic thermostability resulting in Met allele 
carriers having a reduction in COMT activity. It has been shown that Val carriers had 38% reduction 
of COMT activity in PFC tissue in human post mortem studies, with no change in mRNA 
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transcription (Chen et al., 2004).  This leads to reduced degradation and therefore higher levels of 
catecholamines in the Met allele carriers.  
Concurrent stimulation of cannabinoid and dopaminergic receptors, leads to the formation of a D2-
CNR1 protein complex that increases cAMP levels, by coupling to Gs (Mackie et al., 1995). This 
is in contrast with the behaviour usually observed intracellularly (Luzi et al., 2008). This mechanism 
could potentially hold the key to the interaction between cannabinoid, dopaminergic receptors and 
cannabis.  Genetic differences among individuals could be responsible for moderating this 
behaviour. 
9.3 Future directions 
One of the strength of this study, is that data collected on environment, make the Study Sample 
very well characterised. Data collected with the Cannabis Experience Questionnaire, for example, 
realistically reflect the range of experiences upon cannabis consumption. Analysing correlation or 
interaction of these dimensions with genetic predisposing factors, is very interesting and could 
contribute to the understanding of the interaction between the genetic basis and drug abuse in 
schizophrenia. A future direction on this matter, would be to increase the sample size, to obtain 
more statistical power and to analyse experiences, during and after cannabis consumption in a 
separate fashion. This would avoid possible confounders discussed above. This is especially true in 
light of the fact that schizophrenia is now considered a complex disorder for which, at least 
hundreds of genes of small effect are likely contribute and interact, with many different aspect of 
the environment. A lesson learnt from the GWA studies which only started to discover statistically 
significant and potentially pathological polymorphisms when sample sizes were increased 
significantly.  
This study gives a contribution to the field investigating on the aetiology of psychosis. It is, to my 
knowledge, the only one that systematically analysed polymorphisms covering the entire length of 
the CNR1 gene, exploring its relationship with cannabis use, in a cohort of first episode of psychosis 
patients and matched controls. Furthermore, it is one of the very few analysing the role of the AATn 
microsatellite within the CNR1 gene in psychosis. This study is also the first one to explore the 
relationship of the LPS haplotype with cannabis use and psychosis and with experiences upon 
cannabis consumption. 
Results cannot considered conclusive as the study is significantly underpowered, they can, however, 
be considered as an indication of the possible involvement of the CNR1 and the COMT gene in the 
aetiology of psychosis. By implementing points discussed as future directions, this study will be 
able to give a substantial contribution to the field. 
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THE CANNABIS EXPERIENCE QUESTIONNAIRE 
 
SECTION 15 - Cannabis Experiences Questionnaire 
Rater’s Initials: ............................ Date of Completion: .............. / .............. / ......... 
Not assessed/missing -66                    Participant refused to answer -88 
 
Instructions to researcher: Please tick boxes as appropriate to indicate patient’s responses. 
Please be reminded that some questions allow for more than one response. 
 
15.1 Have you ever smoked/used cannabis? Yes 1            No 2 (go to 15.17) 
15.2 How old were you when you first tried cannabis? .............. years 
15.3 Why did you first try cannabis? (You can tick more than one box) 
 
a) My friends were using it                                       Yes 1 No 2 
b) My family members were using it                        Yes 1 No 2 
c) To feel better (to get relief from either physical    Yes 1 No 2 
or psychological discomfort) 
d) Other (please explain) (not for data entry)          Yes 1 No 2 
........................................................................................................................................ 
Instructions to researcher: Please consider as current smokers all participants who report 
usually/customarily smoking cannabis (incl. patients who have not smoked while inpatient/in 
prison and patients who report occasional use even if it is once every couple of years etc) 
15.4 Do you currently use cannabis? 
a) Yes 1 (please answer b, then go to 15.5)    No 2 (please answer c, then go to 15.6) 
b) If YES, why did you continue to use cannabis? (You can tick more than one box) 
i) I like the effect, it gives me a buzz                  Yes 1 No 2 
ii) It makes me feel relaxed                                Yes 1 No 2 
iii) It makes me feel less nervous and anxious  Yes 1 No 2 
iv) It makes me feel more sociable                    Yes 1 No 2 
v) Other (please explain)                                    Yes 1 No 2 
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..................................................................................................................................................... 
c) If NO, at what age did you stop? .............. 
Please state why you stopped (not for data entry): 
.................................................................................................................................................... 
 
15.5 Would you like to stop using cannabis one day? 
a) Yes 1 No 2 
b) If yes, please explain: 
..................................................................................................................................................... 
 
15.6 Does/did cannabis affect your health in any way? 
a) Yes 1 No 2 
b) If yes, please explain (not for data entry): 
..................................................................................................................................................... 
 
15.7 Does/did cannabis facilitate social situations? 
a) Yes 1 No 2 
 
 
15.8 How do/did you mostly use cannabis? 
 
a) I smoke/smoked it in a joint with tobacco 1 
b) I smoke/smoked it in a joint without tobacco 2 
c) I smoke/smoked it using a bong 3 
d) I eat/ate or drink/drank it 4 
e) Other (please explain) 5 
..................................................................................................................................................... 
 
15.9 How often do/did you use cannabis? 
a) Every day 1 
b) More than once a week 2 
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c) A few times each month 3 
d) A few times each year 4 
e) Only once or twice 5 
 
 
15.10 When do/did you mostly use cannabis? 
 
a) At weekends 1 
b) During the day 2 
c) During the evening 3 
d) During the day and evening 4 
e) Other (please explain) 5 
..................................................................................................................................................... 
 
15.11 Do you/did you mostly use cannabis: 
 
a) Socially (with friends) 1 
b) On my own 2 
 
 
15.12 On average how much money per week do/did you usually spend on cannabis? 
 
a) Less than £2.50 1 
b) £2.50 - £5 2 
c) £6 - £10 3 
d) £11 - £15 4 
e) £16 - £20 5 
f) Above £20  
 
15.13 What type of cannabis do/did you mostly use? 
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a) Hash (cannabis resin/solid) 1  d) Super skunk 4 
b) Imported herbal cannabis 2   e) Other (please state) 5 
c) Home-grown skunk/ Sensimilla 3 
 
 
15.14 How often have you had these experiences while smoking cannabis? Please rate 
whether it was agood, bad or neutral experience. If rarely or never, ignore rating (good, bad, 
neutral) and go to next item. 
 
a) Fearful 
i) Rarely or never 1                     ii) Good 1 
From time to time 2       Bad 2 
Sometimes 3        Neutral 3 
More often than not 4 
Almost always 5 
 
b) Feel like going crazy/mad 
i) Rarely or never 1                    ii) Good 1 
From time to time 2       Bad 2 
Sometimes 3        Neutral 3 
More often than not 4 
Almost always 5 
 
c) Nervy 
i) Rarely or never 1                     ii) Good 1 
From time to time 2       Bad 2 
Sometimes 3        Neutral 3 
More often than not 4 
Almost always 5 
 
d) Suspicious 
i) Rarely or never 1                    ii) Good 1 
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From time to time 2       Bad 2 
Sometimes 3        Neutral 3 
More often than not 4 
Almost always 5 
 
 
e) Feeling happy 
i) Rarely or never 1                    ii) Good 1 
From time to time 2       Bad 2 
Sometimes 3        Neutral 3 
More often than not 4 
Almost always 5 
 
f) Full of plans/ideas 
i) Rarely or never 1                    ii) Good 1 
From time to time 2       Bad 2 
Sometimes 3        Neutral 3 
More often than not 4 
Almost always 5 
 
g) Hearing voices 
i) Rarely or never 1                   ii) Good 1 
From time to time 2       Bad 2 
Sometimes 3        Neutral 3 
More often than not 4 
Almost always 5 
 
h) Able to understand the world better 
i) Rarely or never 1                   ii) Good 1 
From time to time 2       Bad 2 
Sometimes 3        Neutral 3 
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More often than not 4 
Almost always 5 
 
i) Seeing visions 
i) Rarely or never 1                    ii) Good 1 
From time to time 2       Bad 2 
Sometimes 3        Neutral 3 
More often than not 4 
Almost always 5 
 
15.15 How often have you had these experiences after the initial effects of cannabis have 
worn off? 
Please rate whether it was a good, bad or neutral experience. If rarely or never, ignore rating 
(good, bad, neutral) and go to next item 
 
a) Not wanting to do anything 
i) Rarely or never 1                    ii) Good 1 
From time to time 2       Bad 2 
Sometimes 3        Neutral 3 
More often than not 4 
Almost always 5 
 
b) Being suspicious without reason 
i) Rarely or never 1                    ii) Good 1 
From time to time 2       Bad 2 
Sometimes 3        Neutral 3 
More often than not 4 
Almost always 5 
 
c) Slowed down thinking 
i) Rarely or never 1                    ii) Good 1 
From time to time 2       Bad 2 
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Sometimes 3        Neutral 3 
More often than not 4 
Almost always 5 
 
d) Difficulty in concentrating 
i) Rarely or never 1                     ii) Good 1 
From time to time 2       Bad 2 
Sometimes 3        Neutral 3 
More often than not 4 
Almost always 5 
 
e) Not able to think clearly 
i) Rarely or never 1                    ii) Good 1 
From time to time 2       Bad 2 
Sometimes 3        Neutral 3 
More often than not 4 
Almost always 5 
15.16 Life Time Cannabis History questionnaire. 
Instructions to researcher: Please hand this section over to participant for completion. Explain 
to participant how to complete this part by using (a) as an example: If you were smoking cannabis 
when you were 15, were smoking 2-3 joints per day on average, you usually smoked hash and 
you only smoked by yourself. 
 
a) AGE RANGE: 0-16 
 
i)Did you use cannabis between the ages of 0 and 16? Yes 1 No 2 
 
ii) Frequency 
Every day 1 
More than once a week 2 
About once a week 3 
About once/twice a month 4 
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A few times each year 5 
About once a year 6 
I have only used cannabis once or twice 7 
 
iii) Quantity (average per day) 
1 joint 1 
2 or 3 joints 2 
4 or more joints 3 
 





Hash (cannabis resin/solid) 1 
Imported herbal cannabis 2 
Skunk/ Sensimilla 3 
Super skunk 4 
Other 5 
 
vi) Setting of use 
Socially (with friends) 1 
On my own 2 
Both 3 
 
b) AGE RANGE: 17-20 
 
i)Did you use cannabis between the ages of 17 and 20? Yes 1 No 2 
 
ii) Frequency 
Every day 1 
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More than once a week 2 
About once a week 3 
About once/twice a month 4 
A few times each year 5 
About once a year 6 
I have only used cannabis once or twice 7 
 
iii) Quantity (average per day) 
1 joint 1 
2 or 3 joints 2 
4 or more joints 3 
 





Hash (cannabis resin/solid) 1 
Imported herbal cannabis 2 
Skunk/ Sensimilla 3 
Super skunk 4 
Other 5 
 
vi) Setting of use 
Socially (with friends) 1 
On my own 2 
Both 3 
c) AGE RANGE:ABOVE THE AGE OF 21 
 
i)Did you use cannabis from the age of 21 onwards? Yes 1 No 2 
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ii) Frequency 
Every day 1 
More than once a week 2 
About once a week 3 
About once/twice a month 4 
A few times each year 5 
About once a year 6 
I have only used cannabis once or twice 7 
 
iii) Quantity (average per day) 
1 joint 1 
2 or 3 joints 2 
4 or more joints 3 
 





Hash (cannabis resin/solid) 1 
Imported herbal cannabis 2 
Skunk/ Sensimilla 3 
Super skunk 4 
Other 5 
 
vi) Setting of use 
Socially (with friends) 1 
On my own 2 
Both  
 
15.17 Instructions to researcher: Please give participant prompt sheet and then read out 
following instruction: ‘Please have a look at the list I handed to you and indicate which drugs you 
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use/have used recreationally in the past. Also please state how often you use/have used it, the 
age at which you first tried the drug(s) and whether you are a past or current user’. Use a new box 






Every day 1 A few times each year 4 
More than once a week 2 Only once or twice 5 
A few times each month 3 
 
















Every day 1 A few times each year 4 
More than once a week 2 Only once or twice 5 
A few times each month 3 
 
ii) Age .............. 

















Every day 1 A few times each year 4 
More than once a week 2 Only once or twice 5 
A few times each month 3 
 



















Every day 1 A few times each year 4 
More than once a week 2 Only once or twice 5 
A few times each month 3 
 

















Every day 1 A few times each year 4 
More than once a week 2 Only once or twice 5 
A few times each month 3 


















Every day 1 A few times each year 4 
More than once a week 2 Only once or twice 5 
A few times each month 3 
 
















Every day 1 A few times each year 4 
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More than once a week 2 Only once or twice 5 
A few times each month 3 
 














Every day 1 A few times each year 4 
More than once a week 2 Only once or twice 5 
A few times each month 3 
 









Both day and night 3 
 







Every day 1 A few times each year 4 
More than once a week 2 Only once or twice 5 
A few times each month 3 
 
















Every d.ay 1 A few times each year 4 
More than once a week 2 Only once or twice 5 
A few times each month 3 
 
ii) Age .............. 
 
iii) Use 














Every day 1 A few times each year 4 
More than once a week 2 Only once or twice 5 
A few times each month 3 
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TABLE C.1:  Hardy Weinberg Equilibrium (HWE) Test among non psychotic participants from the GAP Black sample 









(N) O(HET) E(HET) 
HWE P-
Value 
6 CNR1 rs10485171 26963224   C/T 0.41 14/31/26 71 0.44 0.49 0.463 
6 CNR1 rs806365 26965783   T/C 0.40 8/36/27 71 0.51 0.46 0.609 
6 CNR1 rs806366 26967423   T/C 0.49 14/34/22 70 0.49 0.49 1.000 
6 CNR1 rs12189668 26969199   C/C 0.06 2\6\65 73 0.08 0.13 0.028 
6 CNR1 rs1049353 26973469   A/G 0.25 3/24/48 75 0.32 0.32 1.000 
6 CNR1 rs806369 26976012   T/C 0.23 5/16/49 70 0.23 0.30 0.048 
6 CNR1 rs806371 26976197   G/T 0.17 4/23/47 74 0.31 0.33 0.723 
6 CNR1 rs806374 26977154   C/T 0.37 10/35/29 74 0.47 0.47 1.000 
6 CNR1 rs12195101 26977659   G/T 0.04 0/7/67 74 0.09 0.09 1.000 
6 CNR1 rs806375 26978355   T/A 0.50 21/31/19 71 0.44 0.50 0.341 
6 CNR1 rs806377 26978557   C/T 0.49 21/37/16 74 0.50 0.50 1.000 
6 CNR1 rs806378 26979385   T/C 0.30 8/28/39 75 0.37 0.41 0.406 
6 CNR1 rs2023239 26980316   C/T 0.22 9/23/40 72 0.32 0.41 0.081 
6 CNR1 rs1535255 26981042   G/T 0.17 3/25/44 72 0.35 0.34 1.000 
6 CNR1 rs6454672 26981404   C/T 0.14 3/17/51 71 0.24 0.27 0.371 
 
MAF= Minor allele frequency 
O(HET)= Observed heterozygosity 
E(HET)= Expected heterozygosity 
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TABLE C.2:  Hardy Weinberg Equilibrium (HWE) Test among non psychotic participants from the GAP Caucasian sample 
 
CHR Gene SNP Position 
Minor 
allele/ 





(N) O(HET) E(HET) 
HWE P-
Value 
6 CNR1 rs10485171 89261282 C/T 0.44 8/19/8 35 0.54 0.50 0.742 
6 CNR1 rs806365 89263841 T/C 0.32 26/67/42 32 0.38 0.45 0.431 
6 CNR1 rs806366 89265481 C/T 0.29 6/15/14 35 0.43 0.47 0.720 
6 CNR1 rs12189668 89267257 C/T 0.02 0/3/32 35 0.09 0.08 1.000 
6 CNR1 rs1049353 89271527 A/G 0.06 2/11/123 35 0.23 0.24 0.526 
6 CNR1 rs806369 89274070 T/C 0.12 5/39/95 35 0.23 0.28 0.237 
6 CNR1 rs806371 89274255 G/T 0.28 8/34/91 32 0.38 0.34 1.000 
6 CNR1 rs806374 89275212 C/T 0.42 5/47/83 31 0.32 0.46 0.119 
6 CNR1 rs12195101 89275717 G/T 0.04 19/59/56 35 0.06 0.11 0.086 
6 CNR1 rs806375 89276413 A/T 0.45 7/15/12 34 0.44 0.49 0.725 
6 CNR1 rs806377 89276615 T/C 0.36 6/15/13 34 0.44 0.48 0.722 
6 CNR1 rs806378 89277443 T/C 0.15 1/16/18 35 0.46 0.38 0.395 
6 CNR1 rs2023239 89278374 C/T 0.36 10/57/71 35 0.29 0.45 0.055 
6 CNR1 rs1535255 89279100 G/T 0.30 2/13/20 35 0.37 0.37 1.000 
6 CNR1 rs6454672 89279462 C/T 0.29 1/14/20 35 0.40 0.35 0.651 
 
MAF= Minor allele frequency 
O(HET)= Observed heterozygosity 
E(HET)= Expected heterozygosity 
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TABLE C.3:  Hardy Weinberg Equilibrium (HWE) Test among non psychotic participants from the PICOS Study sample 
 
CHR Gene SNP Position 
Minor allele/ 





(N) O(HET) E(HET) 
HWE P-
Value 
6 CNR1 rs10485171 89261282 C/T 0.38 68/257/180 505 0.51 0.48 0.134 
6 CNR1 rs806365 89263841 T/C 0.49 121/260/129 510 0.51 0.50 0.723 
6 CNR1 rs806366 89265481 T/C 0.46 106/239/159 504 0.47 0.49 0.368 
6 CNR1 rs12189668 89267257 C/T 0.00 0/0/510 510 0.00 0.00 1.000 
6 CNR1 rs1049353 89271527 A/G 0.23 24/175/303 502 0.35 0.35 0.898 
6 CNR1 rs806369 89274070 T/C 0.35 60/233/216 509 0.46 0.45 0.845 
6 CNR1 rs806371 89274255 G/T 0.15 9/115/380 504 0.23 0.23 0.847 
6 CNR1 rs806374 89275212 C/T 0.33 46/242/219 507 0.48 0.44 0.087 
6 CNR1 rs12195101 89275717 G/T 0.00 0/2/512 514 0.00 0.00 1.000 
6 CNR1 rs806375 89276413 T/A 0.42 86/261/154 501 0.52 0.49 0.202 
6 CNR1 rs806377 89276615 C/T 0.50 123/259/120 502 0.52 0.50 0.532 
6 CNR1 rs806378 89277443 T/C 0.26 36/212/259 507 0.42 0.40 0.442 
6 CNR1 rs2023239 89278374 C/T 0.17 13/143/354 510 0.28 0.28 0.873 
6 CNR1 rs1535255 89279100 G/T 0.17 13/141/350 504 0.28 0.28 0.873 
6 CNR1 rs6454672 89279462 C/T 0.12 5/106/400 511 0.21 0.20 0.660 
 
MAF= Minor allele frequency 
O(HET)= Observed heterozygosity 
E(HET)= Expected heterozygosity 
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CNR1 rs10485171 C/T 26/79/48 153 8/19/8 35 1.27 0.529 
CNR1 rs806365 T/C 16/67/74 157 5\12\15 32 0.88 0.645 
CNR1 rs806366 C/T 14/54/84 152 6/15/14 35 3.35 0.187 
CNR1 rs1049353 A/G 1/12/143 156 1\8\26 35 NA NA 
CNR1 rs806371 G/T 21/48/88 157 1\12\19 32 NA NA 
CNR1 rs806374 C/T 30/76/53 159 6\10\15 31 3.03 0.220 
CNR1 rs12195101 G/T 3/7/147 157 1\2\32 35 NA NA 
CNR1 rs806375 A/T 28/84/43 155 7/15/12 34 1.18 0.554 
CNR1 rs806377 T/C 12/86/58 156 6/15/13 34 3.57 0.168 
CNR1 rs806378 T/C 2/34/119 155 1/16/18 35 NA NA 
CNR1 rs2023239 C/T 27/59/71 157 7\10\18 25 1.01 0.603 
CNR1 rs1535255 G/T 15/71/73 159 2/13/20 35 NA NA 
CNR1 rs6454672 C/T 16/62/76 154 1/14/20 35 NA NA 
 
(a)= number of participants for genotype groups at each locus presented as homozygous for the minor allele, heterozygous and homozygous for the major allele 
(b)= number of participants (Psychotic and non psychotic) for genotype groups at each locus 
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CNR1 rs10485171 C/T 19/40/38 97 14/31/26 71 0.13 0.938 
CNR1 rs806365 T/C 16/51/29 96 8/36/27 71 1.62 0.445 
CNR1 rs806366 T/C 24/54/19 97 14/34/22 70 3.11 0.211 
CNR1 rs1049353 A/G 8/40/51 99 3/24/48 75 NA NA 
CNR1 rs806371 G/T 3/22/73 98 4/23/47 74 NA NA 
CNR1 rs806374 C/T 17/37/42 96 10/35/29 74 1.43 0.490 
CNR1 rs12195101 G/T 2\3\95 100 0/7/67 74 NA NA 
CNR1 rs806375 T/A 27/39/30 96 21/31/19 71 0.40 0.819 
CNR1 rs806377 C/T 24/43/32 99 21/37/16 74 2.42 0.298 
CNR1 rs806378 T/C 10/39/47 96 8/28/39 75 0.20 0.907 
CNR1 rs2023239 C/T 6/23/70 99 9/23/40 72 4.63 0.099 
CNR1 rs1535255 G/T 2/25/74 101 3/25/44 72 NA NA 
CNR1 rs6454672 C/T 3/18/78 99 3/17/51 71 NA NA 
 
(a)= number of participants for genotype groups at each locus presented as homozygous for the minor allele, heterozygous and homozygous for the major allele 
(b)= number of participants (Psychotic and non psychotic) for genotype groups at each locus 
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CNR1 rs10485171 C/T 39/122/105 266 68/257/180 505 1.77 0.413 
CNR1 rs806365 T/C 59/141/73 273 121/260/129 510 0.51 0.777 
CNR1 rs806366 T/C 60/135/68 263 106/239/159 504 2.69 0.261 
CNR1 rs1049353 A/G 19/86/162 267 24/175/303 502 2.06 0.356 
CNR1 rs806371 G/T 5/83/187 275 9/115/380 504 5.14 0.077 
CNR1 rs806374 C/T 27/127/111 265 46/242/219 507 0.30 0.861 
CNR1 rs12195101 G/T 0/0/270 270 0/2/512 514 NA NA 
CNR1 rs806375 T/A 35/132/97 264 86/261/154 501 3.72 0.156 
CNR1 rs806377 C/T 62/133/71 266 123/259/120 502 0.73 0.693 
CNR1 rs806378 T/C 10/104/155 269 36/212/259 507 5.23 0.073 
CNR1 rs2023239 C/T 8/83/177 268 13/143/354 510 0.94 0.627 
CNR1 rs1535255 G/T 9/79/179 267 13/141/350 504 0.69 0.709 
CNR1 rs6454672 C/T 5/64/202 271 5/106/400 511 2.03 0.362 
 
(a)= number of participants for genotype groups at each locus presented as homozygous for the minor allele, heterozygous and homozygous for the major allele 
(b)= number of participants (Psychotic and non psychotic) for genotype groups at each locus 
* Degrees of  freedom=2 
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TABLE C.7:  Hardy Weinberg Equilibrium (HWE) Test among non psychotic participants from the GAP Caucasian sample 
 
CHR Gene SNP 
Minor allele/ 





(N) O(HET) E(HET) HWE P-Value 
22 COMT rs737865 G/A 0.15 4/42/88 43 0.19 0.21 0.446 
22 COMT rs6269 G/A 0.36 4/16/21 41 0.39 0.41 0.712 
22 COMT rs4633 T/C 0.36 8/19/16 43 0.44 0.48 0.544 
22 COMT rs4818 G/C 0.19 0/15/26 41 0.37 0.30 0.312 
22 COMT rs165599 A/G 0.39 10/13/18 41 0.32 0.48 0.048 
22 COMT rs4680 A/G 0.34 5/14/13 32 0.44 0.47 0.714 
22 COMT rs2075507 G/A 0.35 4/17/12 33 0.52 0.47 0.722 
 
MAF= Minor allele frequency 
O(HET)= Observed heterozygosity 
E(HET)= Expected heterozygosity 
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TABLE C.8  Hardy Weinberg Equilibrium (HWE) Test among non psychotic participants from the GAP Black sample 
 
CHR Gene SNP 
Minor allele/ 
Other allele MAF 
Genotypes 
distribution (N)* subjects (N) O(HET) E(HET) 
HWE P-
Value 
22 COMT rs737865 G/A 0.2912 4/42/43 89 0.4719 0.404 0.1867 
22 COMT rs6269 G/A 0.4093 19/37/32 88 0.4205 0.4891 0.1945 
22 COMT rs4633 T/C 0.4681 22/39/30 91 0.4286 0.4961 0.207 
22 COMT rs4818 G/C 0.3813 15/40/34 89 0.4494 0.4772 0.6566 
22 COMT rs165599 G/A 0.335 14/36/44 94 0.383 0.4491 0.1689 
22 COMT rs4680 A/G 0.4848 15/36/21 72 0.5 0.4965 1 
22 COMT rs2075507 G/A 0.37 11/25/35 71 0.3521 0.4429 0.1057 
 
MAF= Minor allele frequency 
O(HET)= Observed heterozygosity 
E(HET)= Expected heterozygosity 
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